paclitaxel has been researched along with Carcinoma, Epidermoid in 1055 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.09) | 18.7374 |
| 1990's | 123 (11.66) | 18.2507 |
| 2000's | 377 (35.73) | 29.6817 |
| 2010's | 467 (44.27) | 24.3611 |
| 2020's | 87 (8.25) | 2.80 |
| Authors | Studies |
|---|---|
| Hosoyama, H; Kobayashi, J; Shigemori, H; Sudo, Y; Tsuruo, T; Wang, XX | 1 |
| Agostini, M; Almeida, LY; Bastos, DC; Coletta, RD; Cuadra Zelaya, FJM; Daher, URN; Graner, E; Kowalski, LP; Mariano, FS; Moreira, FDS; Ortiz, CA; Santos, GASD | 1 |
| Chiba, Y; Harada, H; Haratani, K; Ito, K; Kenmotsu, H; Kogure, Y; Miyawaki, T; Nakagawa, K; Nishimura, Y; Ohde, Y; Okimoto, T; Sakamoto, T; Sakata, S; Uemura, T; Wakuda, K; Yamamoto, N | 1 |
| Bai, J; Chen, G; Chen, K; Cui, J; Dong, X; Fan, Y; Gu, K; Guo, Q; He, J; Hu, C; Hu, X; Jiang, D; Jiang, L; Li, J; Li, Y; Liu, J; Pan, Y; Peng, M; Shi, Q; Song, Y; Tan, W; Wang, G; Wang, H; Wang, Z; Wu, L; Wu, X; Xie, W; Xiong, J; Yang, N; Yao, W; Yi, T; Yu, G; Yue, L; Zang, A; Zhang, G; Zhang, J; Zhang, X; Zhao, G; Zhao, W; Zhou, C | 1 |
| Bazzett-Matabele, L; Bigirimana, JB; DeBoer, RJ; Katznelson, E; Nguyen, C; Nsabimana, N; Ntasumbumuyange, D; Paciorek, A; Ruhangaza, D; Shulman, LN; Shyirambere, C; Triedman, SA; Umutoni, V; Umwizerwa, A | 1 |
| Chen, J; Liu, A; Shi, B; Shi, Y | 1 |
| Cang, S; Cao, P; Chen, G; Chen, J; Cheng, Y; Fang, J; Fang, Y; Geng, Y; Guo, R; Hu, S; Huang, Y; Jiang, T; Li, X; Luo, H; Lv, D; Pan, Y; Ren, S; Shi, J; Shi, W; Wang, D; Wang, Q; Wang, R; Wang, Z; Xing, C; Xu, X; Yang, Z; Yao, W; Yu, J; Zhang, W; Zhang, Y; Zhou, C; Zou, J | 1 |
| Almotlak, H; André, T; Baba-Hamed, N; Borg, C; Bouché, O; Buecher, B; de la Fouchardiere, C; Desrame, J; El Hajbi, F; Ghiringhelli, F; Jacquin, M; Jary, M; Kaminsky, MC; Kim, S; Meurisse, A; Nguyen, T; Parzy, A; Pernot, S; Saint, A; Samalin, E; Smith, D; Stouvenot, M; Taieb, J; Vernerey, D; Vienot, A; Zoubir, M | 1 |
| Hanamura, N; Ishitobi, M; Kashikura, Y; Kozuka, Y; Mizuno, T; Noro, A; Ogawa, T; Saito, K; Yamashita, M | 1 |
| Jin, LF; Shen, WZ; Zhang, M; Zhao, M | 1 |
| Dong, X; Jia, Y; Song, X; Song, Y; Wang, W; Yi, Y; Zhang, J | 1 |
| Cai, L; Chen, C; Deng, H; Li, S; Lin, X; Liu, M; Qin, Y; Qiu, G; Xie, X; Xie, Z; Yang, Y; Zhou, C | 1 |
| Reguart, N; Reyes, R | 1 |
| Fang, J; Feng, L; Huang, T; Wang, L; Wang, R; Yang, Y | 1 |
| Du, M; Fang, Y; Gu, D; Li, H; Sun, L; Ye, J; Zhang, Z; Zhou, G | 1 |
| Castellano, GM; Garbuzenko, OB; Malhotra, J; Minko, T; Pine, SR; Sabaawy, HE; Zeeshan, S | 1 |
| Baker, S; Blanchard, E; Brahmer, JR; Celano, P; Duma, N; Elkins, IB; Ellis, PM; Haddad, RY; Hesketh, PJ; Jain, D; Jaiyesimi, IA; Johnson, DH; Leighl, NB; Mamdani, H; Masters, G; Moffitt, PR; Phillips, T; Riely, GJ; Robinson, AG; Rosell, R; Schiller, JH; Schneider, BJ; Singh, N; Spigel, DR; Temin, S | 1 |
| Kii, T; Sakuma, K; Tanaka, A; Yoda, M | 1 |
| Gibson, MK; Weidenbaum, C | 1 |
| Chen, J; Dang, J; Li, S; Liu, T; Wang, H | 1 |
| Besch, BM; Henson, C; Hsieh, ML; Peterson, JEG | 1 |
| Guo, S; Li, S; Ma, K; Wang, J; Wei, S; Xu, Y; Zhang, F | 1 |
| Bai, H; Han, H; Shi, H; Wang, F | 1 |
| Li, L; Song, C; Sun, Z; Wang, W; Xu, H; Yin, J | 1 |
| Chen, X; Han, Y; Jiang, L; Leng, X; Peng, L; Wan, G; Wang, Q; Wang, Y; Wu, L; Zhu, J | 1 |
| Ikemura, M; Komura, A; Miyamoto, Y; Mori, M; Nishijima, A; Oda, K; Osuga, Y; Sone, K; Taguchi, A; Tanikawa, M | 1 |
| Bodiwala, K; Khadela, A; Mansuri, M; Sureja, D; Vyas, B | 1 |
| Asahina, H; Hosomi, Y; Kobayashi, K; Maemondo, M; Matsuyama, K; Miyanaga, A; Morita, S; Okano, T; Seike, M; Shukuya, T; Sugawara, S; Tsubata, Y; Watanabe, S | 1 |
| Guo, L; Wang, S; Wang, W; Xie, X; Zhang, Y | 1 |
| Cui, Y; Fan, X; Li, Y; Liu, C; Wu, K; Yang, Y; Yi, Q | 1 |
| Hussein, HA; Khaphi, FL | 1 |
| Dadgar, E; Esfahaniani, M; Hassani, P; Mortezagholi, B; Movahed, E; Nasiri, K; Nejati, ST; Rafieyan, S | 1 |
| Choueiri, MA; Dietz, MD; Zelmanski, MH | 1 |
| Chen, Y; Dong, M; Dou, S; Huang, Y; Ju, W; Li, J; Liu, Y; Shi, W; Sun, J; Sun, Q; Tang, Y; Zhang, D; Zhao, T; Zhong, L; Zhou, X; Zhou, Z; Zhu, D; Zhu, G; Zhu, Q | 1 |
| Deng, X; Guo, S; Liu, L; Yang, S | 1 |
| Benedix, F; Croner, RS; Hass, P; Lorenz, E; Reinstaller, T; Weitz, A | 1 |
| Cai, XW; Fu, XL; Li, Y; Lin, L; Liu, J; Ma, XM; Song, XY; Yu, W; Zhang, Q; Zhao, SG | 1 |
| Ajani, JA; Rogers, JE | 1 |
| Fontanilles, M; Jamelot, M; Vaschalde, Y | 1 |
| Guo, J; Jia, R; Shao, J; Sun, Y; Yan, L | 1 |
| Kumagai, T; Kunimasa, K; Nakamura, H; Nakatsuka, SI; Nishino, K | 1 |
| Ding, Y; Liu, L; Qiu, S; Si, L; Yan, W; Zhang, Q | 1 |
| Bagot, M; Baroudjian, B; Basset-Seguin, N; Chapalain, M; Dupont, A; Lambert, J; Lebbe, C; Lhote, R | 1 |
| Al Sayed, AD; Al-Tweigeri, T; Elshenawy, MA; Ghebeh, H; Tulbah, A | 1 |
| Burke, T; Cicin, I; Gümüş, M; Hermes, B; Kato, T; Kopp, HG; Kowalski, D; Laktionov, K; Li, X; Luft, A; Mazieres, J; Novello, S; Paz-Ares, L; Piperdi, B; Ramlau, R; Reddy, S; Rodríguez-Cid, J; Tafreshi, A; Vicente, D; Wilson, J | 1 |
| Chakraborty, K; Costello, PN; Manthri, S; Rehman, HH | 1 |
| Herrmann, R; Holzgrabe, U; Polednik, C; Roller, J; Schmidt, M; Skaf, J | 1 |
| Faggioni, L; Gadducci, A; Manassero, F; Selli, C; Tognarelli, A | 1 |
| Boekhoff, MR; Borggreve, AS; Brosens, LAA; Goense, L; Heethuis, SE; Lagendijk, JJW; Meijer, GJ; Mook, S; Ruurda, JP; van Hillegersberg, R; van Lier, ALHMW; van Rossum, PSN | 1 |
| Haratake, N; Matsubara, T; Miura, N; Seto, T; Takamori, S; Takenoyama, M; Toyozawa, R; Uchi, H; Yamaguchi, M | 1 |
| Bastien, C; Campitiello, M; Gehin, W; Hennequin, L; Jaud, C; Longo, R; Plastino, F; Rozzi, A | 1 |
| Bradford, DS; Crane, J; Deal, AM; Irvin, W; Lee, C; Morgensztern, D; Muss, HB; Pecot, C; Pennell, N; Socinski, M; Stevenson, JP; Stinchcombe, T; Villaruz, LC; Weiss, JM; West, HJ | 1 |
| Gundu, N; Jain, D; Kancharla, H; Khurana, S; Kumar, S; Malik, PS; Mohan, A; Pathak, N; Pathy, S; Pushpam, D; Vandidassane, I | 1 |
| Huang, H; Liu, B; Lu, C; Qi, W; Song, S; Zhang, W | 1 |
| Asari, R; Beer, A; Ilhan-Mutlu, A; Jomrich, G; Kristo, I; Paireder, M; Preusser, M; Rieder, E; Schmid, R; Schoppmann, SF | 1 |
| Althouse, S; Anouti, B; Durm, G; Hanna, N | 1 |
| Boulinguez, S; Casassa, E; Chira, C; Gangloff, D; Lamant, L; Meyer, N; Montastruc, M; Paul, C; Riffaud, L; Sibaud, V | 1 |
| An, T; Chen, H; Chi, Y; Duan, J; Liang, Q; Wang, J; Wang, S; Wang, Y; Wang, Z; Yang, X; Zhao, J; Zhong, J; Zhuo, M | 1 |
| Chen, B; Ding, Y; Fan, J; Gao, W; Nan, X; Wang, B; Wang, J; Wen, S; Wu, Y; Zhao, Q | 1 |
| Chen, J; Chen, L; Fan, L; Pu, Y; Wang, J; Wang, Y; Xia, C; Zhang, Q | 1 |
| Darilay, A; Hansen, RN; Ramsey, SD; Ryan, K; Seal, B; Yong, C; Zhang, Y | 1 |
| Cha, SI; Choi, JE; Choi, SH; Do, SK; Hong, MJ; Jeong, JY; Jin, CC; Kang, HG; Kim, CH; Kim, JH; Lee, J; Lee, JH; Lee, SY; Lee, WK; Lee, YH; Park, JY; Seo, H; Shin, KM; Yoo, SS | 1 |
| Guo, Y; Li, Y; Wang, Y; Zhang, D | 1 |
| Ballinger, M; Cappuzzo, F; Conter, HJ; Graupner, V; Hoang, T; Huang, KC; Hussein, M; Jessop, H; Jotte, R; Kozuki, T; McCleland, M; Rodríguez-Abreu, D; Sandler, A; Socinski, MA; Soo, R; Stroyakovskiy, D; Sun, SW; Vynnychenko, I | 1 |
| Blom, GJ; Bogers, JHA; Braam, PM; de Greef, BTA; de Jong, MA; de Vos-Geelen, J; Geurts, SME; Grabsch, HI; Hoeben, A; Hoebers, FJP; Hulshof, MCCM; Jeene, PM; Kasperts, N; Lemmens, VEPP; Muijs, CKT; Nieuwenhuijzen, GAP; Rozema, T; Tjan-Heijnen, VCG; van Dieren, JM; van Laarhoven, HWM; Voncken, FEM | 1 |
| Baweja, A; Mar, N | 1 |
| Kosaka, M; Sakaguchi, K; Yamazaki, Y | 1 |
| Li, X; Wang, W; You, J; Yuan, Y | 1 |
| Liang, Y; Yu, M; Zhou, C; Zhu, X | 1 |
| Ihira, K; Kaneuchi, M; Kato, T; Kobayashi, N; Konno, Y; Mitamura, T; Murakami, G; Nozaki, A; Sakuragi, N; Shimada, C; Todo, Y; Umazume, T; Watari, H | 1 |
| Furuya, N; Goto, Y; Hida, N; Hosomi, Y; Ikeda, S; Ishihara, M; Misumi, T; Miura, Y; Niho, S; Nogami, N; Ohe, Y; Okamoto, H; Saito, H; Seki, N; Shimokawa, T; Tanaka, H; Tokito, T; Umemura, S; Yamanaka, T; Zenke, Y | 1 |
| Fujii, T; Fujiwara, K; Fukuhara, T; Koyama, S; Morisaki, T; Nakamura, Y; Takeuchi, H | 1 |
| Stinchcombe, TE | 2 |
| Fukumoto, C; Hasegawa, T; Hitomi-Koide, M; Hyodo, T; Kamimura, R; Kawamata, H; Komiyama, Y; Nakashiro, KI; Sawatani, Y; Shimura, M; Uchida, D | 1 |
| Benedetti Panici, P; D'Alessandris, N; Della Rocca, C; Di Maio, V; Di Pinto, A; Leopizzi, M; Musacchio, L; Palaia, I; Pecorella, I; Pernazza, A; Tomao, F | 1 |
| Aoe, K; Atagi, S; Ebiana, V; Fukuhara, T; Han, SR; Hida, T; Horiike, A; Horinouchi, H; Hotta, K; Katakami, N; Kishi, K; Kurata, T; Nakagawa, K; Noguchi, K; Nosaki, K; Ohira, T; Okamoto, H; Okamoto, I; Saka, H; Sakai, H; Satouchi, M; Sekine, A; Sugawara, S; Takahashi, T; Umemura, S; Yamamoto, N | 1 |
| Bastos, DA; Jardim, D; Marques Montiero, FS; Schutz, FA; Soares, A | 1 |
| Ai, Y; Ding, X; Gao, X; Ju, Y; Tian, T | 1 |
| Borg, C; Kim, S; Vernerey, D | 1 |
| de Vincenzo, R; Fagotti, A; Fanfani, F; Ferrandina, G; Gallotta, V; Gui, B; Ricci, C; Scambia, G | 1 |
| Aoki, M; Hasegawa, Y; Hatayama, Y; Ishioka, Y; Itoga, M; Makiguchi, T; Okumura, F; Shiratori, T; Tabe, C; Taima, K; Tanaka, H; Tasaka, S; Yokouchi, J | 1 |
| de Carvalho Fraga, CA; de Souza, MG; Farias, LC; Guimarães, ALS; Guimarães, TA; Jones, KM; Xavier, GM | 1 |
| Chen, G; Chen, K; Cui, J; Dong, X; Fan, Y; Fang, L; Gu, K; Guo, Q; He, J; Hu, C; Hu, X; Jiang, D; Jiang, L; Jiang, T; Li, J; Li, Y; Liang, D; Liu, J; Pan, Y; Peng, M; Ren, S; Shi, Q; Song, Y; Tan, W; Wang, G; Wang, H; Wang, Z; Wu, L; Wu, X; Xie, W; Xiong, J; Yang, N; Yao, W; Yi, T; Yu, G; Yue, L; Zang, A; Zhang, G; Zhang, H; Zhang, X; Zhao, G; Zhao, W; Zhao, Y; Zhou, C | 1 |
| Bidard, FC; Borg, C; Cabel, L; Kim, S; Spehner, L | 1 |
| Feng, G; Hu, C; Hu, Y; Leaw, SJ; Liang, L; Lin, X; Lu, S; Sun, Y; Wang, J; Wang, Z; Wu, J; Yang, K; Yang, N; Ying, K; Yu, X; Yu, Y; Zhang, J; Zhao, J; Zhou, J; Zhuang, W | 1 |
| Cooper, L; De León, LE; Dezube, AR; Dumontier, C; Enzinger, P; Frain, LN; Jaklitsch, MT; Kucukak, S; Mamon, H; Mazzola, E; Wee, JO | 1 |
| Havelund, BM; Kronborg, CS; Serup-Hansen, E; Spindler, KG; Storm, KS; Truelsen, CG | 1 |
| Cao, C; Chen, G; Cui, Z; Du, X; Gong, D; Hu, Z; Huang, L; Huang, X; Jin, P; Li, R; Li, T; Li, X; Liu, J; Liu, T; Luo, B; Pan, G; Shi, C; Tian, R; Tian, X; Wang, X; Wu, J; Xia, M; Xie, Y; Zeng, Z; Zhang, H; Zhang, M; Zhang, Q | 1 |
| Bharadwaj, R; Medhi, S | 1 |
| Guo, M; Zhou, Q; Zou, D | 1 |
| Imaizumi, S; Iwaki, S; Iwasaki, S; Kawakita, D; Masaki, A; Matoba, T; Matsumura, A; Minohara, K; Murase, T; Murashima, A; Ogawa, M; Oguri, K; Sawabe, M; Takano, G; Tanaka, N; Tsuge, H | 1 |
| Abe, T; Aoshika, T; Hirai, R; Igari, M; Iino, M; Kagamu, H; Kaira, K; Kato, S; Kumazaki, Y; Miura, Y; Noda, SE; Ohta, T; Ryuno, Y; Saito, S | 1 |
| Bell, K; Cardozo, S; Elmograbi, A; Micho Ulbeh, T; Sara, A; Uddin, MM | 1 |
| Liu, S; Pan, Y; Wang, C; Wang, M; Yue, D; Zhang, Y; Zhang, Z; Zhu, J | 1 |
| Chen, Y; Fang, Y; Ji, L; Jiang, N; Shi, J; Sun, H | 1 |
| Ansell, P; Bach, BA; Bar, J; Bentsion, D; Bernabe, R; Byers, LA; Clingan, P; Dunbar, M; Glasgow, J; Govindan, R; Guclu, SZ; He, L; Huang, X; Mazieres, J; Novello, S; Ramalingam, SS; Sehgal, V; Syrigos, K; Szilasi, M; Vokes, EE; Zvirbule, Z | 1 |
| Barsotti, C; Cosio, S; Fabrini, MG; Fanucchi, A; Gadducci, A; Laliscia, C; Tana, R | 1 |
| Chen, X; Lan, L; Liu, Y; Lu, B; Lu, Y; Mo, S; Wei, W; Wu, X; Zhang, F; Zhang, X | 1 |
| Chao, GY; Depenbrock, H; Khalil, M; Kim, JH; Luft, A; Mayo, C; Natale, R; Obasaju, C; Ramlau, R; Spigel, DR | 1 |
| Abemayor, E; Chen, AM; Choi, J; Juarez, JE; St John, M; TenNapel, M | 1 |
| Fiocco, M; Grootenboers, DA; Marijnen, CA; Neelis, KJ; Peters, FP; Slingerland, M; van Ruler, MA; Vulink, AJ | 1 |
| Fang, M; Jia, Y; Li, J; Liang, X; Luo, L; Lv, S; Song, T; Xu, H | 1 |
| Deng, W; Liu, J; Yue, J; Zhang, W; Zhang, Y | 1 |
| Bahadir, A; Erduran, E; Reis, GP; Sarihan, H; Yöney, A | 1 |
| Bueno, R; Catalano, PJ; Enzinger, PC; Hong, TS; King, BL; Mamon, HJ; Martin, NE; Sanford, NN; Wo, JY | 1 |
| Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y | 1 |
| Chen, Z; Gao, J; Lai, Y; Li, Q; Li, Z; Liu, Z; Shen, L; Wang, J; Yuan, J | 1 |
| Bournakis, E; Dimopoulos, MA; Gazouli, M; Karageorgopoulou, S; Kostakis, ID; Markaki, S; Papadimitriou, CA; Papadimitriou, M | 1 |
| Chen, T; Jing, Z; Wu, S; Zhang, X | 1 |
| Anker, CJ; Chakravarthy, AB; Crane, CH; Dicker, AP; Dubey, A; Giguere, J; Greenberger, JS; Horiba, N; Ilson, D; Kachnic, L; Konski, A; Pollock, J; Raben, A; Roof, K; Safran, H; Suntharalingam, M; Thakrar, H; Videtic, G; Winter, K | 1 |
| Aleman, BMP; Grootscholten, C; Sikorska, K; Snaebjornsson, P; van der Kaaij, RT; van Dieren, JM; van Sandick, JW; van Werkhoven, E; Voncken, FEM | 1 |
| Brunette, LL; Ciccone, MA; Machida, H; Matsuo, K; Moeini, A; Mostofizadeh, S; Roman, LD; Takiuchi, T | 1 |
| Hou, X; Hu, K; Lian, X; Liu, Z; Meng, Q; Qiu, J; Shen, J; Sun, S; Wang, D; Wang, W; Yan, J; Zhang, F; Zhao, M | 1 |
| Adkins, D; Daly, M; Gay, HA; Jackson, R; Ley, J; Nussenbaum, B; Oppelt, P; Paniello, RC; Pipkorn, P; Rich, J; Thorstad, W; Trinkaus, K; Wildes, TM | 1 |
| Anker, CJ; Francis, SR; Lloyd, S; Orton, A; Stoddard, G; Thorpe, C | 1 |
| Altan, B; Asao, T; Azuma, Y; Bai, T; Bao, P; Iijima, M; Kaira, K; Kawabata-Iwakawa, R; Kuwano, H; Mogi, A; Nagashima, T; Nakazawa, S; Nishiyama, M; Obayashi, K; Ohtaki, Y; Onozato, R; Shimizu, K; Watanabe, A; Yajima, T; Yokobori, T | 1 |
| Fukushima, H; Kawabata, K; Marshall, S; Mitani, H; Nakano, K; Sasaki, T; Sato, Y; Shimbashi, W; Taira, S; Takahashi, S; Tomomatsu, J; Yonekawa, H | 1 |
| Fan, HN; Jiang, QK; Liu, YD; Lu, HL; Qian, Y; Wang, Y; Yang, LY; Zhu, XJ | 1 |
| Airoldi, M; Bossi, P; Caldara, A; Caponigro, F; Denaro, N; Ferrari, D; Ferrau, F; Hollander, L; Licitra, L; Lo Vullo, S; Locati, LD; Miceli, R; Moretti, G; Moro, C; Nolè, F; Rinaldi, G; Sponghini, A; Tettamanzi, F; Vaccher, E; Vecchio, S | 1 |
| Baxi, SS; Dunn, LA; Fury, MG; Haque, S; Ho, AL; Katabi, N; Korte, S; Pfister, C; Pfister, DG; Sherman, EJ; Xiao, H | 1 |
| Dunn, LA; Fury, MG; Haque, SS; Ho, AA; Katabi, N; Pfister, DG; Sherman, EJ | 1 |
| Hayashi, K; Higashi, M; Hodatsu, A; Kawashiri, MA; Mori, M; Ohira, M; Tada, H; Uchiyama, K | 1 |
| Fan, H; Li, J; Lu, P; Qin, Y; Xu, L | 1 |
| Bonenkamp, JJ; Cuesta, MA; Hulshof, MCCM; Lagarde, SM; Nieuwenhuijzen, GAP; Noordman, BJ; Plukker, JTM; Shapiro, J; Spillenaar Bilgen, EJ; Sprangers, MAG; Steyerberg, EW; van Berge Henegouwen, MI; van der Gaast, A; van Lanschot, JJB; Verdam, MGE; Wijnhoven, BPL | 1 |
| Carvalho, AL; Cordeiro, FB; da Silva, IDCG; de Souza Viana, L; Laus, AC; Lo Turco, EG | 1 |
| Huo, J; Li, L; Liu, W; Qin, T; Shi, X; Wang, C; Yang, D; Zhang, X; Zhang, Y; Zhou, K | 1 |
| Bartscht, T; Hakim, SG; Idel, C; Rades, D | 1 |
| Bou-Gharios, G; Hira-Miyazawa, M; Hirai, M; Kawashiri, S; Kitahara, H; Kobayashi, Y; Nakamura, H | 1 |
| Badwe, R; Engineer, R; Gaikar, M; Gawade, R; Ghosh, J; Gulia, S; Gupta, S; Hawaldar, R; Kembhavi, Y; Kerkar, R; Kumar, N; Mahantshetty, U; Maheshwari, A; Menon, S; Parab, P; Sastri Chopra, S; Shrivastava, S; Shylasree, TS; Thakur, M; Tongaonkar, H | 1 |
| Amano, H; Fujita, T; Hayama, N; Hirano, S; Hiroishi, T; Nakamura, M; Nakamura, S; Shikano, K; Tabeta, H; Yanagisawa, A | 1 |
| Goense, L; Haj Mohammad, N; Meijer, GJ; Mook, S; Ruurda, JP; van Hillegersberg, R; van Rossum, PSN; Verhoeven, RHA; Visser, E | 1 |
| Chen, T; Dong, X; Li, Y; Ma, H; Meng, X; Qi, D; Su, J; Wang, W; Yang, L; Zhang, X | 1 |
| Agócs, L; Döme, B; Fábián, K; Fillinger, J; Kajdácsi, Z; Moldvay, J; Pipek, O; Reiniger, L; Rojkó, L; Szállási, Z; Téglási, V; Tímár, J; Vágvölgyi, A | 1 |
| Rao, S; Sclafani, F | 1 |
| Autorino, R; Cosentino, F; Ferrandina, G; Gallotta, V; Gambacorta, MA; Gui, B; Macchia, G; Mattoli, MV; Palluzzi, E; Ronzino, G; Scambia, G; Turco, LC; Valentini, V | 1 |
| Alan, O; Ercelep, O; Hasanov, R; Kaya, H; Mutis, A; Ones, T; Simsek, ET; Telli, TA; Yumuk, PF | 1 |
| Doosti-Irani, A; Haddad, P; Holakouie-Naieni, K; Mansournia, MA; Rahimi-Foroushani, A | 1 |
| Chikazawa, K; Konno, R; Netsu, S | 1 |
| Botteman, M; Hirsh, V; Langer, C; Lin, FJ; Margunato-Debay, S; Ong, TJ; Wan, Y | 1 |
| Attencourt, C; Chatelain, D; Fumery, M; Le Mouel, JP; Trédez, E | 1 |
| Chen, G; Du, X; Sheng, L | 1 |
| Bae, DS; Choi, CH; Choi, HJ; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Paik, ES | 1 |
| Cheng, JD; Chirovsky, D; Lala, M; Mayawala, K | 1 |
| Cavaliere, AF; Cefalo, MG; De Vincenzo, R; Fagotti, A; Ricci, C; Scambia, G; Tortorella, L; Zannoni, GF | 1 |
| Hasegawa, Y; Isogaki, J; Kawabe, A; Koga, A; Okumura, T; Suzuki, K; Yajima, K; Yamashita, K | 1 |
| Morio, A | 1 |
| Itasaka, S; Matsuoka, T; Nakashima, T; Okumura, N; Takahashi, A; Yamanashi, K; Yokoyama, T | 1 |
| Amant, F; Annibali, D; Goffin, F; Han, S; Nooij, L; van den Bulck, H; van Rompuy, AS | 1 |
| Abbasi, AN; Ali, N; Hafiz, A; Mansha, MA; Qureshi, BM; Valimohammad, AT | 1 |
| Dai, CL; Dai, SB; Han, GH; Huang, JX; Lu, KJ; Zhang, LX | 1 |
| Aitken, K; Athauda, A; Chau, I; Cunningham, D; Mohammed, K; Rao, S; Starling, N; Tait, D; Watkins, D | 1 |
| Ambudkar, SV; Cai, CY; Chen, ZS; Gupta, P; Ji, N; Kong, D; Lei, ZN; Shukla, S; Wang, JQ; Yang, Y | 1 |
| Liang, Y; Lü, B; Lü, W; Zhang, X | 1 |
| Lv, C; Wang, J; Wu, N; Yan, S; Yang, Y | 1 |
| Diao, P; Lang, J; Li, C; Li, F; Li, T; Liu, L; Lyu, J; Wang, Q | 1 |
| Agrawal, N; Blair, EA; Brisson, RJ; Dekker, A; Foster, CC; Ginat, DT; Gooi, Z; Haraf, DJ; Karrison, TG; Kochanny, S; Lingen, MW; Melotek, JM; Portugal, L; Seiwert, TY; Villaflor, VM; Vokes, EE | 1 |
| Fukuda, Y; Harada, T; Koga, S; Mukae, H; Ogawara, D; Okuno, D; Soda, H; Taniguchi, H; Tomono, H; Umemura, A; Yamaguchi, H; Yoshida, M | 1 |
| Chang, JY; Chang, KY; Chen, CC; Chiu, CF; Chu, CY; Hsieh, CY; Tsai, KY; Tsai, ST; Tsao, CJ; Tsou, HH; Yen, CJ | 1 |
| Chen, J; Han, C; Jiao, S; Kong, W; Liu, T; Song, D; Zhang, T | 1 |
| Hirashima, T; Kijima, T; Koba, T; Komuta, K; Minami, S; Mori, M; Morimura, O; Niki, M; Shiroyama, T; Sugimoto, H; Torii, Y; Yokoi, T | 1 |
| Ben, XS; Chen, GY; Chen, HJ; Cheng, Y; Huang, C; Jiang, BY; Song, Y; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhou, Q | 1 |
| Bakhski, S; Gupta, B; Kashyap, S; Meel, R; Sharma, S; Surve, A | 1 |
| Akiyama, N; Asada, K; Enomoto, N; Fujii, M; Fujisawa, T; Furuhashi, K; Hozumi, H; Inami, N; Inui, N; Kaida, Y; Karayama, M; Matsuda, H; Matsui, T; Matsuura, S; Nakamura, Y; Suda, T; Suzuki, Y; Toyoshima, M; Uto, T; Yasui, H | 1 |
| Chen, Y; Fan, M; Jia, H; Li, J; Li, L; Li, Y; Lin, Q; Lu, S; Tang, H; Wu, C; Xia, Y; Ye, J; Zhang, Z; Zhao, K; Zhao, W; Zhou, J; Zhu, Z | 1 |
| Barker, CA; Cohen, MA; Cracchiolo, JR; Dunn, LA; Ganly, I; Katabi, N; Lee, A; Lee, N; Mah, D; McBride, S; McGill, M; Mimica, X; Sine, K; Yu, Y | 1 |
| Chen, Q; Chen, Y; He, Z; Kan, Q; Li, Z; Luo, C; Sun, B; Sun, J; Sun, M; Wang, C; Wang, Y; Yu, H; Zhang, H; Zhang, X; Zhao, H | 1 |
| Asakij, T; Atjimakul, T; Chomprasert, K; Chottetanaprasith, T; Hanprasertpong, J; Isaranuwatchai, W; Janweerachai, W; Katanyoo, K; Khunnarong, J; Kridakara, A; Lertsanguansinchai, P; Lorvidhaya, V; Paengchit, K; Pariyawateekul, P; Penpattanagul, S; Rongsriyam, K; Sangthawan, D; Srisomboon, J; Sukhaboon, J; Supawattanabodee, B; Tangjitgamol, S; Tanprasert, P; Tharavichitkul, E; Tovanabutra, C; Wanglikitkoon, S | 1 |
| Guo, Y; Li, R; Yan, H; Zhang, Y; Zheng, R | 1 |
| Cho, Y; Kim, YD; Lee, JH; Park, HR; Song, JM; Woo, BH; Yoon, S | 1 |
| Ding, WW; Mao, BD; Meng, QZ; Xu, P; Zhong, Y | 1 |
| Levy, BP; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Xiang, CQ; Yang, H | 1 |
| Akamine, M; Ishikawa, M; Kawakami, M; Maeshiro, K; Miyagi, J; Nagamine, S; Nagayoshi, S; Naha, Y; Nakazato, H; Ohmine, Y; Sasaki, H; Tomiyama, T; Tomori, T; Toume, R; Uchihara, T; Yoshino, Y | 1 |
| Aoe, M; Date, H; Hotta, K; Morita, S; Nakamura, H; Nakata, M; Okumura, N; Sakamoto, J; Soh, J; Toyooka, S; Yamashita, M | 1 |
| Zhao, K | 1 |
| Adenis, A; Conroy, T; Crehange, G | 1 |
| de Castria, TB; Fujiki, FK; Hoff, PMG; Takeda, FR; Victor, CR | 1 |
| Gebhardt, BJ; Kirwan, J; McAfee, WJ; Mendenhall, CM; Mendenhall, WM; Morris, CG | 1 |
| Dyckhoff, G; Haefeli, WE; Herold-Mende, C; Reuter, T; Rigalli, JP; Theile, D; Weiss, J | 1 |
| Burgetova, A; Cibula, D; Dundr, P; Dusek, L; Fischerova, D; Pinkavova, I; Slama, J; Svarovsky, J; Zikan, M | 1 |
| Fang, J; Li, S; Lv, C; Ma, Y; Sun, Y; Wu, N; Yan, S; Yang, Y; Zheng, Q | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Gong, Y; Liu, Y; Peng, F; Sun, L; Tu, L; Wang, Y; Wei, Y; Xu, Y; Zhou, L; Zhu, J | 1 |
| Alves, FV; de Melo, AC; do Carmo, CC; Fernandes, AC; Garces, ÁH; Grazziotin, R; Mora, PA; Nogueira-Rodrigues, A | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Bal, A; Behera, D; Goyal, A; Singh, N | 1 |
| Bellile, E; Bradford, CR; Byrd, S; Carey, TE; Chepeha, DB; Cordell, KG; Dobrosotskaya, IY; Eisbruch, A; Feng, F; Kumar, B; Maxwell, JH; McHugh, JB; Moyer, JS; Prince, ME; Spector, ME; Teknos, T; Urba, S; Walline, HM; Ward, PD; Wolf, GT; Worden, FP | 1 |
| Almhanna, K; Chuong, MD; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Weber, JM | 1 |
| Kang, SB; Kim, JH; Kim, KT; Kim, SM; Kim, YM; Kim, YT; Lee, JM; Lee, TS; Park, BJ | 1 |
| Alcaraz, D; Caballero, M; Feliz, L; Grau, JJ; Muñoz-García, C; Pereira, V; Sosa, AE | 1 |
| Feeney, A; Fernando, I; Hackshaw, A; Hall-Craggs, MA; Hammond, M; James, L; Kadalayil, L; Ledermann, JA; McCormack, M; Simonds, H; Symonds, RP; Warwick, V | 1 |
| Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
| Fu, JH; Gao, Z; Ren, CC; Shi, YG | 1 |
| Huang, XE; Qian, YD; Wang, L; Xiang, J; Xu, HQ; Xu, X | 1 |
| Dellian, M; Dunau, C; Gellrich, D; Jäger, L; Michaelis, U; Strieth, S; Wollenberg, B | 1 |
| Chen, J; Chen, M; Li, J; Liao, Z; Liu, J; Pan, J; Zheng, X; Zhu, K | 1 |
| Barringer, DA; Garden, AS; Holsinger, FC; Hutcheson, KA; Kies, MS; Lewin, JS; Lin, HY; Lisec, A; Papadimitrakopoulou, V; Steinhaus, G; Villalobos, S | 1 |
| Isohashi, F; Ito, K; Kimura, T; Mabuchi, S; Ogata, T; Ogawa, K; Takahashi, R; Tsutui, T; Yokoi, T; Yoshioka, Y | 1 |
| Beukema, JC; Burgerhof, JG; Güler, S; Hospers, GA; Mul, VE; Plukker, JT; Smit, JK | 1 |
| Lee, DW; Lee, HN; Lee, JW; Lee, KH; Park, JS; Park, ST | 1 |
| Zhang, H; Zhang, WH; Zhu, YL | 1 |
| Guo, LB; Li, YM; Liu, HM; Ma, JY; Wang, C | 1 |
| Siesto, G; Vitobello, D | 1 |
| Chen, WW; Cheng, AL; Hsu, CH; Huang, TC; Lin, CC; Yeh, KH | 1 |
| Baba, T; Konishi, I; Mandai, M; Matsumura, N; Mikami, Y; Takamatsu, S | 1 |
| Bowlin, GL; Bulysheva, AA; Petrova, SP; Yeudall, WA | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Ozdemir, O; Ozdemir, P; Ozhan, MH; Uluer, H; Veral, A | 1 |
| Khemapech, N; Oranratanaphan, S | 1 |
| Huang, XE; Shen, K; Yan, HA | 1 |
| Biermann, K; Shapiro, J; ten Kate, FJ; van Hagen, P; van Lanschot, JJ; Wijnhoven, BP | 1 |
| Beukema, JC; Bosch, DJ; Burgerhof, JG; Hospers, GA; Muijs, CT; Mul, VE; Plukker, JT | 1 |
| Chen, J; Fan, PS; He, YF; Hu, B; Hu, CL; Ji, CS; Jiang, FS; Wang, W; Yao, YW; Zhu, L | 1 |
| Harada, T; Imanaga, T; Inoue, K; Kawasaki, M; Kuba, M; Matsumoto, T; Nakanishi, Y; Oshima, T; Shioyama, Y; Takayama, K; Takeshita, M; Tokunaga, S | 1 |
| Clark, JI; Kucuk, O; Malhotra, B; Moon, J; Urba, SG; Wolf, GT; Worden, FP | 1 |
| Kim, SM; Lee, HH; Lee, KB; Li, XJ; Park, MH; Ye, S | 1 |
| Chen, Y; Cheng, K; Ge, J; Gou, HF; He, JP; Liu, JY; Men, HT; Qiu, M | 1 |
| Feng, ZY; Liao, QP; Liu, TY; Ma, K; Wen, HW; Yang, X; Yang, YH | 1 |
| Crawford, J; Freeman, DJ; Johnson, CW; Johnson, D; Krishnan, K; Prager, D; Sandler, A; Schwarzenberger, P; Swanson, P; Zhang, K | 1 |
| Beukema, J; Hospers, G; Karrenbeld, A; Kluin, P; Langendijk, J; Muijs, C; Mul, V; Plukker, J; Smit, J; van Dam, G | 1 |
| Beukema, JC; Hulshof, MC; Oppedijk, V; Reinders, JG; Richel, DJ; Rütten, H; Spruit, PH; van Berge Henegouwen, MI; van der Gaast, A; van der Sangen, MJ; van Hagen, P; van Lanschot, JJ; van Os, R; van Rij, CM | 1 |
| Dyckhoff, G; Gal, Z; Grabe, N; Herold-Mende, C; Lahrmann, B; Rigalli, JP; Theile, D; Warta, R; Weiss, J | 1 |
| Chambers, CJ; Liu, H; Sharon, VR; White, CR; White, KP | 1 |
| Dong, JR; Feng, HH; Guo, N; Li, Y; Liu, PD; Zhao, JP | 1 |
| Hulshoff, JB; Plukker, JT; Smit, JK; van der Jagt, EJ | 1 |
| Dutta, PR; Fury, MG; Gelblum, DY; Haque, S; Katabi, N; Kurz, S; Lee, JL; Lee, NY; Mueller, B; Ng, KK; Pfister, DG; Rao, SS; Shen, R; Sherman, EJ; Smith-Marrone, S; Wolden, S | 1 |
| Armes, SP; Avila-Olias, M; Battaglia, G; Canton, I; Cecchin, D; Colley, HE; Hearnden, V; Hu, K; MacNeil, S; Madsen, J; McKeating, JA; Murdoch, C; Thornhill, MH; Warren, N | 1 |
| Jakobsen, JN; Santoni-Rugiu, E; Sørensen, JB | 1 |
| Cai, L; Li, CH; Li, DD; Liu, MY; Liu, W | 1 |
| Chen, J; Feng, Y; Liu, Y; Shao, N; Wang, Y; Zhang, L | 1 |
| Corrado, G; Cutillo, G; Maggioni, A; Mancini, E; Tomaselli, T; Vizza, E; Zanagnolo, V | 1 |
| Castaneda, L; Chang, DT; Cheng, JC; Graber, MS; Hsu, FM; Koong, AC; Lee, JM; Tsai, CL | 1 |
| Baxley, A; Khawandanah, M; Pant, S | 1 |
| Deng, W; Guan, Z; Huang, M; Huang, W; Jiang, W; Kang, T; Li, L; Li, S; Liu, Q; Liu, R; Pan, C; Tan, W; Thomas, GR; Wu, J; Ye, W; Ying, X; Zeng, M; Zhang, L | 1 |
| Burtness, BA; Forastiere, AA; Kosmidis, EK; Lee, JW; Pectasides, E; Psyrri, A; Rimm, DL; Vassilakopoulou, M; Wanebo, HJ | 1 |
| Cheng, Y; Cun, Y; Li, M; Li, Z; Peng, Y; Qian, C; Ren, T; Wang, D; Xia, L; Xiong, Y; Zhang, S | 1 |
| An, SM; Badakhshi, H; Chen, Y; Deng, JY; Guo, XM; Jiang, GL; Ma, HF; Tang, HR; Zhang, JH; Zhang, Z; Zhao, KL | 1 |
| Chen, Y; Chen, Z; Ma, C; Ma, L; Zhang, W | 1 |
| Batus, M; Bonomi, P; Dandekar, VK; Fidler, MJ; Kiel, K; Sher, DJ; Young, J | 1 |
| Chen, J; Chen, M; Li, J; Lin, Y; Liu, J; Pan, C; Pan, J; Zhu, K | 1 |
| Chen, X; Hou, Y; Li, C; Li, H; Li, K; Lou, G; Ning, X; Sun, F; Yin, M; Zhang, T; Zheng, J; Zhou, X | 1 |
| Ahn, HK; Cho, EK; Jeong, SH; Jung, M; Kang, SM; Kyung, SY; Park, JW; Shin, DB; Sym, SJ | 1 |
| Affara, NI; Bergsland, E; Bornstein, S; Coussens, LM; Gong, Q; Gunderson, AJ; Irving, B; Johansson, M; Kulesz-Martin, M; Li, Y; Ma, Y; Medler, TR; Ruffell, B; Steinhoff, M; Wiesen, JF; Wong, MH | 1 |
| Bayley, A; Chan, K; Chen, EX; Chin, S; Diaz-Padilla, I; Hope, A; Hossain, M; Kim, J; Loong, HH; Palma, D; Razak, AR; Read, N; Siu, LL; Waldron, J; Wang, L; Winquist, E | 1 |
| Geng, YC; Hu, YX; Li, HQ; Li, QS; Lu, B; Ma, Z; Ouyang, WW; Su, SF | 1 |
| Feng, Q; Gao, S; He, J; Huang, J; Jiang, Y; Liu, Y; Lyu, X; Mao, Y; Shao, K; Wang, J | 1 |
| Byer, J; Dinwoodie, W; Fulp, WJ; Kim, R; Mahipal, A; Shibata, D | 1 |
| Cai, MY; He, LR; Huang, H; Huang, XX; Kung, HF; Li, CP; Liao, YJ; Mai, SJ; Qian, D; Tian, XP; Xie, D; Zeng, YX | 1 |
| Chandrasekaran, R; Mohan, S; Thiagarajan, K | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Barthet, M; Gonzalez, JM; Vanbiervliet, G | 1 |
| Blackhall, F; Hei, YJ; McCoy, S; Novello, S; Scagliotti, GV; Schneider, CP; Spigel, DR; Sydorenko, O; Volovat, C; Vynnychenko, I | 1 |
| Bergman, JJ; Hulshof, MC; Kapiteijn, E; Klinkenbijl, JH; Kordes, S; Meijer, SL; Richel, DJ; van Berge Henegouwen, MI; van der Vliet, HJ; van Laarhoven, HW; Wilmink, JW | 1 |
| Blatt, R; Cahal, S; Giladi, M; Itzhaki, A; Kirson, ED; Munster, M; Onn, A; Palti, Y; Porat, Y; Schneiderman, RS; Voloshin, T; Weinberg, U | 1 |
| Du, J; Hu, B; Hu, C; Wang, F; Zhang, Y | 1 |
| Fang, Y; Shi, MQ; Wang, L; Xia, GH | 1 |
| Ferdous, T; Harada, K; Kobayashi, H; Ueyama, Y | 1 |
| Chen, GY; Cheng, Y; Huang, C; Song, Y; Wu, YL; Yan, HH; Yang, JJ; Zhou, Q | 1 |
| Simon, GR | 1 |
| Bellile, E; Bradford, CR; Carey, T; Chanowski, EJ; Chepeha, DB; Chinn, SB; Eisbruch, A; Gallagher, KK; Ibrahim, M; McHugh, JB; Moyer, JS; Prince, ME; Spector, ME; Vainshtein, J; Walline, HM; Wolf, GT; Worden, FP | 1 |
| Chen, H; Cheng, L; Huang, JM; Tao, L; Tian, J; Xin, Y; Zhou, L | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y | 1 |
| Chen, G; Peng, J; Song, Y; Tao, G; Wang, W; Zhou, X; Zhu, W | 1 |
| Cracchiolo, BM; DiPaola, RS; Gibbon, DG; Hellmann, M; Nieves-Neira, W; Rodriguez-Rodriguez, L; Shih, WJ; Song, M; Vaidya, A; Wagreich, AR | 1 |
| Chang, TC; Chao, A; Chen, MY; Chou, HH; Hsueh, S; Huang, HJ; Lai, CH; Lin, G; Lin, H; Liou, JD; Liou, YL; Liu, FY; Yang, LY | 1 |
| Chang, GJ; Crane, CH; Das, P; Eng, C; Ohinata, A; Pathak, P; Phillips, JK; Rodriguez-Bigas, M; Rogers, JE; Sethi, S; Vauthey, JN; Wolff, RA; Xing, Y; You, YN | 1 |
| Du, K; Gong, HY; Gong, ZM | 1 |
| Han, N; Li, G; Liu, Z; Yin, J; Zhou, C; Zhou, J | 1 |
| Fan, Q; Shi, Y; Wang, X; Zhang, X; Zheng, Y | 1 |
| Colbert, PL; Lee, JH; Vermeer, DW; Vermeer, PD; Wieking, BG | 1 |
| Kamei, T; Miwa, I; Nakamura, Y; Sakamoto, Y; Shinagawa, M | 1 |
| Atanaskova Mesinkovska, N; Conic, RZ; Kiracofe, EA; Vidimos, AT | 1 |
| Arai, D; Betsuyaku, T; Ikemura, S; Ishioka, K; Kawada, I; Kuroda, A; Nakachi, I; Nakamura, M; Nakatani, M; Nakayama, S; Naoki, K; Nishino, M; Ohgino, K; Sato, T; Satomi, R; Soejima, K; Tani, T; Terai, H; Watanabe, H; Yasuda, H; Yoda, S | 1 |
| Feng, W; Liuxing, W; Qingxia, F; Ran, Z; Xiangke, L; Xiaoyan, X; Xuan, Y; Zichang, Y | 1 |
| Beitler, J; Blumenschein, G; Bogart, J; Bradley, JD; Choy, H; Curran, W; Forster, K; Garces, YI; Gaur, R; Hu, C; Iyengar, P; Kavadi, V; Komaki, R; Koprowski, C; Magliocco, A; Masters, G; Meng, J; Narayan, S; Paulus, R; Robinson, C; Schild, S; Wynn, RB | 1 |
| Adkins, DR; Diaz, J; Gay, H; Lewis, J; Ley, J; Michel, L; Nussenbaum, B; Paniello, RC; Rich, J; Schell, A; Thorstad, W; Trinkaus, K; Wildes, TM; Wu, N | 1 |
| Kadalayil, L; KhoshZaban, M; Kuku, S; Ledermann, J; Loddo, M; McCormack, M; Proctor, I | 1 |
| Amani, M; Broucek, M; Monga, V; Ramaswamy, S | 1 |
| Du, XL; Li, HQ; Lu, CH; Pan, CX; Sheng, XG; Wang, C; Yin, YJ | 1 |
| Arakawa, H; Deguchi, T; Horie, K; Kato, H; Kubota, Y; Matsuoka, K; Nagai, S; Nakano, M | 1 |
| Liu, D; Qian, J; Su, B; Xu, W; Zhang, J; Zhang, ZW; Zheng, H | 1 |
| Banna, GL; D'Agate, G; Gieri, S; Lipari, H; Scandurra, G; Scibilia, G; Scollo, P | 1 |
| Lu, WB; Ni, XC; Sun, SP; Sun, ZQ; Wang, J; Wang, JL; Yu, JP | 1 |
| Arnold, SM; Brill, Y; Dressler, EV; Gleason, JF; Kudrimoti, M; Silver, NL; Valentino, J | 1 |
| Ageshio, F; Kagawa, H; Kimura, H; Matsui, H; Mori, M; Niinaka, M; Satomi, A; Uenami, T; Yamaguchi, T; Yano, Y; Yokota, S; Yoneda, T | 1 |
| Ehling, J; Fens, MH; Hennink, WE; Lammers, T; Oude Blenke, E; Pieters, EH; Schiffelers, RM; Shi, Y; Storm, G; Theek, B; van der Meel, R; van Nostrum, CF | 1 |
| Li, QL; Qiu, MQ; Wang, T; Yang, JS | 1 |
| Ding, W; Li, J; Li, Y; Wang, X | 1 |
| Hurkmans, CW; Koëter, M; Luyer, MD; Nieuwenhuijzen, GA; Rutten, HJ; van der Sangen, MJ | 1 |
| Abdulaal, Y; Gooneratne, AT; Gupta, J; James, AO | 1 |
| Chen, KN; Chen, Y; Fan, MY; Li, XT; Liang, Z; Sun, Y; Sun, YS; Wang, ZL; Wu, Y; Xiong, HC; Yan, WP; Zhang, XY | 1 |
| Akhtar, J; Wang, S; Wang, Z | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Ali-El-Dein, B; Babjuk, M; Burger, M; Chang, SS; Clayman, RH; Daneshmand, S; Efstathiou, JA; Fritsche, HM; Gakis, G; Galland, S; Hrbacek, J; Keegan, KA; Mischinger, J; Morgan, TM; Olugbade, K; Rink, M; Schubert, T; Stenzl, A; Thalmann, GN; Todenhöfer, T; Zaid, HB | 1 |
| Das, S; Isiah, R; KantiPal, S; Oommen, R; Rami Reddy, JK; Subhashini, J | 1 |
| Huang, CB; Huang, LL; Lin, SJ; Pan, JJ; Qiu, SF; Xu, YJ; Zheng, W; Zong, JF | 1 |
| Andrade Dos Anjos Jacome, A; Arthur Jacinto, A; Boldrini Junior, D; Calheiros Campelo Maia, D; de Aguiar Silva, FC; de Castro Capuzzo, R; de Souza Viana, L; Duarte de Mattos, M; Elias Mamere, A; Lopes Carvalho, A; Roberto Santos, C | 1 |
| Deng, J; Deng, JH; Niu, PG; Ouyang, XN; Shi, DH | 1 |
| Dolan, JP; Elliott, DA; Holland, JM; Hunter, JG; Maggiore, RJ; Mitin, T; Nabavizadeh, N; Schipper, PH; Shukla, R; Thomas, CR; Vaccaro, GM | 1 |
| Leunen, K; Moerman, P; Neven, P; Salihi, R; Van Limbergen, E; Vergote, I | 1 |
| Berbée, M; Buijsen, J; Houben, R; Janssen, L; Lambin, P; Larue, R; Schraepen, MC; Sosef, M; Van De Voorde, L; Vanneste, B | 1 |
| Chen, S; Chen, X; Ding, Y; Li, Y; Mo, K; Mo, X; Yang, S; Zhang, F | 1 |
| Che, J; Cheng, R; Giroux-Leprieur, E; Hao, X; He, B; Jablons, DM; Jin, JQ; Li, H; Luh, TW; Mo, M; Tolani, B; Tseng, HH; Wang, C; Woodard, GA; Yang, C; Yang, Y; Yue, D; Zhang, H; Zhang, Y; Zheng, Q | 1 |
| Conte, P; Corradini, P; Dominici, M; Fontana, A; Frassoldati, A; Maiorana, A; Maur, M; Toss, A | 1 |
| Bhasker, S; Biswas, A; Gandhi, AK; Mohanti, BK; Raza, MW; Roy, S; Saxena, T; Sharma, A; Thakar, A | 1 |
| Biagioli, E; Bonazzi, C; Buda, A; Chiari, S; Dell'Anna, T; Floriani, I; Gerardi, C; Lissoni, AA; Locatelli, L; Mangioni, C; Milani, R; Signorelli, M | 1 |
| Chen, HX; Wang, Z | 1 |
| Hsu, CH; Huang, TC; Lin, CC; Tu, YK | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kamide, Y; Koga, Y; Kuwako, T; Masuda, T; Ono, A; Sunaga, N; Yamada, M | 1 |
| Dai, Z; Kang, H; Min, W; Ren, H; Sui, X; Wang, XJ; Zhang, Y; Zhao, Y | 1 |
| Ban, X; Guan, XY; Li, L; Li, XD; Li, Y; Xie, D; Yang, H; Yun, J; Zeng, TT; Zhang, BZ; Zhou, Y | 1 |
| Hao, YZ; Lan, WG; Ma, LB; Wang, P; Xu, DH; Zhou, YL | 1 |
| Anderegg, MC; Gisbertz, SS; Hulshof, MC; Lagarde, SM; Meijer, SL; Spierings, LE; van Berge Henegouwen, MI; van Laarhoven, HW; van Oijen, MG; Wilmink, JW | 1 |
| Karam, A; Kong, CS; O'Keefe, MC; Westhoff, GL; Wheeler, L | 1 |
| Ando, N; Harada, K; Inozume, T; Kawamura, T; Matsuzawa, M; Onuma, T; Sano, S; Shimada, S | 1 |
| Banno, E; Kanno, N; Kino, S; Nagai, Y; Nishino, A; Tahara, H; Yasuda, M | 1 |
| Banu, H; Hamal, S; Jiao, S; Li, H; Li, X; Wang, X | 1 |
| Aloisi, A; Angioli, R; Capriglione, S; Fiore, L; Luvero, D; Montera, R; Panici, PB; Plotti, F; Scaletta, G; Terranova, C | 1 |
| Cui, Y; Gao, J; Gong, J; Jia, J; Li, J; Li, Y; Liu, C; Lu, M; Lu, Z; Shen, L; Sun, Z; Wang, X; Yu, J; Zhang, X; Zhou, J | 1 |
| Maushagen, R; Pries, R; Wollenberg, B | 1 |
| Im, YH; Kim, M; Kim, S; Lee, J; Lee, SJ; Park, SH; Park, YH | 1 |
| Bi, Y; Chen, X; Chen, Y; Cheng, C; Cheng, X; Cui, H; Cui, Y; Guo, J; Guo, S; Hu, X; Jia, J; Jia, Z; Kong, P; Li, G; Li, H; Li, Q; Li, Y; Liang, J; Liu, H; Liu, J; Qian, Y; Shi, R; Song, B; Wang, C; Wang, F; Wang, J; Wang, T; Xi, Y; Xu, E; Yan, T; Yang, B; Yang, J; Zhan, Q; Zhang, L; Zhang, Y; Zhao, Z; Zhou, Y | 1 |
| Chen, D; Duan, C; Huang, C; Lai, L; Wang, L; Yang, X | 1 |
| Higo, M; Kasama, H; Kasamatsu, A; Koyama, T; Miyamoto, I; Nakashima, D; Ogawara, K; Okamoto, A; Shiiba, M; Tanzawa, H; Uzawa, K; Yokoe, H | 1 |
| Azuma, Y; Hirashima, T; Kawase, I; Morishita, N; Okamoto, N; Osa, A; Shiroyama, T; Suzuki, H; Takeoka, S; Tamiya, M | 1 |
| Chen, Y; Cheng, K; Du, Y; Gou, HF; Li, C; Liu, JY; Wu, J; Xu, F; Yang, Y; Yuan, L | 1 |
| An, G; Ma, Y; Wang, J; Wang, Q; Xu, F; Yang, L | 1 |
| Chen, KN; Dong, B; Lin, Y; Shen, LY; Shi, Q; Wang, H; Yan, WP | 1 |
| Fushida, S; Harada, S; Hayashi, H; Kinoshita, J; Makino, I; Miyanaga, S; Miyashita, T; Nakagawara, H; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Tajima, H; Takamura, H; Tsukada, T | 1 |
| Cho, HJ; Kim, DK; Kim, HR; Kim, YH; Park, SI; Park, YS | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Sumi, M; Tamura, T; Yamamoto, N | 1 |
| Bonerigo, S; Chung, CH; Cmelak, A; Gilbert, J; John, P; Kang, H; Kiess, A; Marur, S; Murphy, BA; Quon, H; Rudek, MA; Tsottles, N; Veasey, A | 1 |
| Iwata, T; Nakajima, T; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I | 1 |
| Bisen, PS; Khan, AA; Khan, N; Khan, Z; Prasad, GB; Tiwari, RP | 1 |
| Kovács, G; Meyer, JE; Ritter, M; Schröder, U; Teudt, IU; Wollenberg, B | 1 |
| Gong, J; Jia, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Zhang, X; Zhou, J | 1 |
| Benepal, T; Cadranel, J; Christoph, DC; Das, M; Fennell, DA; Ferry, D; Lal, R; Maxwell, F; Summers, Y; Visseren-Grul, C | 1 |
| Audigier-Valette, C; Auliac, JB; Baize, N; Bérard, H; Bota, S; Chouaïd, C; Corre, R; Dansin, E; Daurès, JP; Decroisette, C; Descourt, R; Dujon, C; Falchero, L; Greillier, L; Lamy, R; Le Caër, H; Léna, H; Marcq, M; Massuti, B; Monnet, I; Pérol, M; Plassot, C; Vergnenègre, A | 1 |
| Qin, RQ; Wang, WP; Wen, YS; Xi, KX; Yu, XY; Zhang, LJ | 1 |
| Chen, Y; Fang, X; Gao, F; Huang, Y; Zhang, W | 1 |
| Costantini, M; Di Leone, A; Ferrucci, M; Franceschini, G; Masetti, R; Mulè, A; Sanchez, AM; Scaldaferri, A | 1 |
| Hahlbrock, A; Maushagen, R; Pfannerstill, AC; Pries, R; Rades, D; Rahmanzadeh, R; Reers, S; Stauber, R; Wollenberg, B | 1 |
| Boupaijit, K; Suprasert, P | 1 |
| Chikamatsu, S; Imai, H; Ishioka, C; Kasahara, Y; Kobayashi, A; Komine, K; Oishi, T; Okada, Y; Okita, A; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Ghosh-Laskar, S; Jambhekar, N; Joshi, A; Mahajan, A; Mehta, SA; Nakti, D; Noronha, V; Patil, PS; Patil, VM; Prabhash, K; Purandare, N; Sahu, A; Shah, S; Talole, S | 1 |
| Coraggio, G; Delishaj, D; Fabrini, MG; Gadducci, A; Laliscia, C; Morganti, R; Paiar, F; Tana, R | 1 |
| Borel, C; Ciftci, S; Debry, C; Dupret-Bories, A; Schmaltz, H; Schultz, P; Takeda-Raguin, C | 1 |
| Chen, ZG; Majumdar, D; Rahman, MA; Shin, DM | 1 |
| Qin, T; Qu, B; Ren, R; Wang, H; Wu, H; Zhen, J; Zhou, M | 1 |
| Chen, KN; Chen, Y; Li, XT; Sun, YS; Wang, ZL | 1 |
| Abdi, R; Alikhasi, A; Amouzegar-Hashemi, F; Esmati, E; Kalaghchi, B | 1 |
| Adenis, A; Clisant, S; Dahan, L; El Hajbi, F; Glehen, O; Kramar, A; Lacornerie, T; Mariette, C; Messager, M; Mirabel, X; Paumier, A; Piessen, G; Robb, WB; Tresch, E; Vasseur, F; Vendrely, V | 1 |
| Chen, Q; Fan, Y; Gong, L; Huang, Z; Jiang, Y; Lei, T; Liu, J; Mao, W; Xu, Y; Yang, H; Yu, H; Zhao, Q; Zhou, X | 1 |
| Cárdenas-Rebollo, JM; Colombo, N; Maggioni, A; Minig, L; Zanagnolo, V | 1 |
| Chen, YS; Li, K; Liu, Y; Qiao, L; Wu, XY; Xu, SN; Yuan, L | 1 |
| Gill, HS; Mody, MD; Saba, NF | 1 |
| Dang, YZ; Hu, J; Li, WW; Li, X; Ping, LJ; Shi, M; Wei, LC; Zhang, Y; Zhao, LN | 1 |
| Ahn, P; Algazy, K; Alonso-Basanta, M; Bauman, J; Chalian, AA; Cohen, RB; Desai, A; Grover, S; Kevin Teo, BK; Lin, A; Lukens, JN; Masroor, F; Mitra, N; O'Malley, BW; Sharma, S; Wan, F; Weinstein, GS | 1 |
| Guo, J; Han, X; Hu, G; Liu, L; Tang, N; Wang, Y; Wang, Z; Zhang, Q | 1 |
| Belda-Iniesta, C; Boyer, M; Braiteh, F; Cosgriff, T; Gandara, DR; Govindan, R; Hirsch, FR; Isla, D; Phan, S; Rittmeyer, A; Ueda, M; Zvirbule, Z | 1 |
| Fang, JG; Feng, L; Lian, M; Liu, HG; Ma, HZ; Meng, LZ; Shi, Q | 1 |
| Copur, MS; DeSpiegelaere, H; Ganti, AK; Huerter, MM; Kessinger, A; Ketcham, M; Kos, ME; Kruse, S; Marr, AS; Meza, JL; Radniecki, SE; Swenson, K; Tolentino, A | 1 |
| Kaido, Y; Kikuchi, A; Murakami, K; Shoji, T; Sugiyama, T; Takatori, E; Takeuchi, S | 1 |
| Kamura, T; Kitagawa, R; Konishi, I; Nishio, S; Shibata, T; Ushijima, K; Yoshikawa, H | 1 |
| Grauer, D; Henry, D; Kathol, E; Narveson, L; Neupane, P; Rockey, M | 1 |
| Han, HY; Jeong, SH; Kim, H; Kim, HJ; Kim, JH; Lee, HE; Ryu, MH | 1 |
| Adkins, D; Daly, M; Gay, HA; Jackson, R; Ley, J; Michel, L; Nussenbaum, B; Paniello, R; Rich, J; Thorstad, W; Trinkaus, K; Uppaluri, R; Wildes, TM | 1 |
| Hier, M; Kay-Rivest, E; Mascarella, MA; Mlynarek, A; Roskies, M; Sultanem, K | 1 |
| Bergmann, JJ; Geijsen, ED; Hulshof, MC; Jeene, PM; Muller, K; van Berge Henegouwen, MI; van Laarhoven, HW; Versteijne, E | 1 |
| Hakim, SG; Rades, D; Schild, SE; Seidl, D; Wollenberg, B | 1 |
| Achtari, C; Surbone, A | 1 |
| Chen, L; Chen, Y; Cheng, B; Tang, Q; Xie, M; Zhao, J; Zhou, X | 1 |
| Belani, CP; Chakraborty, BC; Khamar, BM; Modi, RI | 1 |
| Adansa Klain, JC; Berrocal, A; Caballero Daroqui, J; Cruz-Hernández, JJ; Del Barco Morillo, E; González-Rivas, C; Martínez-Galán, J; Martínez-Trufero, J; Mesía, R; Pastor Borgoñon, M; Vázquez Fernández, S; Vera, R | 1 |
| Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP | 1 |
| Baik, CS; Baker, KK; Chow, LQM; Eaton, KD; Goulart, B; Lee, SM; Martins, R; Pellini Ferreira, B; Redman, M; Rodriguez, CP; Santana-Davila, R | 1 |
| Chen, H; Dai, D; Tang, J; Tang, Y | 1 |
| Isohashi, F; Kimura, T; Kitada, F; Mabuchi, S; Maruoka, S; Ogawa, K; Okazawa, M | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Adkins, D; Daly, K; Ley, J; Oppelt, P; Wildes, TM | 1 |
| Chen, Y; Ge, F; Jia, R; Jin, Y; Lin, L; Liu, J; Liu, R; Wang, Y; Xu, J; Zhao, C | 1 |
| Adjei, AA; Garces, YA; Graham, DL; Hillman, SL; Jett, JR; McGinnis, WL; Ross, HJ; Schild, SE; Tan, AD | 1 |
| Luo, W; Zhou, L | 1 |
| Li, JF; Liu, M; Wang, XX; Zhang, J | 1 |
| Aimone, P; Alyasova, A; Barone, C; Chakravartty, A; Chol, M; Dechaphunkul, A; Erfán, J; Faivre, S; Hirawat, S; Karpenko, A; Kasper, S; Kim, SB; Kiss, LA; Li, SH; Licitra, L; Lin, JC; Mesía, R; Nagarkar, R; Ochsenreither, S; Remenár, É; Soulières, D; Tamás, L; Turri, S | 1 |
| Dou, Y; Guo, L; Ke, Y; Li, Y; Liu, H; Shi, H; Wang, C; Wang, J; Wang, R; Wang, S | 1 |
| Bogardus, C; Canfield, V; Hancock, SB; Kaneaster, SK; Kojouri, K; Krempl, GA; Medina, JE | 1 |
| Argiris, A; Brockstein, BE; Cohen, EE; Haraf, DJ; Kistner, EO; Mittal, BB; Rosen, F; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Chu, SC; Kao, RH; Li, CC; Wang, TF; Yao, CY | 1 |
| Menolasino, MJ; Shaw, BL | 1 |
| Arioz, DT; Koker, G; Ozalp, S; Sahin, FK; Tokyol, C; Yilmaz, S; Yilmazer, M | 1 |
| Ajani, JA; Arora, R; Bhutani, MS; Correa, AM; Hofstetter, WL; Izzo, JG; Javeri, H; Lee, JH; Liao, Z; Maru, D; McAleer, MF; Swisher, SG | 1 |
| Milani, A; Nicolai, N; Pizzocaro, G | 1 |
| Li, HP; Li, LY; Luo, B; Pan, M; Shu, KY; Zeng, SY | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Dennetta, D; Fedeli, SL; Giordani, P; Graziano, F; Rossi, D; Ugolini, M | 1 |
| Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Yamada, K; Yamamoto, H; Yamamoto, N | 1 |
| Bonazzi, C; Chiari, S; Maneo, A; Mangioni, C | 1 |
| Gagnon, PJ; Galderisi, C; Holland, JM; Page, BR | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Kamiyama, Y; Kano, Y; Kobayashi, H; Kodama, T; Mori, K | 1 |
| Borghaei, H; Cohen, R; Langer, CJ; Litwin, S; Millenson, M; Mintzer, D; Rovito, M; Ruth, KJ; Seldomridge, JS; Treat, J; Tuttle, H | 1 |
| Adenis, A; Conroy, T; Mariette, C; Mirabel, X; Seitz, JF | 1 |
| Bartelsman, JF; Busch, OR; Koning, CC; Koppert, LB; Muller, K; Offerhaus, GJ; Richel, DJ; Steyerberg, EW; Tilanus, HW; van Berge Henegouwen, MI; van Dekken, H; van der Gaast, A; van Heijl, M; van Lanschot, JJ; Wijnhoven, BP | 1 |
| Gong, Y; Hou, M; Huang, M; Lu, Y; Ren, L; Wang, J; Wei, Y; Zhou, L; Zhou, X; Zhu, J | 1 |
| Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C | 1 |
| Hakenberg, OW | 1 |
| Hirota, M; Husain, SR; Kioi, M; Nakashima, H; Puri, RK; Shimamura, T; Tohnai, I | 1 |
| Chen, Z; Cho, K; Müller, S; Nie, S; Saba, NF; Shin, DM; Tighiouart, M; Wang, X | 1 |
| Jiang, YY; Sun, CC; Wang, J; Wu, SX; Xie, CY; Zhang, P | 1 |
| Cho, BC; Choi, HJ; Kim, H; Kim, JH; Kim, KJ; Lee, YJ; Shin, S | 1 |
| Clayman, GL; El-Naggar, AK; Henderson, YC; Mazumdar, A; Sen, S | 1 |
| Albert, PS; Citrin, D; Colevas, AD; Cooley-Zgela, T; Cotrim, A; Herscher, L; Likhacheva, A; Mansueti, J; Morris, JC; Rudy, SF; Russo, A; Sciuto, L; Smith, S; Solomon, B; Van Waes, C | 1 |
| Bier, C; Engels, K; Fetz, V; Habtemichael, N; Knauer, SK; Kovács, AF; Kunkel, M; Mann, W; Schneider, S; Schuon, R; Schweitzer, A; Stauber, RH | 1 |
| Arao, T; Fujiwara, Y; Fukui, T; Kato, T; Kawaishi, M; Koizumi, F; Kunitoh, H; Nishio, K; Nokihara, H; Ohe, Y; Sekine, I; Shimoda, Y; Tamura, T; Watabe, T; Yamada, K; Yamamoto, N | 1 |
| Buda, A; Chiari, S; Colombo, N; Dell'anna, T; Floriani, I; Fossati, R; Fruscio, R; Grassi, R; Katsaros, D; Landoni, F; Lissoni, AA; Parma, G; Peiretti, M; Pellegrino, A; Rulli, E; Signorelli, M; Torri, V; Zola, P | 1 |
| Hsiao, JR; Huang, BM; Leu, SF | 1 |
| Ahn, SD; Choi, EK; Kim, JH; Kim, YM; Kim, YS; Kim, YT; Lee, SW; Nam, JH; Shin, SS | 1 |
| Ball, D; Campeau, MP; Drummond, E; Herschtal, A; Hogg, A; Mac Manus, M; Michael, M; Wheeler, G; Wirth, A | 1 |
| Altieri, V; Autorino, R; Cartenì, G; De Placido, S; Di Lorenzo, G; Doria, F; Faiella, A; Ferro, M; Gonnella, A; Imbimbo, C; Longo, N; Mirone, V; Palmieri, G; Perdonà, S; Rescigno, P | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Mabuchi, S; Morishige, K; Sakata, M; Tsutsui, T | 1 |
| Ark, N; Diaz, EM; El-Naggar, AK; Garden, AS; Gillenwater, AM; Ginsberg, LE; Glisson, BS; Holsinger, FC; Khuri, FR; Ki Hong, W; Kies, MS; Lee, JJ; Lewin, JS; Lin, HY; Shin, DM | 1 |
| Fujimoto, T; Koshiji, M; Nambu, Y; Yamamoto, N | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 1 |
| Pavamani, S; Prasad, E; Ram, TS; Rangad, VF; Viswanathan, PN | 1 |
| Bordin, V; Bozzoni, S; Caldiera, S; Codecà, C; Di Maria, G; Ferrari, D; Fiore, J; Floriani, I; Foa, P; Luciani, A; Zonato, S | 1 |
| Bral, S; De Grève, J; De Mey, J; Decoster, L; Fontaine, C; Ilsen, B; Meysman, M; Neyns, B; Schallier, D | 1 |
| Cano, ER; Carrau, RL; Caylakli, F; Ferris, RL; Gooding, WE; Johnson, JT; Lai, SY; Myers, EN; Simenthal, AA; Snyderman, CH | 1 |
| Doval, DC; Kumar, JV; Rao, R; Rawal, S | 1 |
| Chen, A; Davis, LW; Edelman, S; Gaultney, J; Grist, W; Khuri, FR; Saba, NF; Shin, DM; Tighiouart, M | 1 |
| Lv, L; Song, B; Song, X; Wang, X; Wei, L; Xie, L; Yu, J | 1 |
| Cao, W; Geng, M; Jiang, J; Jin, Y; Li, H; Lou, G; Xi, W; Xu, C; Zhao, S | 1 |
| Economopoulos, T; Fountzilas, G; Koumarianou, A; Panayiotides, J; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Sykiotis, C; Xiros, N | 1 |
| Honova, H; Kralova, D; Pazdro, A; Pazdrova, G; Petruzelka, L; Smejkal, M; Zemanova, M | 1 |
| Burges, A; Ditsch, N; Hillemanns, P; Kuemper, C; Lenhard, M; Mueller-Egloff, S; Strauss, A | 1 |
| Park, DC; Suh, MJ; Yeo, SG | 1 |
| Hanada, S; Hirata, K; Iwata, T; Izumi, N; Kimura, T; Kudoh, S; Nagano, K; Nishiyama, N; Suehiro, S; Tsukioka, T | 1 |
| Balius, TE; Belani, CP; Hershberger, PA; Kanterewicz, B; Owonikoko, TK; Ramalingam, SS | 1 |
| Corry, P; Moros, EG; Peñagarícano, JA; Ratanatharathorn, V; Yan, Y | 1 |
| Allen, A; Braschayko, P; Burke, E; Costello, R; Flynn, J; Haddad, R; Li, Y; Mahadevan, A; Posner, M; Sonis, S; Tishler, RB; Wirth, L | 1 |
| Boonstra, JJ; Koppert, LB; Tilanus, HW; Tran, TC; Van Dekken, H; Van der Gaast, A; Wijnhoven, BP | 1 |
| Blumenschein, G; Esmaeli, B; Ginsberg, LE; Phan, L; Phan, R; Williams, MD | 1 |
| Arpicco, S; Brusa, P; Cattel, L; Dosio, F; Stella, B | 1 |
| Ang, KK; Forastiere, AA; Garden, AS; Harris, J; Kuettel, MR; Myers, JN; Ridge, JA; Rosenthal, DI; Schultz, CJ; Sidhu, K; Trotti, A; Weber, RS | 1 |
| Chen, ZG; Choi, M; El-Naggar, AK; Khuri, FR; Muller, S; Papadimitrakopoulou, VA; Saba, NF; Shin, DM; Shin, HJ; Tighiouart, M | 1 |
| Abad, M; Acién, P; Garcia, S; Garde, J; Mayol, MJ | 1 |
| Alcalde, J; Arbea, L; Aristu, J; Cambeiro, M; López-Picazo, JM; Martínez-Monge, R; Moreno-Jiménez, M; Valero, J | 1 |
| Anderson, E; Birnbaum, A; Dipetrillo, T; Henderson, D; Joyce, D; Kennedy, T; Puthwala, Y; Rathore, R; Ready, N; Safran, H; Sio, TT; Wanebo, H | 1 |
| He, XY; Hu, CS; Liu, TF; Wu, YR; Ying, HM; Zhu, GP | 1 |
| Allen, CT; Chen, Z; Citrin, D; Colevas, AD; Dancey, J; Gius, D; Harold, NA; Morris, JC; Muir, C; Nottingham, L; Rudy, S; Singh, AK; Van Waes, C | 1 |
| Cormier, JN; Du, XL; Hardy, D; Liu, CC; Xia, R; Xing, Y | 1 |
| Byers, L; El-Naggar, AK; Garden, AS; Gillaspy, KA; Ginsberg, LE; Glisson, BS; Holsinger, FC; Hong, WK; Kies, MS; Lee, JJ; Lewin, JS; Lin, HY; Lippman, SM; Massarelli, E; Papadimitrakopoulou, V; William, WN | 1 |
| Greco, FA; Hainsworth, JD; Lane, CM; Murphy, PB; Naot, Y; Spigel, DR; Thompson, DS; Waterhouse, DM | 1 |
| Ishiguro, K; Nishimura, M; Suda, T; Uchida, N | 1 |
| Crinò, L; De Marinis, F; Gridelli, C; Liepa, AM; Peterson, P; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M; Zhao, YD | 1 |
| Chen, LM; Dai, CL; Fu, LW; Liang, YJ; Su, XD; Tao, LY; Wang, FP; Yan, YY; Zhang, X | 1 |
| Kolb, MM; Kozloff, MF; Samant, M; Scappaticci, FA; Socinski, MA | 1 |
| Ansari, RH; Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Aizawa, N; Hayashi, N; Hayashida, H; Higaki, N; Ichihara, T; Ikeda, T; Kan, K; Murakami, M; Nakano, K; Niju, T; Saito, N; Sakon, M; Soma, I | 1 |
| Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Takahashi, H; Toth, G; Tsukuda, M | 2 |
| Aramendía, JM; Arbea, L; Aristu, JJ; Cambeiro, M; Espinós, J; Gaztañaga, M; Jurado, M; Martínez-Monge, R | 1 |
| Blair, EA; Haraf, DJ; Pederson, AW; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Liu, SP; Wang, XE; Zhang, MQ | 1 |
| Abrão Miziara, JE; Albert, I; Arén, O; Balint, B; Barrios, CH; Cihon, F; Csollak, M; Cupit, L; De Marinis, F; Dimatteo, S; Grossi, F; Hanna, N; Keller, A; Krzakowski, M; Novello, S; Pereira, JR; Reck, M; Scagliotti, G; Thomas, M; von Pawel, J | 1 |
| Bachelot, T; Chabaud, S; Favier, B; Fayette, J; Girodet, D; Montbarbon, X; Montella, A; Pommier, P; Racadot, S; Zrounba, P | 1 |
| Bunn, PA; Chansky, K; Crowley, JJ; Franklin, WA; Gandara, D; Ginsberg, RJ; Pisters, KM; Putnam, JB; Vallières, E | 1 |
| Santoni-Rugiu, E; Sørensen, JB; Vilmar, AC | 1 |
| Deng, X; Hu, W; Li, G; Wang, J; Wu, S; Xie, C; Zhang, P; Zhang, X | 1 |
| Choi, K; Kim, IS; Kim, JH; Kim, K; Kim, SY; Kim, YS; Kwon, IC; Lee, S; Nam, H; Park, H; Park, JH; Park, K; Park, RW | 1 |
| Brandwein-Gensler, M; Garg, MK; Haigentz, M; Levine, D; Shifteh, K; Smith, RV; Staffenberg, DA; Tlemcani, K | 1 |
| Iida, K; Ishikawa, M; Katagiri, A; Miyazaki, K; Nakayama, K; Nakayama, N; Yeasmin, S | 1 |
| Arnold, A; Ciuleanu, T; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Goodwin, R; Laberge, F; Laurie, SA; LeMaître, A; Seymour, L; Shepherd, FA; Vincent, M; Walde, D; Zukin, M | 1 |
| Chun, KC; Kim, DY; Kim, JH; Kim, YM; Kim, YT; Nam, JH | 1 |
| Antoniou, D; Bastas, A; Dimitroulis, J; Georgatou, N; Lolis, N; Marosis, K; Michalopoulou, P; Pappas, C; Provata, A; Stathopoulos, GP; Stathopoulos, J; Toubis, M; Tsoukalas, G; Veldekis, D; Yiamboudakis, P | 1 |
| Aurilio, G; Catalano, G; Ciardiello, F; De Vita, F; Del Genio, A; Di Martino, N; Galizia, G; Lieto, E; Martinelli, E; Morgillo, F; Napolitano, V; Orditura, M; Pacelli, R; Vecchione, L | 1 |
| Borroni, G; Brazzelli, V; Ciocca, O; Fiandrino, G; Rosso, R; Vassallo, C | 1 |
| Basu, D; Diehl, JA; Herlyn, M; Lee, JT; Montone, KT; Nguyen, TT; Rustgi, AK; Wang, LP; Weinstein, GS; Zhang, G | 1 |
| Aleman, BM; Boot, H; Cats, A; Courrech Staal, EF; Jansen, EP; van Coevorden, F; van Sandick, JW; van Velthuysen, ML | 1 |
| Bisen, P; Khan, N; Khan, Z; Mouhamad, S; Prasad, GB; Tiwari, RP; Varma, AK | 1 |
| Daliani, D; Kincaid, M; Osai, W; Pagliaro, LC; Pettaway, CA; Thall, PF; Wen, S; Williams, DL; Williams, MB | 1 |
| Andrews, GA; Fooshee, DR; Frederick, MJ; Galer, C; Milas, ZL; Morrow, PK; Myers, JN; Sano, D; Zhao, M | 1 |
| De Vos, FY; de Wilt, JH; den Bakker, MA; Sewnaik, A; Smid, EJ; van Meerten, E | 1 |
| Hosokawa, K; Kitawaki, J; Koshiba, H; Kuroboshi, H; Mori, T; Okubo, T; Sawada, M; Tatsumi, H | 1 |
| Bogart, J; Dipetrillo, T; Garst, J; Graziano, S; Green, MR; Gu, L; Jänne, PA; Ready, N; Vokes, EE; Wang, X | 1 |
| Amano, N; Hamamoto, Y; Hironaka, S; Imamoto, H; Kato, K; Muro, K; Seriu, T; Tahara, M; Takiuchi, H | 1 |
| Araki, O; Chida, M; Fukushima, Y; Honma, K; Inoue, T; Tamura, M; Tatewaki, M; Umezu, H | 1 |
| Bertholet, V; Dyckhoff, G; Efferth, T; Haefeli, WE; Herold-Mende, C; Ketabi-Kiyanvash, N; Theile, D; Weiss, J | 1 |
| Enomoto, T; Matsumoto, A; Muroya, Y; Nomura, K; Saitoh, H; Shingu, A; Sugisaki, M | 1 |
| An, HY; Cao, XF; Ji, L; Lü, J; Tao, L; Wang, DD; Wang, S; Wu, BC; Zhu, B | 1 |
| Berthillot, C; Gaertner, S; Miréa, C; Stephan, D; Welsch, M | 1 |
| Albers, AE; Bas, M; Bergmann, C; Bier, H; Bölke, E; Brandau, S; Greve, J; Hoffmann, TK; Lang, S; Lehnerdt, G; Mattheis, S; Schuler, PJ; Trellakis, S; Whiteside, TL | 1 |
| Liu, S; Pan, T; Wang, MK; Wang, S; Zhang, DS | 1 |
| Wang, L; Wang, T; Zhang, SF | 1 |
| Azzoli, C; Fang, L; Faoro, L; Hainsworth, JD; Huang, JE; Karlin, D; Russell, K | 1 |
| Inoue, M; Nagashima, A; Nakanishi, K; Nakanishi, R; Osaki, T; Sakata, H; Uchiyama, A; Uramoto, H; Yasumoto, K; Yoshimatsu, T | 1 |
| Friehs, G; Froelich, K; Hackenberg, S; Hagen, R; Kessler, M; Kleinsasser, N; Koehler, C; Radeloff, A; Scherzed, A | 1 |
| Argenta, PA; Carson, LF; Chura, JC; Downs, LS; Geller, MA; Ghebre, R; Judson, PL | 1 |
| Agustí, C; Campayo, M; Casas, F; Ferrer, F; Jeremic, B; Lomeña, F; Maria Gimferrer, J; Sanchez, M; Viñolas, N | 1 |
| Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K | 1 |
| Ahn, YC; Choi, JY; Choi, YS; Kim, HK; Kim, J; Kim, K; Lee, KS; Park, K; Shim, YM | 1 |
| Fujii, M; Hasegawa, Y; Kurono, Y; Minami, H; Nibu, K; Onozawa, Y; Sagae, D; Seriu, T; Tahara, M; Tomita, K; Tsukuda, M; Watanabe, A | 1 |
| Hida, T; Hirashima, T; Horai, T; Horio, Y; Kobayashi, K; Nishio, M; Shi, MM; Tamiya, M; Tanii, H; Yamamoto, N | 1 |
| Asmar, L; Kobina, S; Neubauer, MA; Pritchard, S; Reynolds, CH; Weissman, CH | 1 |
| Bergman, JJ; Boellaard, R; Bonenkamp, HJ; Bossuyt, PM; Busch, OR; Cuesta, MA; Hoekstra, OS; Hulshof, MC; Nieuwenhuijzen, GA; Omloo, JM; Plukker, JT; Pruim, J; Sloof, GW; Ten Kate, FJ; Tilanus, HW; van Berge Henegouwen, MI; van Dekken, H; van der Gaast, A; van Heijl, M; van Lanschot, JJ | 1 |
| Fietkau, R; Iro, H; Klautke, G; Kuwert, T; Lell, M; Linke, R; Semrau, S; Uder, M; Waldfahrer, F | 1 |
| Biesma, B; Dalesio, O; Groen, HJM; Slaets, JPJ; Smit, EF; Smit, HJM; Stigt, JA; van Felius, CL; van Putten, JWG; Vincent, A; Wymenga, ANM | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Stewart, DJ; Tsai, CM | 1 |
| Jahnke, K; Keilholz, U; Lüftner, D; Schmittel, A; Thiel, E | 1 |
| Abo-Elyazeed, A; El-Hadaad, HA; Halim, AA; Wahba, HA | 1 |
| Bepler, G; Chen, DT; Chiappori, A; Dilling, TJ; Greenberg, H; Haura, E; Hazelton, T; Simon, G; Stevens, C; Tanvetyanon, T; Wagner, H; Walsh, F; Williams, C | 1 |
| Chougule, P; Johnson, TT; Kennedy, T; Marcello, J; Nadeem, A; Radie-Keane, K; Rathore, R; Ready, NE; Ruhl, C; Theall, K; Wanebo, HJ | 1 |
| Battafarano, R; Birnbaum, A; Burrows, W; Dipetrillo, T; Fontaine, J; Horiba, N; Ng, T; Oldenburg, N; Perez, K; Safran, H; Suntharalingam, M | 1 |
| Chen, JS; Cheng, JC; Chuang, TH; Hsu, CH; Hsu, HH; Huang, PM; Kuo, SW; Lee, JM; Lee, YC; Lin, CC; Shun, CT; Wang, YH; Wu, MT; Yang, PW; Yang, SY | 1 |
| Kato, K; Ushijima, M; Yamakawa, Y | 1 |
| Chen, X; Hou, Y; Li, C; Li, X; Lou, G; Meng, F; Sun, M; Yin, M; Zhang, H; Zhao, F | 1 |
| Lee, DW; Lee, HN; Lee, KH; Lee, YS; Park, EK; Park, JS | 1 |
| Brockhoff, G; Driemel, O; Ettl, T; Felthaus, O; Gosau, M; Hautmann, M; Morsczeck, C; Reck, A; Reichert, TE; Schmalz, G; Zeitler, K | 1 |
| Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Takahashi, H; Tsukuda, M | 1 |
| Abraham, I; Ambudkar, SV; Bates, SE; Chen, ZS; Fu, LW; Kim, IW; Peng, X; Robey, RW; Shi, Z; Shukla, S; Singh, S; Talele, TT; Tiwari, AK | 1 |
| Hu, Y; Wu, Y | 1 |
| Hasegawa, T; Hidaka, T; Ishizawa, S; Nakashima, A; Nomoto, K; Saito, S; Takano, Y; Tsuneyama, K | 1 |
| Ajani, JA; Hofstetter, WL; Komaki, RU; Konski, AA; Swisher, SG; Willett, CG; Winter, KA; Wu, TT | 1 |
| He, L; Huang, L; Huang, X; Li, JD; Liu, JH; Ren, YF; Wang, HY; Xiong, Y; Zheng, M | 1 |
| Chougule, P; DiSiena, MR; Koness, RJ; McRae, RG; Nigri, PT; Radie-Keane, K; Rathore, R; Ready, N; Wanebo, HJ | 1 |
| Ando, M; Fujiwara, Y; Hirata, T; Katsumata, N; Ono, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K | 1 |
| CHEN, XD; LÜ, WG; QIN, JL; SHI, HY | 1 |
| Cullen, KJ; Goloubeva, O; Kwok, Y; Ord, R; Parekh, A; Strome, S; Suntharalingam, M; Taylor, R; Wolf, J; Zimrin, A | 1 |
| Huang, XE; Jin, GF; Li, Y; Shen, HB; Xu, L | 1 |
| Chia-Hsien Cheng, J; Hsu, CH; Hsu, FM; Huang, PM; Lee, JM; Lee, YC; Lin, CC; Tsai, YC | 1 |
| Blasco, A; Cabrera, A; Camps, C; Carrato, A; Gil, M; Gómez-Aldaraví, L; González-Larriba, JL; Guijarro, R; Iranzo, V; Jantus, E; Massuti, B; Provencio, M; Rossell, R; Sanmartín, E; Sirera, R; Velasco, A | 1 |
| Li, J; Lin, ZQ; Peng, YP; Wang, LJ; Zhang, BZ | 1 |
| Deng, AM; Liang, AB; Qu, YQ; Wang, H; Xiu, B; Zeng, HZ; Zhang, WJ | 1 |
| Chen, X; Li, H; Li, K; Li, X; Liu, Y; Lou, G; Yin, M; Zhang, H | 1 |
| Baudrin, L; Bennouna, J; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Ducoloné, A; Herman, D; Laporte, S; Lavolé, A; Lebitasy, MP; Milleron, B; Molinier, O; Moro-Sibilot, D; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Li, J; Lu, S; Ma, J; Tian, J; Wang, H; Xu, W; Yu, L | 1 |
| Caicedo-Granados, EE; Lee, GS; Marker, PH; Ondrey, FG; Wuertz, BR | 1 |
| Cortes-Funes, H; Cruz-Hernandez, JJ; García-Sáenz, JA; Grau, JJ; Hitt, R; Irigoyen, A | 1 |
| Altieri, V; Autorino, R; Buonerba, C; Cartenì, G; D'Aniello, C; De Placido, S; Di Lorenzo, G; Federico, P; Ferro, M; Imbimbo, C; Longo, N; Matano, E; Mirone, V; Palmieri, G; Perdonà, S; Rescigno, P | 1 |
| Dai, YY; Jiang, WZ; Wan, LY; Wei, R; Yang, DY; Yang, Z | 1 |
| Choi, HL; Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yun, T | 1 |
| Auzenne, E; Galer, CE; Ghosh, SC; Hah, JH; Hamir, AN; Klostergaard, J; Myers, JN; Sano, D | 1 |
| Guntinas-Lichius, O; Klubmann, JP; Müller, RP; Preuss, SF; Semrau, R; Temming, S | 1 |
| Hamada, S; Konishi, I; Mogami, H; Sasaki, H; Takahashi, Y | 1 |
| Chen, CP; Jablons, DM; Jahan, TM; Weinberg, VK; Yom, SS | 1 |
| Han, Y; Liu, H; Liu, X; Mi, R; Su, G; Wang, H; Zhang, Y; Zhou, X; Zhu, B | 1 |
| Endo, D; Hosaka, M; Kato, T; Kikawa, S; Konno, Y; Mitamura, T; Odagiri, T; Sakuragi, N; Suzuki, Y; Watari, H | 1 |
| Hokoda, N; Kasahara, K; Kitamura, R; Miyazaki, M; Nakagawa, K; Nakayama, H; Ohyama, A; Okamoto, I; Satouchi, M; Seto, T; Takeda, K; Yamamoto, N; Yoshihara, E; Yoshioka, H | 1 |
| Chiba, Y; Fukuda, H; Fukuoka, M; Kokubo, M; Kudoh, S; Nakagawa, K; Nakanishi, Y; Negoro, S; Nishimura, Y; Tada, T; Tsujino, K | 1 |
| Jiang, W; Li, L; Liu, Y; Wu, YY; Zeng, SY; Zhong, ML | 1 |
| Adamo, B; Adamo, V; Denaro, N; Ferraro, P; Franchina, T; Pergolizzi, S; Ricciardi, GR; Santacaterina, A; Settineri, N | 1 |
| Choong, N; Firat, S; Kharofa, J; Sadasiwan, C; Schultz, C; Wang, D; Wong, S | 1 |
| Cha, IH; Li, S; Nam, W | 1 |
| Dreher, MR; Jang, BS; Kim, HS; Lee, SM; Paik, CH; Pastan, I; Razjouyan, F; Shin, IS; Wang, S; Yao, Z | 1 |
| Ahn, SG; Jeon, DI; Kim, SA; Kwon, SM; Park, JH; Yoon, HE; Yoon, JH | 1 |
| Aguirre-González, EH; Verduzco-Aguirre, HC; Verduzco-Rodríguez, L | 1 |
| Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H; Watanabe, S | 1 |
| Abbas, A; Fakih, M; Nehme, E | 1 |
| Inoue, S; Miyata, M; Ohashi, I; Takami, K; Tamura, C; Wakasa, T | 1 |
| Bacoyiannis, C; Bafaloukos, D; Boukovinas, I; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Pavlidis, N; Pectasides, D; Skarlos, D; Syrigos, K | 1 |
| Alcalde, J; Aristu, J; Cambeiro, M; Gaztañaga, M; Martínez-Monge, R; Montesdeoca, N; Pagola, M; Rodriguez Ruiz, ME | 1 |
| Knecht, R; Laban, S; Münscher, A; Schafhausen, P; Tribius, S; Wang, CJ | 1 |
| Eisbruch, A; Feng, F; Pak, D; Ten Haken, RK; Vineberg, K | 1 |
| Berlin, JM; Marcano, DC; Milas, L; Myers, JN; Pham, TT; Sano, D; Tour, JM; Valdecanas, DR; Zhou, G | 1 |
| Bai, P; Li, B; Li, HJ; Li, SM; Li, W; Wu, LY; Zhang, R | 1 |
| Ando, M; Fujiwara, Y; Kamura, T; Katsumata, N; Kitagawa, R; Nakanishi, T; Satoh, T; Shimizu, C; Ushijima, K; Yoshikawa, H | 1 |
| Enomoto, T; Fujita, M; Hamasaki, T; Hisamatsu, T; Kimura, T; Mabuchi, S; Yoshino, K | 1 |
| Colantonio, I; Comino, A; Crook, T; Denaro, N; Gasco, M; Lattanzio, L; Lo Nigro, C; Merlano, M; Monteverde, M; Natoli, G; Russi, E; Syed, N; Vivenza, D | 1 |
| Chang, TC; Chou, HH; Hong, JH; Huang, YT; Lai, CH; Lee, SP; Tsai, CS; Wang, CC | 1 |
| Celia, C; Cilurzo, F; Fresta, M; Paolino, D; Trapasso, E | 1 |
| Annino, DJ; Balboni, TA; Goguen, LA; Haddad, RI; Lorch, J; Norris, CM; Posner, MR; Sher, DJ; Thotakura, V; Tishler, RB | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Behrens, C; Correa, AM; Erasmus, JJ; Kalhor, N; Kim, ES; Lee, JJ; Pataer, A; Raso, MG; Roth, JA; Stewart, DJ; Swisher, SG; Vaporciyan, AA; Wistuba, II | 1 |
| Mammoliti, S; Menada, MV; Menoni, S; Moioli, M; Pacella, E; Papadia, A; Ragni, N | 1 |
| Cmelak, AJ; Diaz, R; Kirby, W; Murphy, BA; Murphy, P; Netterville, JL; Shakhtour, B; Shyr, Y; Sinard, RJ; Thorpe, SW; Vlacich, G; Yarbrough, WG | 1 |
| Amant, F; Han, SN; Vergote, I | 1 |
| Arakawa, A; Furukawa, N; Hirashima, Y; Itani, Y; Ito, K; Murakoshi, H; Tabata, T; Takekuma, M; Takeuchi, S; Tsubamoto, H | 1 |
| Baird, RD; Barton, DP; Kaye, SB; Khan, AZ; Moreno, V; Vitfell-Pedersen, J; Yap, TA | 1 |
| Kim, JH; Kim, TE; Kwack, HS; Kwon, JY; Park, BJ; Yoon, SC | 1 |
| Buiret, G; Ceruse, P; Chabaud, S; Favier, B; Fayette, J; Girodet, D; Lavergne, E; Péron, J; Pham, BN; Ramade, A; Zrounba, P | 1 |
| Fury, MG; Haque, S; Ho, A; Katabi, N; Kelly, KW; Nwankwo, O; Pfister, DG; Sherman, E; Sima, C | 1 |
| Chen, K; Duan, WM; Fan, SJ; Feng, YZ; Li, DM; Li, F; Li, W; Liu, Y; Rong, F; Tao, M; Zhou, XW | 1 |
| Fukushima, M; Higashiyama, T; Hirokawa, M; Ito, Y; Kihara, M; Kobayashi, K; Miya, A; Miyauchi, A; Takamura, Y | 1 |
| Chiantera, V; Köhler, C; Mangler, M; Piek, JM; Schneider, A; Speiser, D; Vercellino, GF | 1 |
| Gong, Y; Huang, M; Li, N; Liu, Y; Peng, F; Wang, J; Xu, Y; Zhang, J; Zhou, L; Zhu, J | 1 |
| Froelich, K; Ginzkey, C; Hackenberg, S; Hagen, R; Harnisch, W; Kleinsasser, N; Koehler, C; Scherzed, A | 1 |
| Alexis, M; Awonuga, AO; Belotte, J; Bolinjkar, R; Deppe, G; Tabassum, F | 1 |
| Bu, S; Chen, Y; Guo, W; He, C; Liu, J; Tan, B; Wang, J; Wang, W; Wang, Y; Wu, X | 1 |
| Chang, AC; Hayman, JA; Lee, JS; Merajver, SD; Orringer, MB; Pan, CC; Pickens, A; Schneider, BJ; Urba, SG | 1 |
| Bian, ML; Higuma, C; Isaka, K; Ito, H; Liang, J; Nishi, H; Sasaki, T | 1 |
| Ahn, SG; Kim, SA; Moon, SM; Yoon, JH | 1 |
| Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Urakci, Z | 1 |
| Chen, LK; Liang, Y; Liu, GZ; Wei, WD; Xu, F; Xu, GC; Yang, QY; Zhou, NN | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| Bergman, JJ; Blom, RL; Busch, OR; Hulshof, MC; Klinkenbijl, JH; Reitsma, JB; Richel, DJ; van Berge Henegouwen, MI; van Heijl, M; Wilmink, JW | 1 |
| Adkins, D; Dehdashti, F; Gay, H; Lewis, J; Ley, J; Mehan, P; Nussenbaum, B; Siegel, BA; Thorstad, W; Trinkaus, K; Wildes, T | 1 |
| Drage, MG; Haddad, RI; Lichtman, AH; Shah, SM | 1 |
| Boudria, A; Brambilla, E; Drissi, R; Eymin, B; Gazzeri, S; Gout, S; Lantuejoul, S | 1 |
| Chen, EC; Chen, XM; Hao, CG; Ma, JB; Qin, G; Song, YP; Wei, L | 1 |
| Akervall, J; Galoforo, S; Geddes, TJ; Grénman, R; Marples, B; Thibodeau, BJ; Wilson, GD | 1 |
| Huang, Z; Ma, L; Ou, Y; Song, Y; Yu, C; Zhan, Q; Zhang, B; Zhao, C; Zhou, W | 1 |
| Ieda, N; Pirovano, C; Siesto, G; Vitobello, D | 1 |
| Cai, Y; Hu, M; Jiang, F; Liu, C; Liu, Q; Luo, J; Luo, M; Shi, Q; Song, P; Tang, M; Weng, Y; Yang, D; Zhan, X; Zhang, F; Zhang, Y; Zhou, L; Zuo, G | 1 |
| Chu, TQ; Ding, H; Du, WD; Garfield, DH; Gu, AQ; Han, BH; Pei, J | 1 |
| Abhold, E; Altuna, X; Blair, KJ; Fan, JB; Kiang, A; Kuo, SZ; Ongkeko, WM; Rahimy, E; Wang-Rodriguez, J | 1 |
| Liu, F; Sun, YL; Wang, LS; Xu, Y; Zhao, XH | 1 |
| He, J; Huang, J; Mao, Y; Qu, T; Quan, L; Sun, Y; Wang, J; Xing, P; Xu, N; Zhang, H; Zhou, Y; Zhu, H | 1 |
| Beukema, JC; Burgerhof, JG; Hospers, GA; Langendijk, JA; Muijs, CT; Mul, VE; Muller, K; Paardekooper, G; Plukker, JT; Smit, JK; Timmer, PR; van Dijk, BA; Woutersen, D | 1 |
| Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX | 1 |
| Fang, Q; Li, Y; Ou, W; Qin, J; Sun, HB; Wang, SY; Zhang, L | 1 |
| Adenis, A; Mariette, C; Mirabel, X | 1 |
| Cheng, HY; Gu, M; Huang, XE; Li, SY; Lin, Y; Liu, L | 1 |
| Bálint, B; Cottrell, S; de Boer, RH; De Souza, P; Galimi, F; Haddad, V; Hei, YJ; Hsu, CP; Pan, Y; Paz-Ares, L; RamLau, R; Sabin, T; van Meerbeeck, JP; Wierzbicki, R | 1 |
| Bonomi, PD; Katz, TL; Lee, HJ; Mace, J; Mandanas, RA; Min, M; Olsen, M; Sheth, G; Youssoufian, H | 1 |
| Cox, J; Fritzsche, A; Gosnell, D; Graham, R; Ledwitch, K; Manning, T; Ogburn, R | 1 |
| Barrios, J; Cohen, E; Hansen, CK; Kertsman, J; Kurtsman, J; Lu, H; Tendler, T; Wieder, R | 1 |
| Hong, WK | 1 |
| Polee, MB; Siersema, PD; Splinter, TA; Stoter, G; Tilanus, HW; Van der Gaast, A; Verweij, J | 1 |
| Baur, M; DeSantis, M; Dittrich, C; Gerber, E; Hudec, M; Kienzer, HR; Pont, J; Schratter-Sehn, AU; Schweiger, J; Wicke, W | 1 |
| Grénman, R; Grénman, S; Helenius, H; Kulmala, J; Raitanen, M; Rantanen, V | 1 |
| Sierra, A; Torre, W | 1 |
| Clayman, G; Diaz, E; Feng, L; Francisco, M; Garden, A; Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Kies, MS; Lippman, SM; Myers, J; Papadimitrakopoulou, V; Shin, DM | 1 |
| Ikeda, H; Koshiba, R; Ohsawa, H; Tanaka, A | 1 |
| Abad, A; Barnadas, A; Font, A; Guillot, M; Manzano, JL; Margeli, M; Martinez, E; Rosell, R; Sanchez, JM; Taron, M | 1 |
| Curyło, A; Grodzicki, T; Orski, J; Telesińska, D | 1 |
| Bains, MS; Ginsberg, R; Ilson, DH; Kelsen, DP; Korst, R; Minsky, B; Rusch, V; Stojadinovic, A; Turnbull, A | 1 |
| Bourhis, J; Faivre, S; Monnerat, C; Raymond, E; Temam, S | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Matsuo, K; Tsuda, H; Watanabe, T | 1 |
| Baselga, J; Bellmunt, J; Clèries, R; Cos, J; Eres, N; Margarit, C; Murio, JE; Pérez, M; Ribas, A | 1 |
| Busse, PM; Case, M; Colevas, AD; Costello, R; Frankenthaler, R; Karp, D; Lake-Willcutt, B; Lamb, CC; Nixon, A; Norris, CM; Posner, MR; Tishler, RB | 1 |
| Burian, M; Cartellieri, M; Fiebiger, W; Formanek, M; Gedlicka, C; Kornek, GV; Kornfehl, J; Marks, B; Selzer, E | 1 |
| Aviles, VM; Chalian, AA; Greenberg, MJ; Hershock, D; Jones, H; Machtay, M; Rosenthal, DI; Weber, RS; Weinstein, GS; Williamson, S | 1 |
| Khanna, N; Kochupillai, V; Pathak, AK; Prasad, KN; Reddy, VG; Singh, N | 1 |
| Baredes, S; Bryan, M; Hameed, M; Korah, R; Pavlick, AC; Pliner, L; Saunders, T; Wieder, R | 1 |
| Kawabori, S; Taniguchi, M; Watanabe, A | 1 |
| Boldt, S; Kolch, W; Weidle, UH | 1 |
| Aoi, H; Inoue, S; Salah-Eldin, AE; Tsuda, M; Tsukamoto, S | 1 |
| Angioli, R; Cutillo, G; Manci, N; Palaia, I; Panici, PB | 1 |
| Ensley, JF; Kewson, D; Lonardo, F; Meng, H; Nguyen, T; Oliver, J; Piechocki, MP; Shibuya, TY; Tainsky, MA; Yoo, GH | 1 |
| Burger, RA; Fruehauf, JP; Monk, BJ; Parker, R; Radany, EH; Redpath, L | 1 |
| Goto, H; Miki, T; Ogawa, H; Shiraga, M; Sone, S; Yamamoto, A; Yano, S; Zhang, H | 1 |
| Busse, P; Case, MA; Colevas, AD; Costello, R; Goguen, L; Haddad, R; Lake-Willcutt, B; Norris, CM; Posner, M; Sullivan, C; Tishler, R | 1 |
| Brockstein, BE; Fung, BB; Haraf, DJ; Kies, MS; List, MA; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, AW; Rosen, FR; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Lefebvre, JL; Posner, MR | 1 |
| Odagiri, K; Okami, K; Onuki, J; Sakai, A; Takahashi, M | 1 |
| Dong, Y; Ni, G; Wang, J | 1 |
| Braaksma, M; Levendag, P | 1 |
| Greene, MA; Malias, MA | 1 |
| Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM | 1 |
| Busse, P; Case, MA; Costello, R; Goguen, LA; Haddad, R; Mahadevan, A; Norris, CM; Posner, MR; Sullivan, CA; Tishler, RB; Wirth, L | 1 |
| Barón, MG; Belda-Iniesta, C; Casado, E; Castelo, B; Corral de la Calle, M | 1 |
| Haddad, R; Posner, M | 1 |
| Altmeyer, P; Ardabili, M; Gambichler, T; Hoffmann, K; Rotterdam, S; Stücker, M | 1 |
| Davis, R; Lance, R; Peterson, AC | 1 |
| Chávez-Blanco, A; Dueñas-González, A; García-López, P; González-Fierro, A; Lizano-Soberon, M; Mariscal, I; Pérez-Cárdenas, E; Segura-Pacheco, B; Taja-Chayeb, L; Trejo-Becerril, C; Treviño-Cuevas, H; Wegman-Ostrosky, T | 1 |
| Chen, W; Guo, W; Lin, L; Xu, Q; Zhou, X | 1 |
| Cho, MJ; Kim, JS; Kim, Ki; Kim, SY | 1 |
| Araki, T; Ishihara, H; Komiyama, T; Kuriyama, K; Nishikawa, K; Onishi, H; Tanaka, S; Yamaguchi, M | 1 |
| Airoldi, M; Bumma, C; Cortesina, G; Gabriele, P; Giordano, C; Pedani, F | 1 |
| Hori, H; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ohnishi, K; Ohnishi, T; Ono, K; Suzuki, M; Takahashi, A; Uto, Y | 1 |
| Matsumura, T; Mese, H; Sasaki, A; Sawada, S; Yoshioka, N | 1 |
| Brockstein, BE; Haraf, DJ; Kies, MS; List, MA; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, AW; Rosen, FR; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Kanamori, S; Masunaga, S; Nakamatsu, K; Nishimura, Y; Suzuki, M | 1 |
| Connor, GP; Mattison, M; Powell, JL; Shiro, BS; Stinson, JA | 1 |
| Bonaccorsi, A; Calò, S; Cantù, G; Costa, L; Crippa, F; Damascelli, B; Di Tolla, G; Frigerio, LF; Garbagnati, F; Gladin, CR; Lanocita, R; Marchianò, A; Mariani, L; Mattavelli, F; Oldini, C; Palazzi, M; Patelli, GL; Spreafico, C; Tichà, V | 1 |
| Dou, QP; Kuhn, DJ; Pross, S; Smith, DM; Whiteside, TL | 1 |
| Barros, AP; Carrara-de Angelis, E; Feher, O; Kowalski, LP; Nishimoto, IN | 1 |
| Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V | 1 |
| Eskens, FA; Hoekstra, R; Polee, MB; Siersema, PD; Stoter, G; Tilanus, HW; Van der Burg, ME; Van der Gaast, A | 1 |
| Ajani, JA; Correa, AM; Cox, JD; Komaki, R; Lahoti, S; Martin, F; Nesbitt, JC; Putnam, JB; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL | 1 |
| Bernhard, H; Bredenkamp, R; Hennig, M; Lordick, F; Peschel, C; von Schilling, C | 1 |
| Alberola, V; Albert, A; Campos, JM; Caranana, V; Casan, R; Juan, O; Sánchez, R; Villarroya, T | 1 |
| Miyahara, H; Naito, K; Yane, K | 1 |
| Ho, ST; Hsu, WH; Huang, WT; Kao, A; Shih, CM; Wang, JJ | 1 |
| Anderson, SE; Ilson, DH; Kelsen, DP; O'Reilly, EM | 1 |
| Beard, M; Coia, L; Colarusso, P; Farma, J; Frucht, H; Goldberg, M; Goosenberg, E; Lampert, C; Weiner, LM | 1 |
| Airoldi, M; Bumma, C; Cortesina, G; Giordano, C; Pedani, F | 1 |
| Bogliun, G; Cavaletti, G; Colombo, N; Cundari, S; Fei, F; Lissoni, A; Marzorati, L; Parma, G; Piatti, M; Zanna, C; Zincone, A | 1 |
| Furukawa, K; Kataba, H; Kato, H; Miura, T; Saito, M | 1 |
| Fazekas, K; Ladányi, A; Lövey, J; Németh, G; Tímár, J | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Ki Hong, W; O'Reilly, MS; Onn, A; Wu, W | 1 |
| Histuda, Y; Igishi, T; Kato, K; Kawasaki, Y; Kotani, M; Matsumoto, S; Sako, T; Shigeoka, Y; Shimizu, E; Sugitani, A; Yamamoto, M; Yasuda, K | 1 |
| Benedicic, Ch; Petru, E; Pickel, H; Seewann, A | 1 |
| Altorki, NK; Keresztes, RS; Korst, RJ; Pasmantier, MW; Port, JL | 1 |
| Argiris, A; Brockstein, BE; Haraf, DJ; List, MA; Mittal, BB; Pelzer, H; Portugal, L; Rosen, FR; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Chiou, JF; Ho, ST; Hsu, WH; Kao, A; Liang, JA; Wang, JJ | 1 |
| Gavi, S; Malbon, CC; Shumay, E; Wang, HY | 1 |
| Egli, F; Jost, L; Moosmann, P; Stahel, RA | 1 |
| Baba, Y; Horiuchi, C; Kato, Y; Mochimatsu, I; Nishimura, G; Taguchi, T; Tanigaki, Y; Tsukuda, M | 1 |
| Argiris, A; Forastiere, AA; Langer, CJ; Li, Y; Murphy, BA | 1 |
| Costello, R; Haddad, R; Posner, M; Weeks, L; Wirth, L | 1 |
| Beri, R; Desai, SR; Pacini, MJ; Rosen, FR | 1 |
| Kim, DH; Kim, JH; Lew, YO; Namkoong, SE; Park, DC | 1 |
| Brafman, LB; Hershman, DL; Resnik, EE; Selleck, MJ; Shriberg, L; Smith, D; Tiersten, AD; Troxel, AB | 1 |
| Adamo, V; Alafaci, E; Ferraro, G; Laudani, A; Pergolizzi, S; Scimone, A; Sergi, C; Settineri, N; Spano, F; Spitaleri, G | 1 |
| Horiike, A; Kodama, T; Kunitoh, H; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Ahmed, MM; Arnold, SM; Desimone, P; Kenady, D; Kudrimoti, M; Mohiuddin, M; Regine, WF; Spring, P; Valentino, J | 1 |
| Gillessen, S; Joerger, M; Klaeser, B; Kluckert, JT; Schmid, HP; Warzinek, T | 1 |
| Daga, H; Fujitaka, K; Isobe, T; Kohno, N; Kondo, K; Miyazaki, M | 1 |
| El-Rayes, BF; Ferris, A; Heilbrun, LK; Jain, V; Philip, PA; Shields, A; Terry, D; Zalupski, M | 1 |
| Ajani, JA; Cohen, DS; Faust, J; Komaki, R; Lynch, PM; Morris, J; Nivers, R; Putnam, JB; Roth, JA; Smythe, R; Swisher, SG; Vaporciyan, A; Walsh, G; Wu, TT | 1 |
| Adamo, V; De Renzis, C; Ferraro, G; Pergolizzi, S; Romeo, A; Rossello, R; Santacaterina, A; Sergi, C; Settineri, N; Zanghì, M | 1 |
| Ghaheri, BA; Grecula, JC; Malone, JP; Rhoades, CA; Schuller, DE; Stephens, JA | 1 |
| Cooper, JS; Demas, W; Forastiere, AA; Garden, AS; Glisson, BS; Gore, E; Harris, J; Horwitz, EM; Jones, C; Nabell, L; Ridge, JA; Vokes, EE | 1 |
| Benda, J; Blessing, JA; Boggess, JF; Cella, D; King, S; McQuellon, RP; Miller, DS; Moore, DH; Olt, G; Rocereto, TF; Thaler, HT | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Castellano, D; Cortés-Funes, H; Hitt, R; Jimeno, A; Millán, JM | 1 |
| Bogliun, G; Buda, A; Cavaletti, G; Colombo, N; Cundari, S; Fei, F; Franchi, D; La Presa, MT; Lissoni, A; Marzorati, L; Piatti, M; Zanna, C; Zincone, A | 1 |
| Abe, T; Fujita, N; Gejyo, F; Kagamu, H; Matsumoto, N; Moriyama, H; Tanabe, Y; Watanabe, S; Yokota, T; Yoshizawa, H | 1 |
| Ancukiewicz, M; Choi, N; Donahue, D; Lynch, T; Mathisen, D; Park, SD; Wain, J; Wright, C | 1 |
| Chang, TC; Chen, IH; Chen, JS; Liao, CT; Liaw, CC; Tsang, NM; Wang, HM | 1 |
| Li, X; Song, HY; Yang, YM; Zhang, SL | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Huang, GC; Kuo, YY; Lin, MH; Liu, SY; Liu, YC | 1 |
| Asahina, H; Dosaka-Akita, H; Imura, M; Kikuchi, E; Kikuchi, J; Kinoshita, I; Konishi, J; Nishimura, M; Oki, H; Shinagawa, N; Yamazaki, K | 1 |
| Edwards, RP; Gallion, HH; Kelley, JL; Kunschner, AJ; Sit, AS | 1 |
| Liu, J; Wang, J | 1 |
| Bekele, BN; Bucana, CD; Doan, D; Fidler, IJ; Jasser, SA; Myers, JN; Schiff, BA; Yigitbasi, OG; Younes, MN | 1 |
| Carvalho, AL; Feher, O; Gomez, MV; Kowalski, LP; Liberman, PH; Pellizzon, AC; Schultz, C; Testa, JR | 1 |
| Bucci, MK; Devine, P; Hershock, D; Kligerman, MM; Machtay, M; Metz, J; Rosenthal, DI | 1 |
| Barone, C; Bertetto, O; Birocco, N; Colantonio, I; Dongiovanni, D; Numico, G; Schena, M | 1 |
| Bao, Y; Chen, M; Chen, YY; Cui, NJ; Deng, XW; Li, Q; Lin, HX; Lu, LX; Lu, TX; Wu, SX; Xian, CG | 1 |
| Chen, Z; Pribluda, VS; Ricker, JL; Swartz, GM; Van Waes, C; Yang, XP | 1 |
| Cohen, RB; DeConti, RC; Forastiere, AA; Jennings, T; Langer, CJ; Li, Y; Nair, S | 1 |
| Amador, ML; Ballestin, C; Benito, A; Ciruelos, E; Cortes-Funes, H; Hitt, R; Sanchez, JJ | 1 |
| Jaglowski, JR; Leure-Dupree, AE; McLaughlin, PJ; Stack, BC; Verderame, MF; Zagon, IS | 1 |
| Babb, JS; Cheng, J; Cohen, RB; Damsker, JA; Feigenberg, SJ; Horwitz, EM; Kramer, NM; Langer, CJ; Nicolaou, N; Ridge, JA; Sherman, EJ | 1 |
| Banglore, M; Jaboin, J; Ord, R; Suntharalingam, M; Taylor, R; Van Echo, D; Wolf, J | 1 |
| Cai, RG; Chu, DT; Cui, CX; Huang, J; Meng, PJ; Sun, Y; Wang, JW; Yang, L; Zhang, MJ | 1 |
| Minobe, S; Sakuragi, N; Sasaki, M; Todo, Y; Yamamoto, R | 1 |
| Jaglowski, JR; Leure-duPree, AE; Manning, JD; McLaughlin, PJ; Stack, BC; Verderame, MF; Zagon, IS | 1 |
| Schrijvers, D; Vermorken, JB | 2 |
| Furutani, K; Fuwa, N; Kodaira, T; Tachibana, H; Yamazaki, T | 1 |
| Ahn, SD; Choi, EK; Kim, DS; Kim, JH; Kim, SW; Kim, WS; Kim, YS; Lee, JS; Lee, SW; Park, CI; Park, HJ; Shin, SS; Suh, C; Yi, BY; Yoon, SM | 1 |
| DeConti, RC; Ensley, J; Forastiere, AA; Gibson, MK; Hussain, MH; Li, Y; Murphy, B | 1 |
| Agulnik, M; Feldman, LE; Mundt, AJ; Rhee, EN; Yao, M | 1 |
| Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T | 1 |
| Argiris, A; Jayaram, P; Pichardo, D | 1 |
| Hada, T; Hara, T; Hirano, M; Hirano, Y; Kikkawa, H; Nakada, K; Nozawa, H; Oyama, K; Takagi, T | 1 |
| Arquette, M; Azarnia, N; Dicke, K; Herbst, RS; Hong, WK; Kies, MS; Shin, DM; Vokes, EE | 1 |
| Faried, A; Faried, LS; Kanuma, T; Kato, H; Kimura, H; Kuwano, H; Miyazaki, T; Nakajima, M; Sohda, M | 1 |
| Abdel-Wahab, M; Abitbol, A; Hamilton, K; Lewin, A; Markoe, A; Troner, M | 1 |
| Biel, MA; El-Naggar, AK; Machtay, M; Rosenthal, DI; Sinard, RJ; Weber, RS; Yom, SS | 1 |
| Chou, W; Lee, N; Puri, DR | 1 |
| Byers, RM; Glisson, BS; Kies, MS; Moore, BA; Shin, DM; Sturgis, EM | 1 |
| Cipolat, M; Colantonio, I; Di Costanzo, G; Garrone, O; Gasco, M; Granetto, C; Heouaine, A; Merlano, M; Numico, G; Pelissero, A; Russi, EG; Vigna Taglianti, R | 1 |
| Bloching, M; Dunst, J; Haensgen, G; Koesling, S; Kuhnt, T; Mueller, AC; Pelz, T; Schubert, J | 1 |
| Athanassiou, E; Bamias, A; Daniilidis, J; Economopoulos, T; Fountzilas, G; Kalogera-Fountzila, A; Karanastassi, S; Karina, M; Makatsoris, T; Misailidou, D; Nikolaou, A; Pavlidis, N; Samantas, E; Skarlos, D; Tolis, C; Tsekeris, P; Zamboglou, N | 1 |
| Amrein, PC; Clark, JR; Colevas, AD; Deschler, DG; Fabian, RL; Finkelstein, DM; McIntyre, JF; Posner, MR; Rocco, JW; Supko, JG; Wang, CC | 1 |
| Abdel-Wahab, M; Abitbol, A; Hamilton-Nelson, K; Harvey, M; Lewin, A; Markoe, A; Troner, M; Wu, J | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Forkert, R; Fronhoffs, S; Ko, Y; Koll, C; Neuhaus, T; Stier, S; Tuohimaa, A; Vetter, H | 1 |
| Aida, Y; Honma, K; Okura, M; Tanaka, N; Tanimura, S; Tsutsumi, K; Yamamoto, H | 1 |
| Adelstein, DJ | 1 |
| Antón, A; Belón, J; Carles, J; Cervantes, A; Chaib, C; Cortés-Funes, H; Escrig, V; Hitt, R; Isla, D; Lobo, F; López-Pousa, A; Martí, JL; Martínez-Trufero, J; Pallarés, C; Pastor, P; Paz-Ares, L; Rizo, A; Sánchez, MA; Valentí, V; Vega, ME | 1 |
| Eckardt, A; Karstens, JH; Wegener, G | 1 |
| Cella, D; McQuellon, RP; Moore, DH; Thaler, HT | 1 |
| Gruensfelder, P; Hoppe, F; Schler, G; Schmidt, M | 1 |
| Ishiguro, Y; Kawakami, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M | 1 |
| Jaglowski, JR; Stack, BC | 1 |
| Bouchet, LG; Bova, FJ; Buatti, JM; Haller, J; Meeks, SL; Pennington, EC; Ryken, TC; Traynelis, V | 1 |
| Biancamano, JD; Gahbauer, RA; Grecula, JC; Jatana, KR; Lang, JC; Schuller, DE; Wang, D | 1 |
| Annable, T; Greenberger, LM; Hari, M; Loganzo, F; Morilla, DB; Musto, S; Nettles, JH; Snyder, JP; Tan, X | 1 |
| Fujisawa, A; Ikeda, H; Inokuchi, T; Nonaka, M; Uehara, M | 1 |
| Fujita, F; Fujita, M; Shakuto, S | 1 |
| Duffy, K; Friedman, CD; Horwitz, EM; Keenan, E; Langer, CJ; Litwin, S; Nicolaou, N; Ridge, JA; Rosvold, E; Schol, J | 1 |
| Amadori, D; Benasso, M; Boni, L; Capaccetti, B; Cavallo, G; Grossi, F; Merlano, M; Numico, G; Ponzanelli, A; Ricci, I; Rosso, R; Taveggia, P; Vigo, V | 1 |
| Agrawal, A; Grecula, JC; Ozer, E; Rhoades, CA; Schuller, DE; Young, DC | 2 |
| Chmura, SJ; Dekker, A; Garofalo, MC; Haraf, DJ; Jackson, W; Kao, J; List, MA; MacCracken, E; Milano, MT; Stenson, KM; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Eijkenboom, WM; Muller, K; Siersema, PD; Tilanus, HW; Tran, TC; van Dekken, H; van der Gaast, A; van Meerten, E | 1 |
| Chua, ET; Goh, BC; Hsieh, WS; Lim, HL; Loh, KS; Lu, JJ; Shakespeare, TP; Soo, RA; Tan, KS; Wong, AS | 1 |
| Kreĭnina, IuM; Povarova, EV; Shevchenko, LN; Shipilova, AN; Titova, VA | 1 |
| Choi, NC; Coen, J; Fidias, P; Lynch, TJ; Roof, KS; Willett, CG; Wright, C | 1 |
| Minsky, BD | 1 |
| Li, Y; Machtay, M; Wong, SJ | 1 |
| Clark, JI; Dakhil, SR; Ensley, J; Hussain, MH; Moon, J; Samlowski, W; Urba, SG; Williamson, S; Worden, FP | 1 |
| Angouridakis, N; Aravantinos, G; Bafaloukos, D; Bamias, A; Christodoulou, C; Dafni, U; Daniilidis, J; Economopoulos, T; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Karina, M; Makatsoris, T; Maniadakis, N; Nikolaou, A; Papakostas, P; Pavlidis, N; Stathopoulos, G; Syrigos, K | 1 |
| Kim, DH; Mok, SC; Park, DC; Shin, EY; Yeo, SG | 1 |
| Akerman, P; Chauhan, B; Cruff, D; Dipetrillo, T; Evans, D; Harrington, D; Iannitti, D; Milas, L; Miner, T; Ng, T; Safran, H | 1 |
| Bryan, B; Dezube, BJ; Konstantinopoulos, PA; Pantanowitz, L; Schlecht, HP | 1 |
| Ha, SW; Kim, IA; Kim, JS; Kim, K; Lee, HP; Lee, MY; Wu, HG | 1 |
| Becker, A; Bloching, M; Dunst, J; Fietkau, R; Klautke, G; Kuhnt, T; Schubert, J | 1 |
| Gejyo, F; Kagamu, H; Suzuki, E; Tanaka, H; Tanaka, J; Tsuboi, K; Watanabe, S; Yoshizawa, H | 1 |
| Kong, W; Zhang, S | 1 |
| Belani, CP; Clark, RH; Dakhil, S; Desch, CE; Monberg, MJ; Obasaju, CK; Rooney, DK; Waterhouse, DM; Ye, Z | 1 |
| Banerjee, R; Huilgol, N; Preetha, A | 2 |
| Bianco, M; Buzzi, F; Cioffi, R; Comella, P; De Cataldis, G; Filippelli, G; Frasci, G; Gambardella, A; Ghiani, M; Maiorino, L; Mancarella, S; Massidda, B; Masullo, P; Milia, V; Natale, D; Palmeri, S; Putzu, C; Roselli, M | 1 |
| Ariyoshi, Y; Fukuoka, M; Kubota, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Ohashi, Y; Ohe, Y; Saijo, N; Tamura, T | 1 |
| Beauchamp, RD; Berlin, J; Blanke, CD; Chakravarthy, B; Kim, DW; Shyr, Y; Wu, H | 1 |
| Aoki, Y; Eguchi, T; Ichinose, Y; Kojo, M; Maruyama, R; Nishiyama, K; Okamoto, T; Seto, T; Suemitsu, R; Wataya, H | 1 |
| Bendell, JC; Blobe, GC; Czito, BG; D'Amico, TA; Fernando, NH; Harpole, DH; Honeycutt, W; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG; Yu, D | 1 |
| Rodriguez, AO | 1 |
| Matsuoka, T; Morisako, T; Nakamura, H; Ohishi, S; Tsuchida, F | 1 |
| Burkey, B; Cmelak, AJ; Douglas, S; Murphy, BA; Netterville, J; Shyr, Y | 1 |
| Armstrong, DK; Giuntoli, RL; Gold, MA; Herzog, TJ; Lewin, S; Moore, KN; Rocconi, RP; Spannuth, WA | 1 |
| Bajorin, DF; Bochner, BH; Boyle, MG; Donat, SM; Galsky, MD; Herr, HW; Iasonos, A; Mironov, S; Russo, P; Scattergood, J | 1 |
| Ilson, DH; Kelsen, DP; Leichman, LP; Wadleigh, RG | 1 |
| Hu, T; Xie, M; Yao, M; Zhou, L | 1 |
| Abu-Rustum, NR; Aghajanian, C; Bowes, RJ; Jhamb, N; Khoury-Collado, F | 1 |
| Sonpavde, G | 1 |
| Dietrich, MS; Murphy, BA; Silver, HJ | 1 |
| Feng, YL; Li, JD; Li, MD; Liu, JH; Shi, HL; Xiao, Y | 1 |
| Chen, CY; Han, F; Lu, LX; Lu, TX; Sun, Y; Zhao, C | 1 |
| Aoe, M; Ibaragi, S; Kishimoto, K; Kiura, K; Mese, H; Oyama, K; Sasaki, A; Shimo, T; Tsukamoto, G | 1 |
| Chopra, A; Cohen, EP; O-Sullivan, I | 1 |
| Chen, WX; Chen, YQ; Gao, GL; Huang, XZ; Wan, HY; Zou, XS | 1 |
| Fujita, K; Ishiguro, Y; Kawakami, M; Kimura, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M; Yamashita, Y | 1 |
| Janus, SC; Ondrey, FG; Weurtz, B | 1 |
| Chen, A; Davis, L; Johnstone, PA; Lawson, JD; Otto, K; Shin, DM | 1 |
| Agarwala, SS; Argiris, A; Bahri, S; Cano, E; Ferris, R; Heron, DE; Johnson, J; Myers, E; Sandulache, V; Wang, Y | 1 |
| Tsukuda, M | 2 |
| Cannon, M; Cmelak, AJ; Forastiere, AA; Gillison, M; Goldwasser, MA; Li, S; Murphy, B; Pinto, H; Rosenthal, DI | 1 |
| Cheng, AL; Hsu, C; Hsu, CH; Hsu, WL; Lin, CC; Tsai, YC; Yang, CH; Yeh, KH | 1 |
| Christie, D; Kennedy, T; Law, A; Pellitteri, P; Wood, C; Yumen, O | 1 |
| Bendell, JC; Cohen, DP; Czito, BG; D'Amico, TA; Hurwitz, HI; Kelsey, CR; Lockhart, AC; Petros, WP; Truax, R; Willett, CG | 1 |
| Creemers, GJ; Nieuwenhuijzen, GA; Romme, EA; Rutten, HJ; van de Schoot, L; van der Sangen, MJ; van Driel, OJ; van Lijnschoten, G | 1 |
| Bellati, F; Graziano, M; Palaia, I; Panici, PB; Pernice, M | 1 |
| Ayoub, JP; Charpentier, D; Del Vecchio, P; Duclos, M; Faria, S; Gruber, J; Hirsh, V; Ofiara, L; Portelance, L; Souhami, L; Soulieres, D | 1 |
| Ang, K; Curran, W; Harris, J; Horwitz, EM; Kies, M; Langer, CJ; Nicolaou, N; Wong, S | 1 |
| Jin, ML; Li, J; Li, Y; Shen, L; Zhang, XD; Zhang, XT | 1 |
| Carbone, A; Fagotti, A; Fanfani, F; Ferrandina, G; Guerriero, M; Ludovisi, M; Petrillo, M; Scambia, G; Zannoni, G | 1 |
| Akerman, P; Dipetrillo, T; Doyle, LA; Evans, D; Kennedy, N; Kennedy, T; Krasna, M; Ng, T; Plette, A; Safran, H; Spector, J; Suntharalingam, M; Wanebo, H | 1 |
| Bruno, A; Damascelli, B; Di Tolla, G; Frigerio, LF; Garbagnati, F; Lanocita, R; Marchianò, A; Mattavelli, F; Patelli, G; Spreafico, C; Tichá, V; Zunino, F | 1 |
| Eisele, DW; Glastonbury, CM; Lin, D; Rafaelian, O; Wang, SJ | 1 |
| Asmis, TR; Ding, K; Goss, GD; Graham, BC; Leighl, NB; Seymour, L; Shepherd, FA; Spaans, JN; Whitehead, M; Winton, TL | 1 |
| Detterbeck, FC; Edelman, MJ; Govindan, R; Gralla, RJ; Jahan, TM; Limentani, SA; Loesch, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Ye, Z; Zaman, MB | 1 |
| Kodali, S; Ratnasabapathy, C; Sivamurthy, S | 1 |
| Gao, L; Jin, J; Liu, XF; Xu, GZ; Yang, WZ; Yuan, ZY | 1 |
| Cmelak, A; Fakhry, C; Forastiere, A; Gillison, ML; Li, S; Pinto, H; Ridge, JA; Westra, WH | 1 |
| Capanu, M; Ilson, DH; Kelsen, DP; Ku, GY; O'Reilly, E; Schwartz, GK; Schwartz, LH; Shah, MA | 1 |
| Argiris, A; Axelrod, R; Burtness, BA; Forastiere, AA; Manola, J | 1 |
| Barakat, HM; Ibrahim, SA; Mostafa, E; Nasar, MN; Rabie, AN; Rabie, NA | 1 |
| Elbendary, AA; Homesley, HD; Lowendowski, GS; Meltzer, NP; Nieves, L; Vaccarello, L | 1 |
| Antonia, S; Bepler, G; Boulware, D; Burton, M; Chiappori, AA; Haura, E; Kapoor, R; Lush, R; Neuger, AM; Padilla, B; Rodriguez, FA; Simon, G; Sullivan, DM; Williams, C | 1 |
| Tian, J; Xie, M; Zhang, M; Zhou, L | 1 |
| Alcindor, T | 1 |
| Chang, HR; Chu, SC; Hsieh, YS; Yang, SF; Yang, WE | 1 |
| Jin, M; Li, J; Li, Y; Shen, L; Zhang, X | 1 |
| Goto, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Yamada, K; Yamamoto, N | 1 |
| Wu, SX; Xie, CY; Zhang, P | 1 |
| Bremer, M; Eckardt, A; Hofele, C; Reuter, C; Sinikovic, B | 1 |
| Ross, HJ; Seung, SK; Smith, JW | 1 |
| Chang, YL; Cheng, JC; Hsu, CH; Hsu, FM; Lee, JM; Lee, YC; Lin, CC; Tsai, YC | 1 |
| Cohen, EE; Haraf, DJ; Knab, BR; Salama, JK; Solanki, A; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Asmar, L; Barrera, D; Boehm, KA; Caracandas, J; Carter, DL; Dakhil, JS; Ilegbodu, D; McCracken, D; O'Rourke, MA; Reid, RL; Rosenberg, RK | 1 |
| Bradford, CR; Carey, TE; Chepeha, DB; Cordell, KG; D'Silva, NJ; Eisbruch, A; Kumar, B; Kurnit, DM; Lee, JS; Mason, HL; Miller, TH; Prince, ME; Taylor, JM; Teknos, TN; Tsien, CI; Urba, SG; Wallace, NE; Wolf, GT; Worden, FP; Yang, K | 1 |
| Blackstock, AW; Bogart, JA; Green, M; Gu, L; Masters, GA; Miller, AA; Munley, M; Rosenman, J; Sleeper, A; Socinski, MA; Ungaro, P; Vokes, EE; Wang, X | 1 |
| Erovic, BM; Heiduschka, G; Kloimstein, P; Martinek, H; Selzer, E; Skoda, C; Thurnher, D; Vormittag, L; Wachek, V; Wrba, F | 1 |
| Belani, CP; Christie, NA; Cooper, K; Gibson, MK; Land, SR; Landreneau, RJ; Luketich, JD; Pennathur, A; Schuchert, M; Ward, J | 1 |
| Clynes, M; Henry, M; Keenan, J; Meleady, P; Murphy, L | 1 |
| Creaven, P; Hicks, W; Levine, E; Loewen, G; Meropol, N; Pendyala, L; Perez, R; Raghavan, D | 1 |
| Aisner, J; Belani, CP; Conley, B; Egorin, MJ; Engstrom, C; Hiponia, D; Kearns, C; Zuhowski, E | 1 |
| Benner, SE; Hong, WK; Huber, MH; Lippman, SM | 1 |
| Ajani, JA; Ilson, DH; Kelsen, DP | 2 |
| Khansur, T; Thigpen, T; Vance, RB | 1 |
| Ajani, J; Daugherty, K; Ilson, D; Kelsen, D; Pazdur, R | 1 |
| Ajani, JA; Daugherty, K; Ilson, DH; Kelsen, DP | 1 |
| Meijer, OW; van den Berg, J; van Rijn, J | 1 |
| Forastiere, AA; Urba, SG | 1 |
| Allen, J; Smith, RE; Thornton, DE | 1 |
| Elomaa, L; Grénman, R; Joensuu, H; Klemi, P; Kulmala, J | 1 |
| Close, LG; Fathallah-Skaykh, H; Gazdar, AF; Griener, J; Kamen, B; Lucci, JA; Rosenthal, DI; Schold, SC; Truelson, J; Vuitch, FM | 1 |
| Abe, S; Fujii, M; Furuse, K; Inoue, Y; Kurita, Y; Oizumi, K; Onoshi, T; Sato, K; Sugiura, T; Watanabe, K | 1 |
| Forastiere, AA | 3 |
| Schalhorn, B | 1 |
| Braakhuis, BJ; Kegel, A; Welters, MJ | 1 |
| Adams, G; DeConti, R; Forastiere, AA; Neuberg, D; Taylor, SG | 1 |
| Ajani, JA; Daugherty, K; Ilson, DH; Kelsen, DP; Lynch, PM; Pazdur, R | 1 |
| Catimel, G; Clavel, M; Franklin, H; Hanauske, A; Kaye, SB; Le Bail, N; Mattijssen, V; Piccart, M; Verweij, J; Wanders, J | 1 |
| Hirabayashi, K; Kono, I; Noda, K; Ogita, Y; Taguchi, T; Terajima, Y; Yakushiji, M | 1 |
| Bochtler, H; Diergarten, K; Hanauske, AR; Heinrich, B; Herzog, M; Kau, R; Quasthoff, S; Rastetter, J; Schilling, T | 1 |
| Elomaa, L; Grenman, R; Joensuu, H; Martikainen, P; Pulkkinen, JO; Servomaa, K | 1 |
| Au, JL; Gan, Y; Schuller, DE; Wientjes, MG | 1 |
| Blessing, JA; Lentz, SS; McGuire, WP; Moore, D; Photopulos, G | 1 |
| Busse, PM; Clark, JR; Costello, R; Dreyfuss, AI; Lucarini, JW; Norris, CM; Posner, MR; Poulin, MD; Rossi, RM; Thornhill, L | 1 |
| Erlich, E; McCall, AR; Potkul, RK; Vaughan, A; Walter, S | 1 |
| Dreps, A; Gatzemeier, U; Heckmayer, M; Neuhauss, R; Schlüter, I; von Pawel, J; Wagner, H | 1 |
| Adams, D; Belli, L; Gottfried, M; LeCesne, A; LeChevalier, T; Pellae-Cosset, B; Ruffie, P; Tete, L | 1 |
| Grénman, R; Grénman, S; Jaakkola, M; Kulmala, J; Rantanen, V | 1 |
| Cardenal, F; Llort, G; Mesía, R; Montes, A; Seguí, J | 1 |
| Chung, WK; Hunter, NR; Mason, KA; Milas, L; Milross, CG; Peters, LJ | 1 |
| Edwards, CL; Ende, K; Fishman, A; Freedman, RS; Kaplan, A; Kavanagh, JJ; Kieback, DG; Kudelka, AP; Levy, T; Mante, R; Steger, M; Verschraegen, CF | 1 |
| Ilson, DH; Kelsen, DP | 1 |
| Bunn, PA; Chan, DC; Chou, TC; Kumar, R; Leonard, CE | 1 |
| Edwards, CL; Kavanagh, JJ; Kudelka, AP; Loyer, E; Piamsomboon, S; Termrungruanglert, W; Verschraegen, CF | 1 |
| Hanske, M; Hecker, D; Heider, A; Koschel, G; Niederle, N; von Pawel, J; Wagner, H | 1 |
| Griffon-Etienne, G; Marchal, C; Merlin, JL | 2 |
| Khansur, T; Malamud, F; Thigpen, T; Vance, R | 1 |
| Aisner, J; Cortés-Funes, H | 1 |
| Brandariz, A; Colomer, R; Cortés-Funes, H; Hidalgo, M; Hitt, R; Hornedo, J; Peña, M; Vicent, JA | 1 |
| Athanassiadis, A; Bacoyiannis, H; Daniilidis, J; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Nikolaou, A; Samantas, E; Skarlos, D; Stathopoulos, G | 1 |
| Bamberg, M; Belka, C; Bochtler, H; Budach, W; Heinrich, V; Hoffmann, W; Rodemann, HP; Schmidberger, H | 1 |
| Aisner, J; Conley, B; Gray, W; Jacobs, M; Ord, RA; Suntharalingam, M; Zacharski, D | 1 |
| Carbone, DP; Fathallah-Shaykh, H; Gazdar, AF; Griener, J; Hamilton, L; Landay, M; McWhorter, J; Mendelsohn, D; Okani, O; Orr, KY; Rosenthal, DI; Tourville, J; Truelson, JM; Vuitch, FM | 1 |
| Gallagher, CJ; Johnson, PW; Oliver, RT; Papamichael, D; Waxman, J | 1 |
| Ingram, ML; Redpath, JL | 1 |
| Hittelman, WN; Jibu, T; Li, D; Milas, L; Milross, CG; Peters, LJ; Saito, Y | 1 |
| Bamberg, M; Belka, C; Bochtler, H; Budach, W; Hess, CF; Hoffmann, W; Schmidberger, H | 1 |
| Ciesielski-Carlucci, C; Jacobs, C; Leong, P | 1 |
| Harada, S; Hunter, NR; Jibu, T; Mason, KA; Milas, L; Milross, CG; Patel, N; Seong, J; Terry, NH | 1 |
| Arbuck, S; Dakhil, SR; Delmore, JE; Downey, G; Edwards, CL; Freedman, RS; Fueger, R; Gacrama, P; Greenberg, H; Kavanagh, JJ; Kudelka, AP; LoCoco, S; Loyer, E; Umbreit, J; Winn, R | 1 |
| Fukuda, S; Inuyama, Y; Satoh, N | 1 |
| Fujimura, M; Fushiki, H; Hidaka, T; Hori, S; Izumi, R; Yamakawa, Y | 1 |
| Boyd, JH; Dunleavy, TL; Dunphy, CH; Dunphy, FR; Kim, HJ; Lowe, V; McDonough, EM; Minster, J; Rodriguez, J; Varvares, MA | 1 |
| Akerley, WL; Chougule, P; Cole, B; Koness, RJ; Leone, L; McRae, R; Nigri, P; Ready, N; Safran, H; Wanebo, HJ; Webber, B | 1 |
| Carey, RW; Choi, NC; Grillo, HC; Grossbard, ML; Lynch, TJ; Mathisen, DJ; Moncure, AC; Wain, JC; Wright, CD | 1 |
| Capri, G; Cavina, R; Fulfaro, F; Gianni, L; Grandi, C; Licitra, L; Tarenzi, E | 1 |
| Alvarez-Vicent, J; Brandariz, A; Colomer, R; Cortés-Funes, H; Hidalgo, M; Hitt, R; Hornedo, J; Paz-Ares, L; Peña, M | 1 |
| Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Lawhorn, K; Lippman, SM; Shin, DM | 1 |
| Greco, FA; Hainsworth, JD; Meluch, AA | 1 |
| Ensley, J; Hussain, M; Kucuk, O; Salwen, W | 1 |
| Akerley, W; Chougule, P; Cole, B; Koness, RJ; Leone, L; McRae, R; Nigri, P; Radie-Keane, K; Ready, N; Safran, H; Wanebo, H | 1 |
| Hassan, M; Hoppel, C; Mackay, W; McGloin, B; Mugharbil, A; Olmsted, L; Sharan, V; Steinberg, L; Stepnick, D; Strauss, M; Subramanyan, S | 1 |
| Carbone, DP; Corak, J; Frenkel, EP; Gazdar, AF; Griener, J; Kamen, B; Kavanaugh, D; Okani, O; Rosenthal, DI; Sinard, RJ; Vuitch, FM | 1 |
| Belani, CP; Day, R; Ferson, PF; Keenan, RJ; Kim, R; Landreaneau, RJ; Lembersky, B; Luketich, JD; Posner, M; Ramanathan, RK; Seeger, J | 1 |
| Coia, LR; Colarusso, P; Dresler, C; Goldberg, M; Weiner, LM | 1 |
| Fountzilas, G; Papakostas, P; Rigatos, S; Stathopoulos, GP | 1 |
| Andreeff, M; Consoli, U; Ling, YH; Perez-Soler, R; Tornos, C | 1 |
| Altmannsberger, HM; Hassenstein, EO; Rexroth, G; Rösch, W | 1 |
| Ang, KK; Callender, DL; Clayman, GL; Gillenwater, AM; Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Lawhorn, K; Lee, JJ; Lippman, SM; Papadimitrakopoulou, V; Shin, DM | 1 |
| Adak, S; Barton, JJ; Busse, PM; Colevas, AD; Costello, R; Dreyfuss, A; Fabian, RL; Fitzgerald, TJ; Fried, M; Norris, CM; Peters, ES; Posner, MR; Poulin, M; Tishler, RB | 1 |
| Eltabbakh, GH; Hempling, RE; O'Neill, CP; Recio, FO | 1 |
| Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM | 2 |
| Ajani, J; Bhalla, K; Donegan, J; Forastiere, A; Huang, Y; Ilson, DH; Kelsen, DP; Martin, L; Patel, P; Pazdur, R; Reed, C | 1 |
| Diergarten, K; Hanauske, AR; Heinrich, B; Herzog, M; Kau, R; Kemmerich, M; Laubenbacher, C; Quasthoff, S; Theiss, F; Thödtmann, F | 1 |
| Adams, G; DeConti, RC; Forastiere, AA; Neuberg, D; Shank, D; Taylor, SG | 1 |
| Eisele, DW; Forastiere, AA; Lee, DJ; Westra, WH | 1 |
| Graeven, U; König, M; Petrasch, S; Reinacher, A; Schmiegel, W; Welt, A | 1 |
| Tan, WW; Walsh, T | 1 |
| Friedl, R; Hagen, R; Hoppe, F; Pfreundner, L; Preisler, VK; Schindler, D; Stopper, H | 1 |
| Colevas, AD; Posner, MR | 1 |
| Capen, CC; Gröne, A; Rosol, TJ; Weckmann, MT | 1 |
| Dakhil, SR; Downey, G; Edwards, CL; Freedman, RS; Fueger, R; Gacrama, P; Greenberg, H; Kavanagh, JJ; Kudelka, AP; Loyer, E; Rusinkiewicz, J; Winn, R | 1 |
| Caldarelli, DD; Coon, JS; Griem, K; Hutchinson, J; Kotelnikov, VM; LaFollette, S; Mundle, S; Panje, W; Preisler, HD; Taylor, S; Wood, N | 1 |
| Colombo, N; Gueli-Alletti, D; Lissoni, A; Mangioni, C; Pellegrino, A; Sessa, C; Zanetta, G | 1 |
| Androulakis, N; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kourousis, C; Maltezakis, G; Metaxaris, G; Samonis, G; Souglakos, J; Vlachonikolis, J | 1 |
| Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G | 1 |
| Baba, S; Ebihara, S; Horiuchi, M; Ichikawa, G; Inuyama, Y; Kamata, S; Kanzaki, J; Kataura, A; Kida, A; Konno, A; Kono, N; Kubota, A; Matsunaga, T; Matsuura, H; Miyake, H; Moriyama, H; Saijo, S; Saito, H; Sakai, M; Sasaki, Y; Satake, B; Taguchi, T; Takeoda, S; Togawa, K; Tsukuda, M | 1 |
| Bömecke, M; Hess, CF; Lehmann, J; Meden, H; Pradier, O; Rave-Fränk, M; Schmidberger, H | 1 |
| Catimel, G; Droz, JP; Gras, L; Hanauske, AR; Planting, AS; Schöffski, P; Schrijvers, A; Schrijvers, D; Verweij, J; Wanders, J | 1 |
| Lippman, SM; Shin, DM | 1 |
| Akerley, W; Akhtar, MS; Bellino, J; Chougule, PB; Koness, J; McRae, R; Nigri, P; Radie-Keane, K; Ready, N; Safran, H; Wanebo, H | 1 |
| DeConti, R; Flood, W; Forastiere, AA; Khuri, F; Lee, DJ; Murphy, B; Spencer, S; Trotti, A; Wheeler, R | 1 |
| Brockstein, BE; Haraf, DJ; Vokes, EE; Weichselbaum, RR | 1 |
| Aviles, V; Carbone, DP; Chalian, AA; Dowell, JE; Machtay, M; Rosenthal, DI; Sinard, R; Weber, RS; Weinstein, GS; Yardley, DA | 1 |
| Bacoyiannis, C; Daniilidis, J; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Kosmidis, P; Nicolaides, C; Nikolaou, A; Papadimitriou, C; Pavlidis, N; Samantas, E; Stathopoulos, G | 1 |
| Kuroda, M; Mizuno, A; Noguchi, S; Ohishi, A; Sakuma, F; Takagi, T; Terashima, K | 1 |
| Higuchi, T; Hunter, N; Inoue, T; Kim, EE; Li, C; Milas, L; Oriuchi, N; Podoloff, DA; Wallace, S; Yang, DJ; Yu, D | 1 |
| Engblom, P; Grènman, R; Grènman, S; Hirvonen, H; Kulmala, J; Pulkkinen, JO; Rantanen, V | 1 |
| Hunter, NR; Mason, KA; Milas, L; Schimming, R | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Armand, JP; Bordessoule, S; Chouaki, N; Couteau, C; De Forni, M; Domenge, C; Groult, V; Janot, F; Lebecq, A; Leyvraz, S; Oulid-Aissa, D | 1 |
| Eckardt, A; Fokas, K; Haindl, J; Hüttmann, C | 1 |
| Adak, S; Amrein, P; Barton, J; Colevas, AD; Costello, R; Fried, MP; Gomolin, HI; Lamb, C; Nixon, A; Norris, CM; Posner, MR; Read, R; Tishler, RB | 1 |
| Eckardt, A; Karstens, JH; Wildfang, I | 1 |
| Blessing, JA; Gershenson, DM; McGehee, R; Rose, PG | 1 |
| Du, W; Ensley, J; Gadgeel, S; Hussain, M; Kucuk, O; Salwen, W | 1 |
| Agrawal, A; Au, JL; Bauer, CJ; Gahbauer, RA; Grecula, JC; Johnson, A; Martinez-Monge, R; Nag, S; Rhoades, CA; Schuller, DE; Young, D | 1 |
| Colpaert, C; Schrijvers, D; Van den Brande, J; Vermorken, JB | 1 |
| Baylor, A; Cullen, KJ; Forastiere, AA; Heath, EI; Johnston, PG; Langmacher, M; Lee, M; Rasmussen, AA; Shiga, H; Trock, B | 1 |
| Akimoto, T; Buchmiller, L; Hunter, N; Kishi, K; Komaki, R; Mason, KA; Milas, L | 1 |
| Furukawa, T; Irie, K; Iwanaga, K; Katoh, O; Kuroki, S | 1 |
| De Mulder, PH | 1 |
| Fukunaga, K; Inoue, T; Kameyama, K; Kawada, I; Oyamada, Y; Takeshita, K; Yamaguchi, K; Yamazaki, K | 1 |
| Goldberg, M; Langer, CJ; Millenson, MM; Movsas, B; Rogatko, A; Rogers, B; Schilder, RJ | 1 |
| Burtness, BA; Canto, MI; Forastiere, AA; Heath, EI; Heitmiller, RF; Kaufman, HS; Kleinberg, L; Knisely, JP; Olukayode, K; Salem, R; Talamini, MA; Topazian, M; Wu, TT; Yang, SC | 1 |
| Fei, F; Mangioni, C; Zanetta, G | 1 |
| Shin, DM | 1 |
| Bessa, EH; Lena, H; Paillotin, D; Pérol, M; Robinet, G; Schuller-Lebeau, MP; Taytard, A; Thomas, P; Vergnenègre, A | 1 |
| Aisner, JA; Conley, BA; Egorin, MJ; Gray, WC; Haas, ML; Herman, JM; Jacobs, MC; Levy, S; Ord, RA; Sivasailam, S; Suntharalingam, M; Van Echo, DA | 1 |
| Aviles, V; Chalian, AA; Kligerman, MM; Machtay, M; Mirza, N; Rosenthal, DI; Treat, J; Weber, RS; Weinstein, GS | 1 |
| Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E | 1 |
| Brockstein, B | 1 |
| Casella, G; De Vivo, R; Ferrari, E; Frezza, P; Iodice, F; Perrone, F; Pignata, S; Ricchi, P; Silvestro, G; Tambaro, R; Tramontana, F; Tramontana, S | 1 |
| Androulakis, N; Dimopoulos, MA; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kouroussis, C; Samonis, G; Souglakos, J; Voloudaki, A | 1 |
| Choy, H; Devore, RF; Hande, KR; Johnson, DH; Porter, LL; Rosenblatt, P; Schlabach, L; Shyr, Y; Smith, C; Yunus, F | 1 |
| Dabas, B; Khattab, J; Terebelo, HR | 1 |
| Adak, S; Amrein, PC; Barton, JJ; Colevas, AD; Costello, R; Posner, MR | 1 |
| Hashimoto, T; Ito, Y; Kawakami, M; Morita, T; Nakao, K; Otsuki, Y; Sasaki, S; Tachibana, S; Tokitsu, H; Tokuhara, T | 1 |
| Atadja, P; Cohen, D; Roninson, IB; Uchiyama, N; Watanabe, T | 1 |
| Baylor, A; Cullen, KJ; Johnston, PG; Langmacher, M; Lee, M; Rasmussen, AA; Shiga, H | 1 |
| Colevas, AD; Posner, MR; Tishler, RB | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Bafaloukos, D; Briasoulis, E; Christodoulou, C; Fountzilas, G; Kalofonos, H; Kosmidis, P; Pavlidis, N; Samantas, E; Skarlos, D; Xiros, N | 1 |
| D'Amico, TA; Harpole, DH | 1 |
| Blackinton, D; Klostergaard, J; Kouttab, N; Mehta, S; Myrick, D; Omar, I; Wanebo, H | 1 |
| Kristopaitis, T; Lee, JM; Petruzzelli, GJ; Thomas, C | 1 |
| Hansen, HS; Larsen, SK; Specht, L | 1 |
| Algazy, KM; Aviles, VM; Chalian, AA; Greenberg, MJ; Hershock, D; Machtay, M; Mirza, N; Neubauer, R; Rosenthal, DI; Weber, RS; Weinstein, GS | 1 |
| Kanaeda, T; Kurihara, M; Masaoka, N; Nagai, N; Ohtani, K; Sakamoto, H; Satoh, K; Shimada, K | 1 |
| Ando, I; Iida, Y; Kusunoki, M; Nakazawa, E; Nishiya, M | 1 |
| Agrawal, A; Allen, J; Goldman, FP; Grecula, JC; Rhoades, CA; Schuller, DE; Sharma, P; Smith, RE; Young, D; Zhang, H | 1 |
| Amo-Takyi, BK; Boabang, P; Kohlhagen, H; Kurbacher, CM; Waida, A | 1 |
| Barnouin, L; Cals, L; Cupissol, D; Guardiola, E; Guerrier, P; Merad, L; Pivot, X; Savary, J; Schneider, M; Tchiknavorian, X; Thyss, A; Wendling, JL | 1 |
| Gomez, J; Jagirdar, J; Kemp, B; Lee, JS; Ling, YH; Mao, L; Perez-Soler, R; Wu, QP; Yee, H; Zeleniuch-Jacquotte, A | 1 |
| Albert, PS; Boss, C; Cook, JA; Duffey, DC; Figg, WD; Herscher, LL; Kroog, GS; McCullugh, L; Mitchell, JB; Muir, C; Ondrey, FG; Rudy, S; Solomon, BI; Sunwoo, JB; Thomas, GR; Van Waes , C; Zhai, S | 1 |
| Ochel, H | 1 |
| Hong, SD; Hong, SP; Kim, MJ; Kim, YY; Myoung, H | 1 |
| Conley, BA; Gray, WC; Haas, ML; Haddad, R; Jacobs, MC; Levy, S; Ord, RA; Suntharalingam, M; Van Echo, DA | 1 |
| Al-Sarraf, M; Colevas, AD; Frenette, G; Garay, CA; Glisson, B; Norris, CM; Olivares, R; Posner, MR; Seroskie, JD; Shin, DM | 1 |
| Adams, GL; DeConti, RC; Forastiere, AA; Leong, T; Murphy, BA; Rowinsky, E; Vlock, DR | 1 |
| Chen, YM; Chou, KC; Lee, YC; Perng, RP; Shih, JF; Tsai, CM | 1 |
| Endo, M; Kadou, T; Kotani, Y; Ohbayashi, K; Satouchi, M; Takada, Y | 1 |
| Wang, H | 1 |
| Carbone, DP; Chalian, AA; Egorin, MJ; Frenkel, EP; Lee, JH; Machtay, M; Miller, LK; Rosen, DM; Rosenthal, DI; Sinard, R; Weber, RS; Weinstein, GS; Yardley, DA | 1 |
| Ajani, JA; Komaki, R; Pisters, PW; Putnam, J; Roth, JA; Schnirer, II; Swisher, S; Yao, JC | 1 |
| Boyd, JH; Dunleavy, TL; Dunphy, FR; Harrison, BR; Kim, HJ; Needles, B; Stack, BC; Trinkaus, KM | 1 |
| Boghun, O; Hess, CF; Lehmann, J; Lücke, E; Pradier, O; Rave-Fränk, M; Schmidberger, H | 1 |
| Brockstein, B; Chung, T; Haraf, DJ; Kies, MS; List, M; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, A; Rosen, F; Stenson, K; Vokes, EE; Weichselbaum, R | 1 |
| Ang, KK; Clayman, G; Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Lee, JJ; Lippman, SM; Papadimitrakopoulou, VM; Shin, DM | 1 |
| Akerman, P; Chen, MH; Gaissert, H; Graziano, S; Hesketh, PJ; Koness, J; Moore, T; Safran, H; Wanebo, HJ | 1 |
| Avallone, A; Biglietto, M; Caponigro, F; Comella, G; Comella, P; De Lucia, L; Mantovani, G; Manzione, L; Massa, E; Rosati, G; Sganga, P; Sguotti, C | 1 |
| Posner, MR | 1 |
| Bittner, C; Feyerabend, T; Peters, SO; Raap, M; Remmert, S; Robins, IH; Sieg, P; Sommer, K; Wiedemann, GJ | 1 |
| Blackburn, A; Buchanan, A; Cunningham, C; Edelman, G; Kirn, D; Maples, P; Nemunaitis, J; Netto, G; Olson, S; Randlev, B; Tong, A | 1 |
| Hori, H; Kinashi, Y; Masunaga, SI; Murayama, C; Nagasawa, H; Nishimura, Y; Ono, K; Sadahiro, S; Suzuki, M; Takagaki, M; Tsuchiya, I; Uto, Y | 1 |
| Ajani, JA; Komaki, R; Lahoti, S; Lynch, PM; Martin, FD; Nesbitt, J; Pisters, PW; Putnam, JB; Raijman, I; Roth, JA; Smythe, R; Swisher, S; Vaporciyan, A; Walsh, G | 1 |
| Hirashima, Y; Kanayama, N; Kobayashi, H; Miura, K; Nishiguchi, T | 1 |
| Baker, MN; Burris, HA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH | 1 |
| Kashimura, M; Matsuura, Y; Murakami, N; Nagashio, E; Toki, N | 1 |
| Ackerley, W; Chougule, P; Kennedy, T; Koness, RJ; Leone, L; McRae, R; Nigri, P; Radie-Keane, K; Ready, N; Reiss, P; Safran, H; Wanebo, H | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Katsumata, N; Miyakawa, K; Takahashi, T; Tsuda, H; Watanabe, T | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Delprino, L; Recalenda, V; Rocco, F; Tagini, V | 1 |
| Fujita, S; Hasegawa, T; Ikeda, A; Kaneshiro, E; Katakami, N; Nishimura, T; Nishio, C; Okazaki, M; Umeda, B | 1 |
| Bidoli, P; Cantù, G; Cerrotta, AM; Damascelli, B; Di Tolla, G; Dosio, F; Frigerio, LF; Garbagnati, F; Lanocita, R; Leo, E; Marchianò, A; Mattavelli, F; Patelli, G; Spreafico, C; Tamplenizza, P; Tichà, V; Vespro, V; Zunino, F | 1 |
| Bastian, R; Choudhury, A; Clark, JI; Collins, S; Emami, B; Hofmeister, C; Matz, G; Melian, E; Petruzzelli, G | 1 |
| Burkey, BB; Coleman, SC; Day, TA; Netterville, JL; Pietenpol, JA; Stewart, ZA | 1 |
| Grénman, R; Grénman, S; Klemi, P; Kulmala, J; Pulkkinen, J; Raitanen, M; Rantanen, V | 1 |
| Yokoyama, J | 1 |
| Aihara, T; Akisada, T; Fukuda, K; Gyoten, M; Harada, T; Hiratsuka, J; Imai, S; Imajo, Y; Kajihara, Y; Morita, N; Takemoto, T | 1 |
| Araki, S; Hongo, A; Kawanishi, K; Kodama, J; Kudo, T; Miyagi, Y; Yamamoto, J; Yoshinouchi, M | 1 |
| Eskens, FA; Polee, MB; Siersema, PD; Splinter, TA; Stoter, G; Tilanus, HW; van der Burg, ME; van der Gaast, A; Verweij, J | 1 |
| Merlano, M; Numico, G | 1 |
| Feher, O; Kowalski, LP; Lima, CA; Martins, SJ; Salvajoli, JV; Simpson, AJ | 1 |
| Forastiere, AA; Frenette, G; Glisson, BS; Khuri, FR; Murphy, BA | 1 |
| Adak, S; Colevas, AD; Costello, R; Fried, MP; Goguen, LA; Gopal, HV; Lamb, CC; Norris, CM; Posner, MR; Read, R; Tishler, RB | 1 |
| Guillet, G; Karam, A; Labat, JP; Leroy, JP; Metges, JP | 1 |
| Ando, N; Shih, CH | 1 |
| Cavina, R; Cerrotta, A; De Palo, G; Garassino, I; Gardan, G; Musumeci, R; Raspagliesi, F; Stefanon, B; Tana, S | 1 |
| Altun, M; Basaran, M; Bavbek, SE; Demirelli, F; Güllü, I; Onat, H; Sakar, B; Tenekeci, N; Yalçin, S | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Kovács, AF; Schiemann, M; Turowski, B | 1 |
| Abdel-Wahab, M; Abitbol, A; Hamilton-Nelson, KL; Lewin, A; Markoe, A; Rodrigues, MA; Troner, M | 1 |
| Arbea, L; Calvo, E; Cambeiro, M; Cortes, J; Diaz-Gonzalez, JA; Garcia-Foncillas, J; Garzon, C; Gil-Bazo, I; Gurpide, A; Martin-Algarra, S; Navarro, V; Nicolas, AI; Rodriguez, J | 1 |
| Slichenmyer, WJ; Von Hoff, DD | 1 |
| De Brabander, M; Geerts, H; Hopkins, CR; Nuydens, R | 1 |
64 review(s) available for paclitaxel and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Approach to Localized Squamous Cell Cancer of the Esophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Epithelial Cells; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Platinum; Quality of Life | 2022 |
Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis.
Topics: B7-H1 Antigen; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoadjuvant Therapy; Paclitaxel | 2022 |
Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Uterine Cervical Neoplasms | 2023 |
Phase II multicenter trial: first-line immunochemotherapy with or without radiotherapy in metastatic esophageal squamous cell cancer (SCR-ESCC-01).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Immunotherapy; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic | 2023 |
Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Brazil; Carcinogenesis; Carcinoma, Squamous Cell; Cell Proliferation; Computational Biology; Etoposide; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mouth Neoplasms; Neoplasm Proteins; Paclitaxel; Plant Extracts; Plants, Medicinal; Vinblastine | 2021 |
[Squamous cell anal carcinoma. What's next ?]
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Contraindications, Drug; DNA, Viral; Fluorouracil; Humans; Immune Checkpoint Inhibitors; Immunity, Cellular; Neoplasm Recurrence, Local; Paclitaxel; Telomerase | 2021 |
Systemic Therapies for Advanced Squamous Cell Anal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biomarkers, Tumor; Carcinoma, Squamous Cell; Clinical Trials as Topic; ErbB Receptors; HIV Infections; Humans; Immunotherapy; Mitomycin; Molecular Targeted Therapy; Paclitaxel | 2018 |
A network meta-analysis of the treatments for esophageal squamous cell carcinoma in terms of survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Network Meta-Analysis; Paclitaxel; Survival Analysis | 2018 |
Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Nivolumab; Organoplatinum Compounds; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Salvage Therapy; Survival Analysis; Treatment Outcome | 2018 |
Eruptive purpuric papules on the arms; a case of chemotherapy-induced inflammation of actinic keratoses and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Eruptions; Epidermis; Forearm; Hepatitis B, Chronic; Humans; Keratosis, Actinic; Lung Neoplasms; Male; Necrosis; Paclitaxel; Purpura; Sunlight; Vasculitis | 2014 |
Endoscopy innovations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug-Eluting Stents; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endoscopy, Gastrointestinal; Esophageal Neoplasms; Esophageal Sphincter, Lower; Humans; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Pancreatic Neoplasms; Portal Vein; Suture Techniques; Tomography, Optical Coherence | 2014 |
nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update.
Topics: Albumins; Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 2014 |
Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Fluorouracil; Humans; Neoadjuvant Therapy; Paclitaxel; Platinum Compounds; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Adenocarcinoma With Breast/Adnexal and Upper Gastrointestinal Differentiation Arising in an Ovarian Mature Cystic Teratoma: A Case Report and Review of the Literature.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cisplatin; Female; Gastrointestinal Neoplasms; Humans; Middle Aged; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Skin Neoplasms; Teratoma; Treatment Outcome | 2016 |
Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Survivin | 2015 |
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Discovery; Gemcitabine; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2016 |
The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2016 |
A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review.
Topics: Adult; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Squamous Cell; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 2016 |
Squamous cell carcinoma presenting as a solitary growing cyst in lung: a diagnostic pitfall in daily clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cysts; Diagnostic Errors; Frozen Sections; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Staging; Paclitaxel; Pneumonectomy; Solitary Pulmonary Nodule; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2009 |
Primary squamous cell carcinoma of the ovary associated with endometriosis.
Topics: Abdominal Pain; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Endometriosis; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Ovarian Neoplasms; Paclitaxel; Prognosis; Uterine Cervical Neoplasms | 2010 |
Neoadjuvant chemotherapy with paclitaxel plus platinum for invasive cervical cancer in pregnancy: two case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Squamous Cell; Cesarean Section; Cisplatin; Female; Humans; Live Birth; Neoadjuvant Therapy; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Cervical Neoplasms | 2011 |
Molecular targeting agents in the context of primary chemoradiation strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease Progression; ErbB Receptors; Fluorouracil; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Oropharyngeal Neoplasms; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
Taxol: efficacy against oral squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Survival; Clinical Trials as Topic; Disease Models, Animal; Drug Therapy, Combination; Humans; Mouth Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Tongue Neoplasms | 2013 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
End points for new agents in induction chemotherapy for locally advanced head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Neoplasm Staging; Paclitaxel; Remission Induction; Taxoids | 2003 |
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Taxoids | 2003 |
Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Hematologic Diseases; Humans; Hysterectomy; Life Tables; Lymphatic Irradiation; Lymphatic Metastasis; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Radiation Injuries; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Retrospective Studies; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Ifosfamide in the treatment of head and neck cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Ifosfamide; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2003 |
Palliative cytostatic treatment of cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Mitomycin; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Survival Analysis; Uterine Cervical Neoplasms; Vindesine | 2003 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Taxanes in the treatment of head and neck cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Medical Oncology; Paclitaxel; Taxoids | 2005 |
Revisiting induction chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Taxoids | 2005 |
[Successful removal of T4 lung cancer with left atrial invasion after induction chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cardiac Surgical Procedures; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Heart Atria; Heart Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pneumonectomy | 2005 |
Primary combined-modality therapy for esophageal cancer.
Topics: Algorithms; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deglutition Disorders; Dose Fractionation, Radiation; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Failure | 2006 |
[Head and neck: molecular-targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Head and Neck Neoplasms; Humans; Paclitaxel; Quinazolines | 2007 |
Metastatic squamous cell carcinoma of the urachus.
Topics: Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Fatal Outcome; Humans; Male; Neoplasm Metastasis; Paclitaxel; Tomography, X-Ray Computed; Urachus; Urinary Bladder Neoplasms | 2007 |
The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms | 1995 |
Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Head and Neck Neoplasms; Humans; Ifosfamide; Paclitaxel | 1995 |
Current and future trials of Taxol (paclitaxel) in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Forecasting; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic | 1994 |
Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Female; Forecasting; Head and Neck Neoplasms; Humans; Male; Neutropenia; Paclitaxel; Thrombocytopenia | 1993 |
Management of esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Esophageal Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Premedication; Radiotherapy, Adjuvant; Vinblastine; Vinorelbine | 1996 |
Remission of recurrent cervical cancer with paclitaxel and carboplatin: a case report and review of literature.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 1996 |
The role of paclitaxel in the management of patients with carcinoma of the cervix.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Female; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
Paclitaxel in head and neck cancer and other tumor types: chairmen's introduction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Paclitaxel; Urinary Bladder Neoplasms | 1997 |
Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles.
Topics: Aged; Anaphylaxis; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Hypersensitivity; Fatal Outcome; Humans; Laryngeal Neoplasms; Lung Neoplasms; Male; Paclitaxel; Respiratory Insufficiency; Vocal Cords | 1997 |
[Head and neck cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Paclitaxel; Taxoids | 1997 |
Update on the taxoids and other new agents in head and neck cancer therapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Replication; DNA, Neoplasm; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Interferon-alpha; Microtubules; Neoplasm Proteins; Organoplatinum Compounds; Paclitaxel; Radiation-Sensitizing Agents; Remission Induction; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome; Tubulin Modulators | 1998 |
Docetaxel in head and neck cancer: a review.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 1998 |
Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel | 1999 |
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Life Tables; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Tomography, X-Ray Computed | 1999 |
The chemotherapy of head and neck cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 1999 |
Taxoids in head and neck cancer: the American approach.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; United States | 1999 |
Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Salvage Therapy; Taxoids; Uterine Cervical Neoplasms | 2000 |
Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Ifosfamide; Mesna; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2000 |
[Recent regimen of chemotherapy for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Prognosis; Taxoids | 2000 |
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Decision Making; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Taxoids | 2000 |
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Molecular biology of esophageal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Barrett Esophagus; Biomarkers, Tumor; Carcinoma, Squamous Cell; DNA Damage; Esophageal Neoplasms; Genes, p53; Humans; Incidence; Mutation; Paclitaxel; Prognosis; Risk Factors | 2000 |
Docetaxel in squamous cell cancer of the head and neck.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Taxoids | 2001 |
[Present role and future prospect of superselective intra-arterial infusion chemotherapy for head and neck cancer].
Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Paclitaxel; Prospective Studies; Taxoids; Thiosulfates | 2002 |
[Chemotherapy for the patients with esophageal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel | 2002 |
New natural products in cancer chemotherapy.
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan | 1990 |
391 trial(s) available for paclitaxel and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Humans; Immune Checkpoint Inhibitors; Induction Chemotherapy; Japan; Lung Neoplasms; Maintenance Chemotherapy; Middle Aged; Paclitaxel; Pemetrexed; Progression-Free Survival | 2021 |
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical stu
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liposomes; Lung; Lung Neoplasms; Middle Aged; Paclitaxel; Young Adult | 2022 |
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camelus; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Paclitaxel | 2022 |
Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel | 2022 |
A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Paclitaxel | 2023 |
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Progression-Free Survival; Quality of Life | 2020 |
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Albumins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Paclitaxel | 2020 |
Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Paclitaxel | 2020 |
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Genes, erbB-1; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Programmed Cell Death 1 Receptor; Progression-Free Survival; Treatment Outcome | 2020 |
Neoadjuvant chemotherapy followed by conization in stage IB2-IIA1 cervical cancer larger than 2 cm: a pilot study.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Conization; Disease-Free Survival; Feasibility Studies; Female; Fertility Preservation; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Paclitaxel; Patient Acceptance of Health Care; Pilot Projects; Pregnancy; Pregnancy Rate; Tumor Burden; Uterine Cervical Neoplasms; Young Adult | 2021 |
A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2021 |
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Paclitaxel | 2021 |
A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Injections, Subcutaneous; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Severity of Illness Index; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2021 |
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Progression-Free Survival; Prospective Studies | 2021 |
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Decision-Making; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Progression-Free Survival; Smokers; Time Factors; Transcriptome | 2021 |
An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Eruptions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Paclitaxel; Remission Induction; Retrospective Studies; Tegafur; Vomiting | 2017 |
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Uterine Cervical Neoplasms | 2017 |
Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Time Factors; Treatment Outcome | 2017 |
nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials, Phase II as Topic; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2017 |
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate | 2017 |
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Sirolimus; Squamous Cell Carcinoma of Head and Neck | 2017 |
Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Progression-Free Survival; Ribavirin | 2018 |
Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Survivors; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Digestive System Surgical Procedures; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quality of Life; Surveys and Questionnaires | 2018 |
Is Lipidomic the Answer to the Search of a Biomarker for Organ Preservation Protocol in Head and Neck Squamous Cell Carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Head and Neck Neoplasms; Humans; Lipids; Paclitaxel; Saliva; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2018 |
Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Humans; Hysterectomy; India; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2018 |
Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Intention to Treat Analysis; Lymph Node Excision; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pelvis; Postoperative Complications; Radiotherapy, Intensity-Modulated; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2018 |
Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Progression-Free Survival; Radiotherapy, Intensity-Modulated | 2018 |
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oropharyngeal Neoplasms; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Prognosis; Survival Rate | 2019 |
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Oxonic Acid; Paclitaxel; Prognosis; Ramucirumab; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur | 2019 |
Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Rate | 2019 |
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2019 |
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maintenance Chemotherapy; Male; Middle Aged; Nanoparticles; Oxonic Acid; Paclitaxel; Prognosis; Survival Rate; Tegafur | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; China; Cisplatin; Consolidation Chemotherapy; Disease-Free Survival; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Photons; Proportional Hazards Models; Treatment Outcome; Young Adult | 2019 |
A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2019 |
Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Tegafur; Treatment Outcome; Uracil | 2019 |
Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Human papillomavirus 6; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organ Preservation; Oropharyngeal Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Pulse Therapy, Drug; Radiotherapy, High-Energy; Risk Assessment; Serologic Tests; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Survival Rate | 2013 |
A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Uterine Cervical Neoplasms; Young Adult | 2013 |
Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Squamous Cell; Drug Delivery Systems; Female; Fibrin Fibrinogen Degradation Products; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Laser-Doppler Flowmetry; Leukocyte Count; Liposomes; Male; Middle Aged; Paclitaxel; Platelet Count; Prospective Studies; Skin; Tumor Necrosis Factor-alpha | 2014 |
Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Deglutition Disorders; Female; Gastrostomy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant | 2014 |
A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Prognosis; Radiotherapy, Intensity-Modulated; Uterine Cervical Neoplasms | 2013 |
Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Teratoma | 2013 |
A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Time Factors; Treatment Outcome | 2013 |
Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Panitumumab; Prognosis; Survival Rate | 2013 |
Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Risk Factors; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).
Topics: Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Intensity-Modulated; Squamous Cell Carcinoma of Head and Neck | 2014 |
Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2014 |
Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma.
Topics: Adenoviridae; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endostatins; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Proteins; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-akt; ras Proteins; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Tissue Array Analysis | 2014 |
A Phase II Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Survival Rate | 2016 |
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2014 |
Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Oropharyngeal Neoplasms; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2014 |
Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; Female; Hemoptysis; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Survival Rate | 2014 |
Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Esophageal Neoplasms; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Panitumumab; Preoperative Care | 2014 |
A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Prospective Studies; Treatment Outcome; Young Adult | 2014 |
Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Squamous Cell; Dermatologic Agents; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Isotretinoin; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Recombinant Proteins; Survival Rate; Uterine Cervical Neoplasms | 2014 |
Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Human papillomavirus 16; Humans; Hysterectomy; Lymph Node Excision; Lymph Nodes; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Papillomavirus Infections; Pelvis; Positron-Emission Tomography; Prospective Studies; Radiotherapy, Adjuvant; Tumor Burden; Uterine Cervical Neoplasms | 2017 |
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2015 |
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Image-Guided; Survival Rate | 2015 |
Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2015 |
Do Cell-Cycle Phase-Specific Markers Predict Disease Grade, Stage, and Outcome in Cervical Carcinoma?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Uterine Cervical Neoplasms; Young Adult | 2015 |
Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Cyclobutanes; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel | 2015 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
Low-dose fractionated radiation and chemotherapy prior to definitive chemoradiation in locally advanced carcinoma of the uterine cervix: Results of a prospective phase II clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2015 |
Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies | 2016 |
Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2016 |
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus: A Phase III Randomized Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis | 2015 |
A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Radiography; Radionuclide Imaging; Survival Rate; Uterine Cervical Neoplasms | 2015 |
The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel | 2016 |
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Retreatment; Treatment Outcome | 2015 |
A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Quinazolines; Treatment Outcome | 2016 |
Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2016 |
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quality of Life; Survival Rate; Taxoids | 2016 |
The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Postoperative Period; Propensity Score; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Concurrent Chemoradiation with Weekly Paclitaxel and Cisplatin for Locally Advanced Cervical Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Iran; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Remission Induction; Uterine Cervical Neoplasms | 2016 |
Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma.
Topics: Aged; Albumins; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Prognosis; Treatment Outcome | 2016 |
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Double-Blind Method; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Safety; Survival Rate | 2017 |
Weekly vinorelbine and paclitaxel in older patients with advanced non-small cell lung cancer: A phase II Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy-Induced Febrile Neutropenia; Disease-Free Survival; Early Termination of Clinical Trials; Female; Heart Arrest; Humans; Hypoxia; Lung Neoplasms; Lymphopenia; Male; Neutropenia; Paclitaxel; Pneumonia; Quality of Life; Respiratory Insufficiency; Survival Rate; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2017 |
Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Hemoglobins; Humans; Karnofsky Performance Status; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platelet Count; Prognosis; Prospective Studies; Uterine Cervical Neoplasms | 2016 |
nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2016 |
A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bacterial Vaccines; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Desmocollins; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Toll-Like Receptor 2; Treatment Outcome | 2017 |
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Panitumumab; Squamous Cell Carcinoma of Head and Neck | 2016 |
A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Paclitaxel; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate | 2017 |
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Double-Blind Method; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; International Agencies; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Survival Rate | 2017 |
Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Radiotherapy, Adjuvant; Survival Rate; Tongue Neoplasms | 2008 |
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction | 2008 |
A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Survival Analysis | 2008 |
[Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Iridium Radioisotopes; Middle Aged; Neoplasm Staging; Paclitaxel; Radioisotope Teletherapy; Survival Rate; Uterine Cervical Neoplasms | 2008 |
Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2008 |
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome | 2009 |
Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2008 |
Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Patient Selection; Quality of Life; Radiotherapy Dosage; Research Design | 2008 |
Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2009 |
High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers.
Topics: Adult; Aged; Amines; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Gefitinib; Head and Neck Neoplasms; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Paresthesia; Prognosis; Quinazolines; Radiation Injuries; Radiotherapy; Stomatitis | 2008 |
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell ce
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Ifosfamide; Middle Aged; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 2009 |
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Penile Neoplasms; Stomatitis; Survival Rate; Treatment Outcome | 2009 |
A landmark point analysis with cytotoxic agents for advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
Maximum tolerated dose and early response - results of a phase I trial of paclitaxel and cisplatin with radiation therapy in carcinoma of the cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Paclitaxel; Radiotherapy; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Follow-Up Studies; Head and Neck Neoplasms; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Treatment Outcome | 2009 |
A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagitis; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Longitudinal Studies; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Thrombocytopenia; Treatment Outcome | 2010 |
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytokines; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Stomatitis; Survival Rate; Xerostomia | 2009 |
Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Radiotherapy; Skin Diseases; Time Factors; Treatment Outcome | 2009 |
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Topics: Acneiform Eruptions; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiodermatitis; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infections; Lung Diseases, Interstitial; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Paclitaxel; Pilot Projects; Quinazolines; Radiotherapy Dosage; Remission Induction; Stomatitis | 2010 |
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Papillomaviridae; Prospective Studies | 2010 |
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Quinazolines; Survival Rate; Young Adult | 2009 |
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate | 2010 |
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Patient Compliance; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Paclitaxel; Radiotherapy; Remission Induction; Uterine Cervical Neoplasms | 2010 |
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Placebos; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Thoracic Surgery; Treatment Outcome | 2010 |
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Feasibility Studies; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Thrombocytopenia | 2010 |
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Female; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Platelet Count; Prognosis; Radiotherapy; Survival Rate; Time Factors | 2010 |
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Penile Neoplasms; Predictive Value of Tests; Prospective Studies; Radiotherapy, Adjuvant; Risk Factors; Treatment Outcome | 2010 |
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds | 2011 |
[A prospective comparison between surgery alone and postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Survival Rate | 2010 |
Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Dose Fractionation, Radiation; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Remission Induction; Survival Rate; Taxoids; Uterine Cervical Neoplasms; Vomiting | 2010 |
[A 24-hour continuous infusion of paclitaxel in the treatment of advanced esophageal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Esophageal Neoplasms; Humans; Infusion Pumps; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2010 |
BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Hemorrhage; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Uterine Cervical Neoplasms; Young Adult | 2011 |
Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
Outcomes of mediastinoscopy and surgery with or without neoadjuvant therapy in patients with non-small cell lung cancer who are N2 negative on positron emission tomography and computed tomography.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Node Excision; Male; Mediastinoscopy; Mediastinum; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease Progression; Endpoint Determination; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 2011 |
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Tissue Distribution; Treatment Outcome; Xanthones | 2011 |
A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy, Adjuvant; ROC Curve; Treatment Outcome | 2011 |
Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Young Adult | 2012 |
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gamma Rays; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiography, Thoracic; Radiotherapy Dosage; Standard of Care; Survival Rate; Treatment Outcome | 2011 |
Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neck Dissection; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Treatment Outcome | 2012 |
Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Dose Fractionation, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Esophagitis; Esophagogastric Junction; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Paclitaxel; Polyglutamic Acid; Treatment Outcome | 2012 |
Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Radiotherapy, Adjuvant; Survival Rate; Uterine Cervical Neoplasms | 2011 |
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Radiotherapy Dosage; Salvage Therapy; Survival Rate | 2012 |
Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Drug Administration Schedule; ErbB Receptors; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Papillomaviridae; Prospective Studies; Remission Induction; Squamous Cell Carcinoma of Head and Neck | 2012 |
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2011 |
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Exanthema; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2012 |
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Humans; Italy; Male; Middle Aged; Paclitaxel; Penile Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2011 |
[Efficacy of Yanshu injection (a compound Chinese traditional medicine) combined with concurrent radiochemotherapy in patients with stage III nasopharyngeal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Leukopenia; Male; Medicine, Chinese Traditional; Mucositis; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Plants, Medicinal; Quality of Life; Radiotherapy, Intensity-Modulated; Sophora; Survival Rate; Thrombocytopenia | 2011 |
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2011 |
Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Dose Fractionation, Radiation; Enteral Nutrition; Feasibility Studies; Female; Follow-Up Studies; Germany; Humans; Hypopharyngeal Neoplasms; Leukopenia; Male; Middle Aged; Mucositis; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Radiation Injuries; Radiotherapy Dosage; Thrombocytopenia | 2011 |
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxindoles; Paclitaxel; Propionates; Pyrroles; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Female; Fever; Humans; Injections, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Radiotherapy, Conformal; Tumor Burden | 2012 |
[A randomized controlled trial of two chemotherapy regimens (paclitaxel liposome combined with platinum and paclitaxel combined with platinum) in concurrent chemoradiotherapy for cervical carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cobalt Radioisotopes; Exanthema; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Iridium Radioisotopes; Liposomes; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Uterine Cervical Neoplasms | 2011 |
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies | 2011 |
Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms | 2012 |
Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Prospective Studies; Vulvar Neoplasms | 2012 |
Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Paclitaxel; Uterine Cervical Neoplasms | 2012 |
A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Hyperglycemia; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Sirolimus; Thrombocytopenia; Treatment Outcome | 2012 |
Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Disease Progression; Disease-Free Survival; ErbB Receptors; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2012 |
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Molybdenum; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Care; Preoperative Care; Prognosis; Remission Induction; Survival Rate | 2013 |
Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Gastrostomy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Osteonectin; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Caspases; Double-Blind Method; Endostatins; Endothelium, Vascular; Female; Humans; Keratin-18; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2012 |
A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2013 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prospective Studies; Remission Induction; Stomach Neoplasms; Survival Rate; Tegafur | 2012 |
A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult | 2012 |
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2013 |
Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2013 |
Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Paclitaxel; Survival Analysis; Treatment Outcome | 2002 |
Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Mesna; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2002 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Diagnostic Imaging; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2002 |
Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Palliative Care; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2002 |
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Paclitaxel; Taxoids | 2002 |
Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Recurrence; Survival Rate; Taxoids; Time Factors | 2002 |
Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neck Dissection; Oropharyngeal Neoplasms; Paclitaxel; Radiotherapy Dosage; Treatment Outcome | 2002 |
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Synergism; Female; Head and Neck Neoplasms; Humans; Isotretinoin; Male; Middle Aged; Paclitaxel; Remission Induction; Uterine Cervical Neoplasms | 2002 |
Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytoprotection; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Radiotherapy, Conformal; Tomography, X-Ray Computed; Xerostomia | 2002 |
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Ifosfamide; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure | 2003 |
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Drug Synergism; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Erythropoietin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Survival Rate; Treatment Outcome | 2003 |
Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Longitudinal Studies; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2003 |
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2003 |
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Preoperative Care; Survival Rate | 2003 |
Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2003 |
Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Confidence Intervals; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Preoperative Care; Risk Assessment; Survival Analysis; Treatment Outcome | 2003 |
Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypopharyngeal Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome | 2003 |
Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Prognosis; Survival Analysis; Treatment Outcome | 2004 |
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Stomatitis; Xerostomia | 2003 |
Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Uterine Cervical Neoplasms | 2004 |
Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2004 |
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Treatment Outcome | 2004 |
Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Paclitaxel; Treatment Outcome | 2004 |
Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Treatment Outcome | 2004 |
A phase II study of carboplatin and paclitaxel in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
Induction chemotherapy to weekly paclitaxel concurrent with curative radiotherapy in stage IV (M0) unresectable head and neck squamous cell carcinoma: a dose escalation study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Dosage; Treatment Outcome | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 2004 |
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Quality of Life; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Sepsis; Survival Analysis; Treatment Outcome | 2004 |
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Nerve Growth Factor; Neurotoxicity Syndromes; Paclitaxel; Predictive Value of Tests; Prognosis; Sensation Disorders; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy; Radiotherapy Dosage; Survival Rate | 2004 |
Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2004 |
Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis | 2004 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Vomiting | 2005 |
Radiation therapy concurrent with weekly paclitaxel for locoregionally advanced nasopharyngeal carcinoma: outcomes of a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Radiotherapy, High-Energy | 2004 |
Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cohort Studies; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2004 |
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Prognosis; Remission Induction; Tumor Suppressor Protein p53 | 2005 |
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Follow-Up Studies; Head and Neck Neoplasms; Humans; Nausea; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prospective Studies; Retreatment; Salvage Therapy; Stomatitis; Vomiting | 2005 |
The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucous Membrane; Paclitaxel; Radiotherapy Dosage | 2004 |
[Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate | 2004 |
Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prospective Studies | 2005 |
Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Prospective Studies; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2005 |
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Postoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Logistic Models; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Drug Eruptions; Esophageal Stenosis; Female; Fluorouracil; Follow-Up Studies; Gastrostomy; Head and Neck Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Radiotherapy, Adjuvant; Surveys and Questionnaires; Survival Rate | 2005 |
Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2005 |
Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2005 |
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Survival Rate; Treatment Outcome | 2005 |
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel | 2005 |
Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Patient Compliance; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Spain; Survival Analysis; Treatment Outcome | 2005 |
Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Middle Aged; Paclitaxel; Pain; Quality of Life; Treatment Outcome; Uterine Cervical Neoplasms | 2006 |
Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Ear Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Recombinant Proteins; Salivary Gland Neoplasms; Survival Analysis | 2006 |
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2006 |
Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypopharynx.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Female; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Oropharyngeal Neoplasms; Otorhinolaryngologic Surgical Procedures; Paclitaxel; Patient Compliance; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome | 2006 |
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Radiotherapy Dosage; Survival Analysis | 2006 |
Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagectomy; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy Dosage; Survival Rate | 2006 |
Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Hydroxyurea; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Survival Analysis; Treatment Failure | 2006 |
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2006 |
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Greece; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Patient Compliance; Polyethylene Glycols; Survival Analysis; Treatment Outcome | 2006 |
Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Polyglutamic Acid; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Stomach Neoplasms | 2006 |
Phase II trial of a simultaneous radiochemotherapy with cisplatinum and paclitaxel in combination with hyperfractionated-accelerated radiotherapy in locally advanced head and neck tumors.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy; Treatment Outcome | 2006 |
Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative On
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy Dosage | 2007 |
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Radiotherapy Dosage | 2007 |
Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Laryngeal Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Tongue Neoplasms | 2007 |
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Paclitaxel; Prospective Studies; Risk Assessment; Survival Rate; Urologic Neoplasms | 2007 |
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Arthralgia; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome | 2007 |
[Weekly paclitaxel with concurrent intensity-modulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Drug Tolerance; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mucositis; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Intensity-Modulated; Remission Induction | 2007 |
Multimodal intensification regimens for advanced, resectable, previously untreated squamous cell cancer of the oral cavity, oropharynx, or hypopharynx: a 12-year experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Humans; Hypopharyngeal Neoplasms; Male; Middle Aged; Mouth; Oropharyngeal Neoplasms; Paclitaxel; Patient Compliance; Prospective Studies; Survival Rate; Treatment Outcome | 2007 |
Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Radiotherapy; Time | 2007 |
Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deglutition Disorders; Female; Follow-Up Studies; Humans; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Pharyngectomy; Platinum; Radiotherapy, Adjuvant; Recovery of Function; Salvage Therapy; Speech Disorders; Taxoids; Treatment Outcome | 2007 |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2007 |
Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Male; Middle Aged; Mucositis; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Xerostomia | 2007 |
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Radiotherapy Dosage; Tegafur; Uracil | 2008 |
A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prospective Studies; Remission Induction; Survival Rate; Treatment Outcome | 2008 |
Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2007 |
[Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fatigue; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Radiotherapy; Radiotherapy, High-Energy; Survival Analysis | 2007 |
Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Drug Hypersensitivity; Esophageal Neoplasms; Esophagitis; Facial Dermatoses; Feasibility Studies; Female; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2008 |
Feasibility and efficacy of percutaneous transcatheter intraarterial chemotherapy with paclitaxel in albumin nanoparticles for advanced squamous-cell carcinoma of the oral cavity, oropharynx, and hypopharynx.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Catheterization; Drug Carriers; Feasibility Studies; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Mouth Neoplasms; Nanoparticles; Paclitaxel; Pharyngeal Neoplasms; Pilot Projects; Serum Albumin; Treatment Outcome | 2007 |
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Comorbidity; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2008 |
Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Head and Neck Neoplasms; Human papillomavirus 16; Humans; In Situ Hybridization; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Papillomavirus Infections; Polymerase Chain Reaction; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Treatment Outcome | 2008 |
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel | 2008 |
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Salvage Therapy; Survival Analysis; Taxoids | 2008 |
Induction chemotherapy with paclitaxel and cisplatin, followed by concomitant cisplatin and radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Patient Compliance; Radiotherapy; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2006 |
A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Paclitaxel; Uterine Cervical Neoplasms | 2008 |
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelin A Receptor Antagonists; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Pyrrolidines; Survival Rate | 2008 |
A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2008 |
Preoperative paclitaxel/carboplatin radiochemotherapy for stage III/IV resectable oral and oropharyngeal cancer: seven-year follow-up of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Preoperative Care; Prognosis; Prospective Studies; Survival Rate | 2007 |
Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate; Taxoids | 2008 |
Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Premedication; Prognosis; Radiation Dosage; Radiotherapy, Adjuvant; Treatment Outcome | 2008 |
Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Analysis | 2008 |
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Prognosis; Radiography; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Survival Rate; Thoracic Neoplasms | 2008 |
Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; In Vitro Techniques; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies | 2008 |
Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Female; Granulocyte Colony-Stimulating Factor; Half-Life; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel | 1995 |
Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Radiotherapy Dosage | 1995 |
Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Premedication | 1995 |
The activity of paclitaxel in gastrointestinal tumors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate | 1995 |
A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: preliminary report.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Treatment Outcome | 1994 |
Paclitaxel in the treatment of carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis | 1995 |
A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cytokines; Female; Head and Neck Neoplasms; Humans; Interleukin-1; Male; Microtubules; Middle Aged; Paclitaxel; Remission Induction; Tumor Necrosis Factor-alpha | 1995 |
Phase I studies of continuous-infusion paclitaxel given with standard aggressive radiation therapy for locally advanced solid tumors.
Topics: Anemia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Glioblastoma; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphopenia; Paclitaxel; Radiation-Sensitizing Agents; Remission Induction; Uterine Cervical Neoplasms | 1995 |
[Late phase II trial of RP56976 (Docetaxel) in patients with non-small-cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Taxoids; Vomiting | 1995 |
Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial.
Topics: Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Paclitaxel | 1993 |
Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 1994 |
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Europe; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1994 |
[Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri].
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 1994 |
Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction | 1995 |
Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Uterine Cervical Neoplasms | 1996 |
Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome | 1996 |
Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Remission Induction | 1995 |
Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axons; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction | 1995 |
MoAb to block growth signals plus chemo may act synergistically to kill tumor cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; ErbB Receptors; Humans; Mice; Mice, Nude; Paclitaxel | 1996 |
Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 1996 |
Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Stomach Neoplasms | 1996 |
Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 1996 |
Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Treatment Outcome | 1997 |
Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction | 1997 |
Paclitaxel in simultaneous radiochemotherapy of head and neck cancer: preclinical and clinical results.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Survival; Dose-Response Relationship, Drug; Feasibility Studies; Fibroblasts; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Tumor Cells, Cultured | 1997 |
A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Radiotherapy, Adjuvant | 1997 |
Intensive radiation therapy concurrent with up to 7-week continuous-infusion paclitaxel for locally advanced solid tumors: phase I studies.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Glioblastoma; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Survival Analysis | 1997 |
Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Ureteral Neoplasms; Urinary Bladder Neoplasms | 1997 |
Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer--results from a Phase I trial.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Stomatitis | 1997 |
An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Recurrence; Survival Rate; Uterine Cervical Neoplasms | 1997 |
Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Preoperative Care; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate | 1997 |
Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagitis; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Survival Rate | 1997 |
Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Palliative Care; Treatment Outcome | 1997 |
Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Survival Rate | 1997 |
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 1997 |
Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Treatment Outcome | 1997 |
Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects | 1997 |
Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 1997 |
A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cells, Cultured; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Mitotic Index; Paclitaxel; Survival Rate; Tumor Cells, Cultured | 1997 |
Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: a phase I study.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Erythropoietin; Female; Head and Neck Neoplasms; Hemoglobinometry; Humans; Infusions, Intravenous; Male; Paclitaxel | 1997 |
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 1997 |
Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome | 1997 |
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids | 1998 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Middle Aged; Paclitaxel; Taxoids | 1998 |
Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 1998 |
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 1998 |
Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 1998 |
Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel | 1998 |
Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Culture Techniques; Diagnosis, Differential; Female; Fibrosis; Fluorouracil; Granuloma, Foreign-Body; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Neck; Neck Dissection; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Registries; Remission Induction; Tirapazamine; Triazines | 1998 |
Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 1998 |
Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 1996 |
Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous Cell; Cell Count; Cell Division; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Mouth Mucosa; Paclitaxel; S Phase; Time Factors | 1996 |
Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Ifosfamide; Middle Aged; Paclitaxel; Pilot Projects; Prospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 1998 |
First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Recombinant Proteins; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1999 |
Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Confidence Intervals; Female; Head and Neck Neoplasms; Humans; Male; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 1999 |
Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Treatment Outcome | 1999 |
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Home Infusion Therapy; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Radiation-Sensitizing Agents | 1999 |
Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Greece; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate | 1999 |
[Evaluation of chemotherapy with docetaxel and cisplatin in advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Evaluation; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1999 |
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Life Tables; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Tomography, X-Ray Computed | 1999 |
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Middle Aged; Mouth Mucosa; Nausea; Paclitaxel; Stomatitis; Taxoids | 1999 |
[Simultaneous radiochemotherapy with taxol/carboplatin in advanced operable head-neck tumors. Preliminary results].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Treatment Outcome | 1999 |
Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Uterine Cervical Neoplasms | 1999 |
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
Intensification regimen 2 for advanced head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Survival Rate | 1999 |
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Glutathione S-Transferase pi; Glutathione Transferase; Head and Neck Neoplasms; Humans; Isoenzymes; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Thymidylate Synthase; Treatment Outcome; Tumor Suppressor Protein p53 | 1999 |
Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Thoracotomy; Treatment Outcome | 2000 |
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2000 |
[Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diosmin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisolone; Premedication; Taxoids; Time Factors | 2000 |
A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Eruptions; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Radiation-Sensitizing Agents; Stomatitis | 1999 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Recurrence; Taxoids | 2000 |
Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 2000 |
A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Survival Rate | 2000 |
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome | 2000 |
Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Platelet Count | 2000 |
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Drug Administration Routes; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel | 2000 |
Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Pilot study of organ preservation multimodality therapy for locally advanced resectable oropharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Humans; Laryngectomy; Neck Dissection; Oropharyngeal Neoplasms; Paclitaxel; Pilot Projects; Prospective Studies; Radiotherapy Dosage; Survival Analysis | 2000 |
Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |
Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Cycle; Combined Modality Therapy; Deglutition; Disease-Free Survival; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pilot Projects; Prospective Studies; Radiation-Sensitizing Agents; Speech; Survival Rate | 2001 |
Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Prognosis; Treatment Outcome | 2001 |
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypocalcemia; Magnesium; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 2001 |
Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel | 2001 |
A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis | 2001 |
Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy | 2001 |
Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Treatment Outcome | 2001 |
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Illinois; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis | 2001 |
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2001 |
Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate | 2001 |
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Italy; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenoviridae; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Papillary; Carcinoma, Squamous Cell; Colonic Neoplasms; Feasibility Studies; Female; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Osteosarcoma; Paclitaxel; Thyroid Neoplasms | 2001 |
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Preoperative Care; Prognosis; Stomach Neoplasms; Survival Analysis | 2001 |
Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2001 |
Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Recovery of Function; Severity of Illness Index; Survival Rate; Treatment Outcome | 2001 |
Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical acti
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Anus Neoplasms; Carcinoma, Squamous Cell; Castor Oil; Chemistry, Pharmaceutical; Female; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neutropenia; Paclitaxel; Particle Size; Surface-Active Agents; Treatment Outcome | 2001 |
Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2001 |
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nervous System; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2002 |
Pilot trial of concomitant chemotherapy with paclitaxel and split-course radiotherapy for very advanced squamous cell carcinoma of head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Radiotherapy; Radiotherapy Dosage; Survival Rate | 2002 |
Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Middle Aged; Paclitaxel; Taxoids | 2002 |
Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Radiation-Sensitizing Agents; Uterine Cervical Neoplasms | 2002 |
A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2002 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Docetaxel; Dose Fractionation, Radiation; Drug Tolerance; Feasibility Studies; Female; Humans; Injections, Intra-Arterial; Lymph Node Excision; Male; Middle Aged; Mouth Neoplasms; Neck; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Patient Compliance; Pilot Projects; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Survival Analysis; Taxoids | 2002 |
Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Time Factors; Treatment Outcome | 2002 |
602 other study(ies) available for paclitaxel and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Modulation of multidrug resistance by taxuspine C and other taxoids from Japanese yew.
Topics: Animals; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia L1210; Leukemia P388; Mice; Phenylpropionates; Taxoids; Trees; Tumor Cells, Cultured; Vincristine | 1998 |
FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin B1; Fatty Acid Synthase, Type I; Fatty Acid Synthases; Fluorouracil; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Orlistat; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2023 |
Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Gynecology; Health Resources; Health Services Accessibility; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Quality Indicators, Health Care; Retrospective Studies; Rwanda; Surgical Oncology; Time Factors; Time-to-Treatment; Uterine Cervical Neoplasms | 2022 |
Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Cost-Benefit Analysis; Female; Humans; Immune Checkpoint Inhibitors; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Quality-Adjusted Life Years; Survival Rate; United States; Uterine Cervical Neoplasms | 2022 |
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Epitopes; Fluorouracil; Humans; Paclitaxel; Prospective Studies | 2022 |
A Case of Metaplastic Squamous Cell Carcinoma of the Breast that Showed a Pathological Complete Response After Neoadjuvant Chemotherapy with Weekly Paclitaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Mastectomy; Neoadjuvant Therapy; Paclitaxel | 2022 |
Successful treatment using immunotherapy in combination with chemotherapy for metastatic squamous cell carcinoma of unknown primary origin with bulky abdominal mass: A case report.
Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Duodenum; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Neoplasms, Unknown Primary; Paclitaxel; Positron Emission Tomography Computed Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Epithelial Cells; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies | 2022 |
Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum; Prospective Studies; Retrospective Studies | 2023 |
Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Camelus; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; China; Feathers; Humans; Lung Neoplasms; Paclitaxel | 2022 |
miR-211-3p enhances induction chemotherapy insensitivity by upregulating CSF2/CCL20/TNF signaling in hypopharyngeal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL20; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Ligands; MicroRNAs; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Tumor Necrosis Factors | 2022 |
Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
Topics: Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; DNA; Humans; Lung; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; TOR Serine-Threonine Kinases; Triazoles | 2022 |
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Lung Neoplasms; Nivolumab; Paclitaxel; Pemetrexed | 2022 |
Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor.
Topics: Antibodies, Monoclonal, Humanized; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Humans; Mouth Neoplasms; Neoplasm Recurrence, Local; NF-kappa B; Paclitaxel; Proteasome Inhibitors; RNA, Messenger | 2022 |
Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report.
Topics: Aged; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Thyroid Gland | 2022 |
A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2022 |
Chemotherapy combined with immunotherapy in primary female urethral squamous cell carcinoma: a case report.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Ligands; Lung Neoplasms; Paclitaxel; Programmed Cell Death 1 Receptor; Urethral Neoplasms | 2022 |
Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
Topics: Agranulocytosis; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Immune Checkpoint Inhibitors; Lung; Lung Neoplasms; Male; Neoadjuvant Therapy; Paclitaxel; Thrombocytopenia | 2022 |
Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies | 2022 |
A case of refractory pelvic squamous cell carcinoma of unknown primary that responded to nivolumab.
Topics: Adult; Carboplatin; Carcinoma, Squamous Cell; Female; Humans; Neoplasms, Unknown Primary; Nivolumab; Paclitaxel; Papillomavirus Infections; Prognosis | 2023 |
Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Quality of Life | 2023 |
Machine learning for genetic prediction of chemotherapy toxicity in cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Uterine Cervical Neoplasms | 2023 |
Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Liposomes; Paclitaxel; Retrospective Studies | 2023 |
The Apoptotic Activity of Curcumin Against Oral Cancer Cells Without Affecting Normal Cells in Comparison to Paclitaxel Activity.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Curcumin; Humans; Mouth Neoplasms; Paclitaxel; Reactive Oxygen Species; Tongue Neoplasms | 2023 |
MiR-34 by targeting p53 induces apoptosis and DNA damage in paclitaxel-resistant human oral squamous carcinoma cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Mouth Neoplasms; Paclitaxel; Tumor Suppressor Protein p53 | 2023 |
Radical Resection of Locally Advanced Chest Wall cSCC With Muscle Flap Reconstruction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Humans; Muscles; Paclitaxel; Skin Neoplasms; Thoracic Wall | 2023 |
Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Microenvironment | 2023 |
Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction - comparison of postoperative mortality and complications, toxicity, and pathologic
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Clinical Trials as Topic; Esophageal Neoplasms; Esophagogastric Junction; Humans; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies | 2023 |
Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Taxoids | 2019 |
[Reversible posterior leukoencephalopathy post-chemotherapy with carboplatin and paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Diagnosis, Differential; Fatal Outcome; Female; Humans; Middle Aged; Paclitaxel; Posterior Leukoencephalopathy Syndrome; Uterine Cervical Neoplasms | 2019 |
Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment.
Topics: Alternative Splicing; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Mouth Neoplasms; Oligonucleotides, Antisense; Paclitaxel; Serine-Arginine Splicing Factors | 2019 |
Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis | 2019 |
Neoadjuvant chemotherapy does not improve the prognosis and lymph node metastasis rate of locally advanced cervical squamous cell carcinoma: A retrospective cohort study in China.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; China; Female; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Progression-Free Survival; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2019 |
Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Radiotherapy; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome | 2020 |
Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Female; Humans; Immunotherapy; Middle Aged; Paclitaxel; Therapies, Investigational; Triple Negative Breast Neoplasms | 2019 |
Thymic basaloid carcinoma: a rare clinical entity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Humans; Liver Neoplasms; Middle Aged; Neoplasms, Second Primary; Paclitaxel; Thymus Neoplasms | 2019 |
Anticancer effects of NSC‑631570 (Ukrain) in head and neck cancer cells: In vitro analysis of growth, invasion, angiogenesis and gene expression.
Topics: Antineoplastic Agents; Berberine Alkaloids; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Paclitaxel; Phenanthridines | 2020 |
A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Foreign-Body Migration; Humans; Hydronephrosis; Neoplasm Recurrence, Local; Paclitaxel; Rectum; Stents; Ureter; Urinary Bladder Fistula; Urinary Tract Infections; Uterine Cervical Neoplasms | 2019 |
Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Prospective Studies; Time Factors; Treatment Outcome; Tumor Burden | 2020 |
Acute Generalized Exanthematous Pustulosis Caused by the Combination of Pembrolizumab Plus Chemotherapy in a Patient With Squamous-Cell Carcinoma.
Topics: Acute Generalized Exanthematous Pustulosis; Aged; Albumins; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Male; Paclitaxel; Prednisolone; Prognosis | 2020 |
Renal Metastases from a Nasal Cavity Mixed Squamous Cell and Adenoid Cystic Carcinoma: A Case Report.
Topics: Carboplatin; Carcinoma, Adenoid Cystic; Carcinoma, Squamous Cell; Cetuximab; Drug Therapy, Combination; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Middle Aged; Nasal Cavity; Nose Neoplasms; Paclitaxel; Palliative Care; Positron-Emission Tomography; Rare Diseases | 2020 |
Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2020 |
(+)-Usnic Acid Induces ROS-dependent Apoptosis via Inhibition of Mitochondria Respiratory Chain Complexes and Nrf2 Expression in Lung Squamous Cell Carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzofurans; Carcinoma, Squamous Cell; Cell Line, Tumor; Electron Transport Chain Complex Proteins; Humans; Lung Neoplasms; Mice; Mitochondria; NF-E2-Related Factor 2; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Transplantation, Heterologous | 2020 |
Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophagectomy; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase II as Topic; Consolidation Chemotherapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2020 |
[Efficacy of combined paclitaxel/cetuximab in cutaneous squamous-cell carcinoma: A retrospective analysis of 14 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2020 |
Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Albumins; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Topics: Animals; Antigens, Ly; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Female; Fluorouracil; GPI-Linked Proteins; Hep G2 Cells; Humans; Laryngeal Neoplasms; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Paclitaxel; Transcriptome | 2020 |
Glutathione-sensitive and folate-targeted nanoparticles loaded with paclitaxel to enhance oral squamous cell carcinoma therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Proliferation; Drug Liberation; Drug Screening Assays, Antitumor; Folic Acid; Glutathione; Humans; Male; Mice; Mice, Inbred BALB C; Mouth Neoplasms; Nanoparticles; Neoplasms, Experimental; Paclitaxel; Particle Size; Surface Properties; Tumor Cells, Cultured | 2020 |
Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mortality; Neoplasm Staging; Paclitaxel; Retrospective Studies; SEER Program; Survival Rate | 2020 |
Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cytokines; Female; Glucose-6-Phosphate Isomerase; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phosphofructokinase-1, Liver Type; Polymorphism, Single Nucleotide; Prognosis; Survival Rate; Treatment Outcome | 2020 |
A case of successful maintained pregnancy after neoadjuvant chemotherapy plus radical surgery for stage IB3 cervical cancer diagnosed at 13 weeks.
Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cesarean Section; Female; Humans; Hysterectomy; Neoadjuvant Therapy; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Cervical Neoplasms | 2020 |
A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Humans; Logistic Models; Male; Middle Aged; Netherlands; Paclitaxel; Propensity Score; Proportional Hazards Models; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome | 2020 |
Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Squamous Cell; Cisplatin; Humans; Ifosfamide; Ipilimumab; Male; Middle Aged; Nivolumab; Paclitaxel; Penile Neoplasms; Prognosis; Taxoids | 2021 |
[A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].
Topics: Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Squamous Cell; Epithelial Cells; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel | 2020 |
Adjuvant chemotherapy after radiotherapy or concurrent chemoradiotherapy for pelvic lymph node-positive patients with locally advanced cervical cancer: a propensity score matching analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; China; Cisplatin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Propensity Score; Retrospective Studies; Uterine Cervical Neoplasms | 2022 |
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Tumor Microenvironment; Uterine Cervical Neoplasms | 2020 |
Tailored radical hysterectomy for locally advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Paclitaxel; Peripheral Nerves; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2020 |
Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ethmoid Sinus; Humans; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Paclitaxel; Paranasal Sinus Neoplasms; Positron-Emission Tomography | 2021 |
IMpower 131: The Exception to the Rule.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Carboplatin; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Paclitaxel | 2020 |
Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro.
Topics: Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Proliferation; Cetuximab; Drug Synergism; Humans; In Vitro Techniques; Mouth Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2020 |
PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Decision-Making; Databases, Factual; Female; Humans; Hysterectomy; Immunohistochemistry; Immunophenotyping; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Treatment Outcome; Tumor Microenvironment; Uterine Cervical Neoplasms | 2021 |
Use of Immunotherapy in Patients With Cancer During the COVID-19 Pandemic.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Consolidation Chemotherapy; Coronavirus Infections; COVID-19; Diagnosis, Differential; Female; Humans; Lung; Lung Neoplasms; Paclitaxel; Pandemics; Pneumonia; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2-IIIB cervical adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy; China; Cisplatin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2021 |
How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial.
Topics: Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Humans; Paclitaxel | 2020 |
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell-Free Nucleic Acids; Circulating Tumor DNA; Cisplatin; Deoxycytidine; DNA Copy Number Variations; Female; Gemcitabine; Humans; Lung Neoplasms; Machine Learning; Male; Middle Aged; Paclitaxel; Prognosis; Progression-Free Survival; Survival Rate; Treatment Outcome | 2021 |
Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Humans; Length of Stay; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Compliance; Postoperative Complications; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Time Factors | 2021 |
Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population-based Danish anal cancer group study.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Denmark; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2021 |
A Fifteen-Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Proteins; Sialyltransferases; Uterine Cervical Neoplasms | 2021 |
Effectual nanotherapy against oral squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Carriers; Folic Acid; Head and Neck Neoplasms; Mouth Neoplasms; Nanoparticles; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Tissue Distribution | 2021 |
Long-term efficacy of weekly paclitaxel therapy in unresectable primary squamous cell carcinoma of the thyroid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Child, Preschool; Female; Humans; Paclitaxel; Thyroid Neoplasms | 2022 |
Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Organoplatinum Compounds; Organs at Risk; Paclitaxel; Radiation Pneumonitis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; User-Computer Interface | 2021 |
Takotsubo cardiomyopathy caused by infusion reaction to paclitaxel.
Topics: Carcinoma, Squamous Cell; Female; Humans; Paclitaxel; Respiratory Distress Syndrome; Takotsubo Cardiomyopathy; Uterine Cervical Neoplasms | 2021 |
A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient: A case report.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Endostatins; Humans; Lung; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pleural Effusion; Recombinant Proteins; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2021 |
Dose-dense Paclitaxel- and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemo-radiotherapy in Cervical Cancer: a Preliminary Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2017 |
Paclitaxel induces apoptosis of esophageal squamous cell carcinoma cells by downregulating STAT3 phosphorylation at Ser727.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; Mitochondria; Paclitaxel; Phosphorylation; Serine; STAT3 Transcription Factor | 2017 |
Patterns of Care for Elderly Patients With Locally Advanced Head and Neck Cancer.
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Decision Making; Delivery of Health Care; Head and Neck Neoplasms; Humans; Karnofsky Performance Status; Middle Aged; Odds Ratio; Paclitaxel; Radiotherapy; Regression Analysis | 2017 |
Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Treatment Outcome | 2017 |
Treatment of esophageal cancer with radiation therapy -a pan-Chinese survey of radiation oncologists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; China; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Four-Dimensional Computed Tomography; Humans; Lymphatic Metastasis; Paclitaxel; Postoperative Care; Practice Patterns, Physicians'; Preoperative Care; Radiation Oncologists; Radiotherapy Planning, Computer-Assisted; Surveys and Questionnaires | 2017 |
Remission Following Paclitaxel and Cisplatin Treatment in a 15-Year-Old Patient With Unresectable Esophageal Squamous Cell Cancer.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Humans; Male; Paclitaxel; Remission Induction | 2017 |
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Readmission; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Young Adult | 2017 |
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Pilot Projects; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids | 2018 |
CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; G1 Phase Cell Cycle Checkpoints; Humans; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Retinoblastoma Protein; Xenograft Model Antitumor Assays | 2017 |
Long-term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2017 |
Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Uterine Cervical Neoplasms | 2018 |
Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Female; Humans; Kaplan-Meier Estimate; Paclitaxel; Prognosis; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2017 |
Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Chi-Square Distribution; Cisplatin; Deglutition Disorders; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Propensity Score; Regression Analysis; Retrospective Studies; Stents; Treatment Outcome | 2017 |
High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; RNA, Small Interfering; Stathmin; Survival Rate | 2017 |
A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2017 |
Cryptotanshinone sensitizes antitumor effect of paclitaxel on tongue squamous cell carcinoma growth by inhibiting the JAK/STAT3 signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Humans; Janus Kinases; Models, Biological; Neoplasm Invasiveness; Paclitaxel; Phenanthrenes; Signal Transduction; STAT3 Transcription Factor; Tongue Neoplasms | 2017 |
Huge right ventricular mass lesion associated with genital malignant tumor: a case report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Echocardiography; Female; Heart Neoplasms; Heart Ventricles; Humans; Paclitaxel; Tomography, X-Ray Computed; Treatment Outcome; Vaginal Neoplasms | 2017 |
Synchronous occurrence of hereditary gastric adenocarcinoma, gastrointestinal stromal tumor, and esophageal small cell and squamous carcinoma in situ: an extremely rare case report.
Topics: Carcinoma in Situ; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Lymph Node Excision; Middle Aged; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Treatment Outcome | 2017 |
Selective anticancer activity of the novel steroidal dihydropyridine spirooxindoles against human esophageal EC109 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Dihydropyridines; Drug Resistance; Esophageal Neoplasms; G2 Phase Cell Cycle Checkpoints; Humans; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Small Molecule Libraries | 2017 |
Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Re-Irradiation; Squamous Cell Carcinoma of Head and Neck | 2018 |
Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Topics: B7-H1 Antigen; Carcinoma, Squamous Cell; Cell Line, Tumor; Coculture Techniques; Dendritic Cells; Female; Head and Neck Neoplasms; Humans; Male; Matrix Metalloproteinase 13; Matrix Metalloproteinase 7; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Paclitaxel; Recombinant Proteins; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2018 |
The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Comorbidity; Female; Humans; Idiopathic Interstitial Pneumonias; Lung Neoplasms; Male; Paclitaxel; Prospective Studies; Retrospective Studies | 2018 |
Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Esophageal Neoplasms; Esophagectomy; Female; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Netherlands; Paclitaxel; Propensity Score; Registries; Retrospective Studies; Treatment Outcome | 2018 |
Natural Borneol Enhances Paclitaxel-Induced Apoptosis of ESCC Cells by Inactivation of the PI3K/AKT.
Topics: Apoptosis; Camphanes; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2018 |
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biopsy; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Programmed Cell Death 1 Receptor | 2018 |
A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Prognosis | 2019 |
Outcomes of concurrent radiotherapy and weekly paclitaxel/carboplatin therapy in cervical cancer: a retrospective study.
Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality-Adjusted Life Years; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
[Ring mitoses].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastritis; Humans; Lung Neoplasms; Male; Mitosis; Paclitaxel; Pneumonectomy | 2018 |
Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2018 |
Locally advanced cervical cancer complicating pregnancy: A case of competing risks from the Catholic University of the Sacred Heart in Rome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cesarean Section; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Infant, Newborn; Male; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Salpingectomy; Uterine Cervical Neoplasms | 2018 |
[A Case of Advanced Squamous Cell Lung Cancer with Hemodialysis Treated with Carboplatin and Paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Renal Dialysis; Treatment Outcome | 2018 |
[A Case of Advanced Lung Squamous Cell Carcinoma with Idiopathic Pulmonary Fibrosis Treated with Salvage Surgery and Chemotherapy Using Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Paclitaxel; Salvage Therapy | 2018 |
[Induction Chemoradiotherapy Followed by Surgery in Non-small-cell Lung Cancer;a Retrospective Study].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Retrospective Studies | 2018 |
Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Retrospective Studies; Treatment Outcome; Vulvar Neoplasms | 2018 |
Chemoradiation and the Role of Adjuvant Chemotherapy in Lymph Nodal-Metastatic Cervical Cancer.
Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Tomography, X-Ray Computed; Uterine Cervical Neoplasms | 2018 |
Association of serum annexin A1 with treatment response and prognosis in patients with esophageal squamous cell carcinoma.
Topics: Adult; Aged; Annexin A1; Carcinoma, Squamous Cell; Cell Movement; Cell Proliferation; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Male; MicroRNAs; Middle Aged; Paclitaxel; Prognosis | 2018 |
Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tertiary Care Centers | 2018 |
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Topics: Adenosine Triphosphatases; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Lung Neoplasms; MAP Kinase Kinase Kinase 5; Mitoxantrone; Models, Molecular; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Kinase Inhibitors | 2019 |
Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; Chemotherapy, Adjuvant; Cisplatin; Female; Forkhead Transcription Factors; Humans; Hysterectomy; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Phenotype; Retrospective Studies; Time Factors; Treatment Outcome; Tumor Microenvironment; Uterine Cervical Neoplasms | 2018 |
Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2019 |
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2018 |
A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms | 2019 |
A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Combinations; Epithelial Cells; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Tegafur | 2019 |
A Rare Case of Pediatric Lacrimal Sac: Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Squamous Cell; Child; Eye Neoplasms; Humans; Lacrimal Apparatus Diseases; Lymphadenopathy; Male; Neoadjuvant Therapy; Paclitaxel; Tomography, X-Ray Computed | 2019 |
Organ preservation for patients with anterior mucosal squamous cell carcinoma of the nasal cavity: Rhinectomy-free survival in those refusing surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Nasal Cavity; Nose; Nose Neoplasms; Organ Sparing Treatments; Paclitaxel; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2019 |
Self-facilitated ROS-responsive nanoassembly of heterotypic dimer for synergistic chemo-photodynamic therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Chlorophyll; Combined Modality Therapy; Dimerization; Drug Delivery Systems; Drug Liberation; Female; Fluorescent Dyes; Humans; Mice, Inbred BALB C; Nanocapsules; Neoplasms, Experimental; Optical Imaging; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Rats, Sprague-Dawley; Reactive Oxygen Species | 2019 |
High expression of survivin predicts poor prognosis in cervical squamous cell carcinoma treated with paclitaxel and carboplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; China; Female; Humans; Ki-67 Antigen; Lymphatic Metastasis; Middle Aged; Neoplasm Grading; Paclitaxel; Retrospective Studies; Survivin; Tumor Burden; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A | 2019 |
Oral Administration of
Topics: Administration, Oral; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Ibuprofen; Inflammation; Male; Mice; Paclitaxel; Porphyromonas gingivalis; Xenograft Model Antitumor Assays | 2019 |
LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Caspase 3; Cell Differentiation; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Matrix Metalloproteinase 9; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Staging; Oligoribonucleotides; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Long Noncoding; Signal Transduction; Survival Analysis; Tumor Burden; Uterine Cervical Neoplasms | 2019 |
Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2019 |
[Two Cases of Lung Stage ⅢSquamous Cell Carcinoma Treated with Carboplatin (CBDCA)plus Nab-Paclitaxel(Nab-PTX)].
Topics: Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel | 2019 |
Reply to A. Adenis et al.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel | 2019 |
Definitive Chemoradiotherapy for Esophageal Squamous Cell Cancer: A Matter of Standard.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel | 2019 |
Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Esophageal Neoplasms; Hospitals, Community; Humans; Irinotecan; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Radiotherapy alone or combined with chemotherapy for the treatment of squamous cell carcinoma of the base of the tongue.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neck Dissection; Paclitaxel; Retrospective Studies; Tongue Neoplasms; Treatment Outcome | 2014 |
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Paclitaxel; Pregnane X Receptor; Real-Time Polymerase Chain Reaction; Receptors, Steroid; Rifampin | 2013 |
Transrectal ultrasound and magnetic resonance imaging in the evaluation of tumor size following neoadjuvant chemotherapy for locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Endosonography; Female; Humans; Ifosfamide; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Treatment Outcome; Tumor Burden; Uterine Cervical Neoplasms; Young Adult | 2013 |
A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2013 |
First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: a retrospective analysis of patients treated at Brazilian National Cancer Institute.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Brazil; Carboplatin; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms; Young Adult | 2013 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
Gynaecomastia, galactorrhoea, and lung cancer in a man.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chorionic Gonadotropin, beta Subunit, Human; Cisplatin; Galactorrhea; Gynecomastia; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2013 |
Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Care; Prospective Studies; Radiotherapy Dosage; Republic of Korea; Survival Rate; Uterine Cervical Neoplasms | 2013 |
Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Failure; Treatment Outcome | 2014 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
Comparison of clinical efficacy of three different neoadjuvant approaches (chemotherapy combined vaginal intracavitary irradiation, neoadjuvant chemotherapy alone or radiotherapy) combined with surgery for patients with stage Ib2 and IIa2 cervical cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Body Mass Index; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Postoperative Complications; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Survival Rate; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vincristine | 2013 |
Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Liposomes; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur | 2013 |
Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Postoperative Period; Radiotherapy; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2013 |
Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stage IIB cervical cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2013 |
[Comparison of the efficacy of three neoadjuvant therapy regimens on locally advanced cervical cancer].
Topics: Adenocarcinoma; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Iridium Radioisotopes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Preoperative Period; Radiotherapy, Adjuvant; Retrospective Studies; Serpins; Treatment Outcome; Uterine Cervical Neoplasms | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Squamous Cell; Caspase 3; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2013 |
Robotic radical hysterectomy following neoadjuvant chemotherapy in FIGO stage IIIB cervical cancer: a case report.
Topics: Adult; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Ifosfamide; Lymph Node Excision; Neoadjuvant Therapy; Paclitaxel; Robotics; Uterine Cervical Neoplasms | 2014 |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Survival Analysis; Taxoids | 2013 |
Humoral hypercalcemia caused by uterine corpus carcinosarcoma consisting of squamous cell carcinoma in its epithelial component.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Carcinosarcoma; Chemotherapy, Adjuvant; Endometrium; Female; Humans; Hypercalcemia; Hysterectomy; Ovariectomy; Paclitaxel; Paraneoplastic Syndromes; Salpingectomy; Treatment Outcome; Uterine Hemorrhage; Uterine Neoplasms; Uterus | 2014 |
Enhanced chemoresistance of squamous carcinoma cells grown in 3D cryogenic electrospun scaffolds.
Topics: Animals; Antineoplastic Agents; Bombyx; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Extracellular Matrix; Head and Neck Neoplasms; Humans; Microscopy, Fluorescence; Paclitaxel; Phenotype; Silk; Tissue Engineering; Tissue Scaffolds | 2013 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Ifosfamide; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Glycopeptides; Humans; Lung Neoplasms; Male; Mannans; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophagectomy; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Mucous Membrane; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm, Residual; Paclitaxel; Treatment Outcome | 2013 |
Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carboplatin; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonia; Postoperative Complications; Prognosis; Prospective Studies; Survival Rate; Thoracotomy | 2014 |
Combination treatment with paclitaxel and doxorubicin inhibits growth of human esophageal squamous cancer cells by inactivation of Akt.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Caspase 7; Caspase 9; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin-Dependent Kinases; Doxorubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; M Phase Cell Cycle Checkpoints; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Tumor Suppressor Protein p53 | 2014 |
A case of penile squamous cell carcinoma treated with a combination of antiepidermal growth factor receptor antibody and chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; ErbB Receptors; Fatal Outcome; Humans; Male; Paclitaxel; Penile Neoplasms | 2014 |
[Efficacy of postoperative simple chemotherapy and concurrent chemoradiotherapy in FIGO stage IB2-IIB cervical cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hysterectomy; Ifosfamide; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Uterine Cervical Neoplasms | 2013 |
Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anatomic Landmarks; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Prospective Studies; Radiography; Radiotherapy Planning, Computer-Assisted; Regression Analysis; Tumor Burden | 2014 |
Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Heterografts; Humans; Ki-67 Antigen; Mice, Inbred NOD; Mice, SCID; Multidrug Resistance-Associated Proteins; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2014 |
Inhibition of nemo-like kinase increases taxol sensitivity in laryngeal cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Laryngeal Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2013 |
Evaluation of progression prior to surgery after neoadjuvant chemoradiotherapy with computed tomography in esophageal cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Disease Progression; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Preoperative Care; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2014 |
Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Dimyristoylphosphatidylcholine; Doxorubicin; Drug Delivery Systems; Head and Neck Neoplasms; Humans; Hydrogen-Ion Concentration; Paclitaxel; Polymethacrylic Acids; Squamous Cell Carcinoma of Head and Neck | 2014 |
Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Thymidylate Synthase | 2014 |
Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Esophageal Neoplasms; Female; Follow-Up Studies; Hematologic Tests; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies | 2014 |
Neoadjuvant chemotherapy followed by robotic radical hysterectomy in locally advanced cervical cancer: a multi-institution study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Epirubicin; Feasibility Studies; Female; Humans; Hysterectomy; Ifosfamide; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pelvis; Retrospective Studies; Robotics; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2014 |
High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Survival Rate; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2014 |
Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Humans; Ifosfamide; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Paclitaxel | 2015 |
Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA Glycosylases; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2014 |
Down regulation of miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical squamous cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Chi-Square Distribution; China; DNA, Viral; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Genotype; Human papillomavirus 16; Human Papillomavirus DNA Tests; Humans; Lymphatic Metastasis; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Papillomavirus Infections; Real-Time Polymerase Chain Reaction; Treatment Outcome; Tumor Burden; Uterine Cervical Neoplasms | 2014 |
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chest Pain; Cohort Studies; Cough; Dyspnea; Esophagitis; Etoposide; Female; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Pemetrexed; Radiation Injuries; Radiation Pneumonitis; Retrospective Studies; Treatment Outcome | 2015 |
[Value of postoperative radiochemotherapy for thoracic esophageal squamous cell carcinoma with lymph node metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagitis; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Particle Accelerators; Postoperative Period; Retrospective Studies; Survival Rate | 2014 |
A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Chromatography, Liquid; Female; Humans; Mass Spectrometry; Metabolomics; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Tryptophan; Uterine Cervical Neoplasms; Valine | 2014 |
B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; CHO Cells; Cricetulus; Female; Humans; Lymphocytes, Tumor-Infiltrating; Macrophages; Mice; Mice, Transgenic; Neoplasms; Organoplatinum Compounds; Paclitaxel; Phenotype; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2014 |
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Thoracic Neoplasms | 2014 |
Carboplatin and paclitaxel treatment is effective in advanced anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome | 2014 |
The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cisplatin; Drug Resistance, Neoplasm; Female; HeLa Cells; Humans; Kinetochores; M Phase Cell Cycle Checkpoints; Mice; Mice, Nude; Middle Aged; Paclitaxel; RNA Interference; Spindle Apparatus; Survival Analysis; Telomerase; Telomere; Time Factors; Transfection; Treatment Outcome; Tubulin Modulators; Tumor Suppressor Proteins; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2014 |
In vitro evaluation of antiproliferative effect of ethyl gallate against human oral squamous carcinoma cell line KB.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; DNA Damage; Gallic Acid; Humans; KB Cells; Membrane Potential, Mitochondrial; Oxidants; Paclitaxel; Reactive Oxygen Species | 2015 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Proliferation; Cisplatin; Combined Modality Therapy; Electric Stimulation Therapy; Glutamates; Guanine; Humans; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Inbred C57BL; Paclitaxel; Pemetrexed; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2014 |
A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Paclitaxel; Retrospective Studies | 2015 |
Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Topics: Adult; Aged; Albumins; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neurotoxicity Syndromes; Paclitaxel; Prospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2014 |
Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Cetuximab; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mouth Neoplasms; Neoplasm Proteins; Paclitaxel; Xenograft Model Antitumor Assays | 2014 |
Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma.
Topics: Biomarkers; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Metastasis; Oropharyngeal Neoplasms; Paclitaxel; Predictive Value of Tests; Radiotherapy, Intensity-Modulated; Sensitivity and Specificity | 2016 |
Cisplatin and paclitaxel target significant long noncoding RNAs in laryngeal squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Delivery Systems; Female; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Paclitaxel; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck | 2014 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Down-Regulation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Male; MicroRNAs; Middle Aged; Paclitaxel; Predictive Value of Tests | 2014 |
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Polyurethanes; Retrospective Studies; Treatment Outcome | 2014 |
Influence of serum VEGF levels on therapeutic outcome and diagnosis/prognostic value in patients with cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1.
Topics: Antineoplastic Agents, Phytogenic; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Down-Regulation; Female; Humans; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Paclitaxel; Protein Kinases; Signal Transduction; Up-Regulation; Uterine Cervical Neoplasms | 2014 |
siRNA blocking the RAS signalling pathway and inhibits the growth of oesophageal squamous cell carcinoma in nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Proliferation; Cyclin D1; Drug Resistance; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Heterografts; Male; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Paclitaxel; ras Proteins; RNA, Small Interfering; Signal Transduction | 2014 |
EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity.
Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Ephrin-B1; Head and Neck Neoplasms; HEK293 Cells; Human papillomavirus 6; Humans; Immunoblotting; MCF-7 Cells; Mice, Inbred C57BL; Microscopy, Confocal; Microtubule-Associated Proteins; Microtubules; Oncogene Proteins, Viral; Paclitaxel; Protein Binding; Repressor Proteins; RNA Interference; Taxoids | 2015 |
Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Retreatment; Treatment Outcome | 2015 |
Treatment of invasive squamous cell carcinomas in an open Clagett window.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Debridement; Empyema; Female; Fluorouracil; Humans; Neoplasm Invasiveness; Paclitaxel; Pleural Cavity; Pleural Neoplasms; Thoracostomy | 2015 |
Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Shape; Cell Survival; Drug Resistance, Neoplasm; Esophageal Neoplasms; G2 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; Humans; Paclitaxel; RNA Interference; RNA, Small Interfering; Stathmin | 2015 |
Clozapine and concomitant chemotherapy in a patient with schizophrenia and new onset esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Carboplatin; Carcinoma, Squamous Cell; Clozapine; Esophageal Neoplasms; Humans; Male; Neutropenia; Paclitaxel; Schizophrenia | 2015 |
The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Prognosis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Remission Induction; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2015 |
[Dramatic response of penile cancer with inguinal lymph node metastases to neoadjuvant chemotherapy with paclitaxel, ifosfamide and cisplatin : a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Diagnostic Imaging; Humans; Ifosfamide; Inguinal Canal; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Penile Neoplasms; Treatment Outcome; Urogenital Surgical Procedures | 2015 |
RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Retinoblastoma Protein; Survival Rate; Taxoids; Young Adult | 2015 |
Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Feasibility Studies; Female; Humans; Ifosfamide; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2015 |
Pathologic response during chemo-radiotherapy and variation of serum VEGF levels could predict effects of chemo-radiotherapy in patients with esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Medullary; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Vascular Endothelial Growth Factor A | 2015 |
p16INK4a Status and Response to Induction Low-Dose Fractionated Radiation in Advanced Head and Neck Cancer.
Topics: Adult; Antineoplastic Agents; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Gene Expression Profiling; Genes, p16; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Papillomavirus Infections; Remission Induction; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2015 |
[Safe treatment of lung squamous cell carcinoma with nanoparticle albumin-bound Paclitaxel in a patient with a previous hypersensitivity reaction after docetaxel administration].
Topics: Albumins; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Hypersensitivity; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2015 |
Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Π-Π Stacking Stabilized Polymeric Micelles.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Carriers; Drug Stability; Female; Humans; Kinetics; Mammary Neoplasms, Experimental; Methacrylates; Mice; Micelles; Multimodal Imaging; Paclitaxel; Polyethylene Glycols; Polymers; Tissue Distribution; Xenograft Model Antitumor Assays | 2015 |
Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Female; Humans; Liposomes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Treatment Outcome; Tumor Burden; Uterine Cervical Neoplasms | 2015 |
Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postoperative Complications; Prognosis; Radiotherapy Dosage; Survival Rate | 2015 |
Squamous cell carcinoma arising in a mature cystic teratoma invading the sigmoid colon: a rare presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Diagnosis, Differential; Diarrhea; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Peritonitis; Sigmoid Neoplasms; Teratoma; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
CT Signs Can Predict Treatment Response and Long-Term Survival: A Study in Locally Advanced Esophageal Cancer with Preoperative Chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Preoperative Care; Prognosis; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2015 |
Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Esophageal Neoplasms; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stathmin; Tubulin Modulators; Tumor Cells, Cultured; Vinblastine; Xenograft Model Antitumor Assays | 2015 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Paclitaxel; Perioperative Care; Retrospective Studies; Urethra; Urethral Neoplasms; Urinary Diversion | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Risk Factors | 2015 |
Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2015 |
Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome | 2016 |
Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer.
Topics: Abortion, Missed; Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cervix Uteri; Chemotherapy, Adjuvant; Cisplatin; Conization; Disease Progression; Female; Fertility Preservation; Follow-Up Studies; Humans; Ifosfamide; Lymph Node Excision; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pelvis; Pregnancy; Pregnancy Rate; Premature Birth; Retrospective Studies; Treatment Outcome; Tumor Burden; Uterine Cervical Neoplasms | 2015 |
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Diabetes Mellitus, Type 2; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Hypoglycemic Agents; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
[Inhibitory effect of 17-AAG combined with paclitaxel on proliferation of esophageal squamous cell carcinoma Eca-109 cells in vitro].
Topics: Apoptosis; Benzoquinones; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Lactams, Macrocyclic; Paclitaxel | 2015 |
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Movement; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pneumonectomy; Prognosis; RNA Interference; RNA, Small Interfering; Transcription Factors; Vinblastine; Vinorelbine | 2015 |
Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Biopsy; Carcinoma, Squamous Cell; Diagnosis, Differential; Dose-Response Relationship, Drug; Humans; Male; Mediastinal Neoplasms; Paclitaxel; Positron-Emission Tomography; Tomography, X-Ray Computed; Young Adult | 2015 |
Treatment of squamous cell carcinoma of external auditory canal: A tertiary cancer centre experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Child; Cisplatin; Disease-Free Survival; Ear Canal; Ear Neoplasms; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Neck Dissection; Neoadjuvant Therapy; Neoplasm Staging; Otologic Surgical Procedures; Paclitaxel; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Tertiary Care Centers; Treatment Outcome; Young Adult | 2016 |
Long-Term Clinical Benefits of Neoadjuvant Chemotherapy in Women With Locally Advanced Cervical Cancer: Validity of Pathological Response as Surrogate Endpoint of Survival.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Uterine Cervical Neoplasms; Young Adult | 2015 |
Retrospective Study of Adjuvant Chemotherapy Effects on Survival Rate after Three-Field Lymph Node Dissection for Stage IIA Esophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2015 |
Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Eukaryotic Translation Initiation Factor 5A; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Stem Cells; Paclitaxel; Peptide Initiation Factors; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Taxoids | 2015 |
Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Proteins; Retrospective Studies; ROC Curve; Survival Rate; Vinblastine; Vinorelbine; WAP Four-Disulfide Core Domain Protein 2 | 2016 |
Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2015 |
A case of recurrent squamous cell carcinoma of the vulva successfully treated by combination therapy with cetuximab and paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Vulvar Neoplasms | 2016 |
[A CASE OF UROTHELIAL CARCINOMA OF THE URINARY BLADDER WITH SQUAMOUS DIFFERENTIATION RESPONDING TO PACLITAXEL AND CARBOPLATIN NEOADJUVANT CHEMOTHERAPY].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Fatal Outcome; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Recurrence; Tomography, X-Ray Computed; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2015 |
Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/β-catenin signaling.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Axin Protein; beta Catenin; Carcinoma, Squamous Cell; Drug Synergism; Female; HeLa Cells; Humans; Mice; Mice, SCID; Minocycline; Paclitaxel; Tigecycline; Up-Regulation; Uterine Cervical Neoplasms; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2015 |
[Chemotherapy with paclitaxel leads to microRNA release].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy; Head and Neck Neoplasms; Humans; MicroRNAs; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; China; Cisplatin; Class I Phosphatidylinositol 3-Kinases; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genomics; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured | 2016 |
Expression of activated signal transducer and activator of transcription-3 as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; China; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Retrospective Studies; STAT3 Transcription Factor; Treatment Outcome | 2015 |
Down-Regulation of Nucleolar and Spindle-Associated Protein 1 (NUSAP1) Expression Suppresses Tumor and Cell Proliferation and Enhances Anti-Tumor Effect of Paclitaxel in Oral Squamous Cell Carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Microtubule-Associated Proteins; Mouth Neoplasms; Paclitaxel | 2015 |
Nanoparticle Albumin-bound Paclitaxel+Carboplatin Therapy for Small Cell Lung Cancer Combined with Squamous Cell Carcinoma and Interstitial Lung Disease.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Humans; Lung Diseases, Interstitial; Male; Nanoparticles; Paclitaxel; Small Cell Lung Carcinoma; Treatment Outcome | 2015 |
Recurrent Penile Squamous Cell Carcinoma Successfully Treated With Cetuximab, Chemotherapy, and Radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Penile Neoplasms; Radiography; Skin Neoplasms; Treatment Outcome | 2016 |
Changes of Lymphocyte Subgroups in Non-Small Cell Lung Cancer Patients Before and During Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; CD28 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cisplatin; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Paclitaxel; Time Factors | 2015 |
Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2016 |
Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; DNA Breaks, Double-Stranded; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Taxoids | 2016 |
Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Selection; Radiotherapy Dosage; Vinblastine; Vinorelbine | 2016 |
Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Oxonic Acid; Paclitaxel; Platinum Compounds; Pneumonectomy; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2016 |
Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genetic Therapy; Head and Neck Neoplasms; Humans; Inhibitor of Apoptosis Proteins; Lentivirus; Mice; Mice, Nude; Neoplasm Proteins; Paclitaxel; Radiation Tolerance; RNA, Small Interfering; Survivin; Xenograft Model Antitumor Assays | 2016 |
Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.
Topics: Aged; Brachytherapy; Carcinoma, Squamous Cell; Cetuximab; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Prognosis; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2016 |
In Vivo Biodistribution and Anti-Tumor Efficacy Evaluation of Doxorubicin and Paclitaxel-Loaded Pluronic Micelles Decorated with c(RGDyK) Peptide.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; Humans; Male; Mice, Inbred BALB C; Micelles; Mouth; Mouth Neoplasms; Paclitaxel; Peptides, Cyclic; Poloxamer; Tissue Distribution | 2016 |
Penile cancer metastasizing to the breast: a case report.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms, Male; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Penile Neoplasms | 2016 |
Effects of paclitaxel on permanent head and neck squamous cell carcinoma cell lines and identification of anti-apoptotic caspase 9b.
Topics: Alternative Splicing; Antineoplastic Agents, Phytogenic; Apoptotic Protease-Activating Factor 1; Carcinoma, Squamous Cell; Caspase 9; Cell Cycle; Cell Death; Cell Line, Tumor; DNA Methylation; Enzyme Activation; Head and Neck Neoplasms; Humans; Membrane Potential, Mitochondrial; Paclitaxel; Promoter Regions, Genetic; Squamous Cell Carcinoma of Head and Neck; Staurosporine | 2016 |
Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Tertiary Care Centers; Thailand; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Concomitant External-beam Irradiation and Chemotherapy Followed by High-dose Rate Brachytherapy Boost in the Treatment of Squamous Cell Carcinoma of the Vagina: A Single-Center Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Vaginal Neoplasms | 2016 |
Induction chemotherapy before surgery for unresectable head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Neoplasms; Oropharyngeal Neoplasms; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2016 |
Anticancer activity of drug conjugates in head and neck cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cysteine; Esters; Head and Neck Neoplasms; Humans; Hydrogen-Ion Concentration; Nuclear Magnetic Resonance, Biomolecular; Paclitaxel; Papillomavirus Infections; Sexually Transmitted Diseases | 2016 |
Efficacy of neoadjuvant chemotherapy plus radical surgery in patients with bulky stage II cervical squamous cell carcinoma: A retrospective cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
Potential of Baseline Computed Tomography to Predict Long-Term Survival of Patients With Locally Advanced Esophageal Cancer Treated With Preoperative Chemotherapy: A Retrospective Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Survival Rate; Time Factors; Tomography, X-Ray Computed; Tumor Burden | 2016 |
Feasibility of robotic radical hysterectomy after neoadjuvant chemotherapy in women with locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Epirubicin; Feasibility Studies; Female; Humans; Hysterectomy; Ifosfamide; Longitudinal Studies; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Robotic Surgical Procedures; Taxoids; Uterine Cervical Neoplasms | 2016 |
Study of single nucleotide polymorphisms of FBW7 and its substrate genes revealed a predictive factor for paclitaxel plus cisplatin chemotherapy in Chinese patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; F-Box-WD Repeat-Containing Protein 7; Female; Genotype; Humans; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prospective Studies | 2016 |
The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk; Uterine Cervical Neoplasms | 2016 |
A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Otorhinolaryngologic Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Tumor Burden | 2016 |
Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate; Young Adult | 2016 |
[A preliminary analysis on potentially targeted genes of induced chemotherapy in supraglottic laryngeal squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression; Gene Expression Profiling; Genes, p53; Humans; Induction Chemotherapy; Laryngeal Neoplasms; Paclitaxel; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2016 |
Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Disease-Free Survival; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Rate | 2016 |
Kochia scoparia induces apoptosis of oral cancer cells in vitro and in heterotopic tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bassia scoparia; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Fruit; Head and Neck Neoplasms; Humans; Male; Methanol; Mice, Inbred C3H; Mouth Neoplasms; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Poly(ADP-ribose) Polymerases; Signal Transduction; Solvents; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2016 |
Survival outcomes in patients with oropharyngeal cancer treated with carboplatin/paclitaxel and concurrent radiotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2016 |
Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Esophagus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2017 |
Radiochemotherapy with Paclitaxel for Recurrent Previously Irradiated Squamous Cell Carcinoma of the Head and Neck.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Head and Neck Neoplasms; Humans; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2016 |
Embryonal rhabdomyosarcoma in a child exposed to chemotherapy in utero: a mere coincidence?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Child, Preschool; Cisplatin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Remission Induction; Retroperitoneal Neoplasms; Rhabdomyosarcoma, Embryonal; Taxoids; Uterine Cervical Neoplasms | 2016 |
Circadian Clock Gene Bmal1 Inhibits Tumorigenesis and Increases Paclitaxel Sensitivity in Tongue Squamous Cell Carcinoma.
Topics: Animals; Antineoplastic Agents; ARNTL Transcription Factors; Blotting, Western; Carcinogenesis; Carcinoma, Squamous Cell; Chromatin Immunoprecipitation; Circadian Clocks; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genes, Tumor Suppressor; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Polymerase Chain Reaction; Squamous Cell Carcinoma of Head and Neck; Tongue Neoplasms; Xenograft Model Antitumor Assays | 2017 |
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cisplatin; Disease Progression; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Retrospective Studies; Tegafur; Time Factors; Treatment Outcome | 2017 |
Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Otorhinolaryngologic Neoplasms; Paclitaxel; Prognosis; Treatment Outcome | 2017 |
Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma.
Topics: Animals; Antimetabolites; Antiviral Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Nucleocytoplasmic Transport Proteins; Paclitaxel; Ribavirin; Signal Transduction; Tongue Neoplasms; TOR Serine-Threonine Kinases | 2017 |
Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms; Young Adult | 2017 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2017 |
Vascular endothelial growth factor-targeted paclitaxel-loaded liposome microbubbles and inhibition of human epidermoid-2 cell proliferation.
Topics: Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Colorimetry; Flow Cytometry; Hep G2 Cells; Humans; Laryngeal Neoplasms; Liposomes; Microbubbles; Molecular Targeted Therapy; Paclitaxel; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2017 |
[Roles of curcumin combined with paclitaxel on growth inhibition and apoptosis of oral squamous cell carcinoma cell line CAL27 in vitro].
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Curcumin; Humans; Mouth Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2 | 2016 |
Anti-proliferative effect of Jesridonin on paclitaxel-resistant EC109 human esophageal carcinoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Diterpenes, Kaurane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Mice; Neoplastic Stem Cells; Paclitaxel; Xenograft Model Antitumor Assays | 2017 |
Metastatic penile squamous cell carcinoma to the retroperitoneum in a man with human papillomavirus type 45.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Humans; Male; Middle Aged; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Penile Neoplasms; Retroperitoneal Neoplasms; Retroperitoneal Space | 2008 |
Squamous cell carcinoma arising in a mature cystic teratoma of the ovary in young patient with elevated carbohydrate antigen 19-9.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma, Squamous Cell; Cisplatin; Dermoid Cyst; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2008 |
Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Preoperative Care; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Penile Neoplasms; Taxoids | 2009 |
Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Sex Factors; Survival Rate; Treatment Outcome | 2008 |
Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Conization; Epirubicin; Female; Humans; Hysterectomy; Ifosfamide; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms; Young Adult | 2008 |
Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Follow-Up Studies; Hemangiosarcoma; Humans; Immunohistochemistry; Laryngeal Neoplasms; Male; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Risk Assessment; Skin Neoplasms; Treatment Outcome | 2009 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
Cetuximab with concurrent chemoradiation for esophagogastric cancer: in regard to Safran et al. (Int J Radiat Oncol Biol Phys 2008;70:391-395).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Female; Humans; Male; Paclitaxel | 2008 |
A new neoadjuvant chemotherapy regimen for penile cancer with nodal metastases: a step forward.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Humans; Lymphatic Metastasis; Male; Paclitaxel; Penile Neoplasms | 2009 |
IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Exotoxins; Humans; Interleukin-13; Mice; Mouth Neoplasms; Paclitaxel; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tongue Neoplasms; Transplantation, Heterologous | 2009 |
Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Carrier Proteins; Female; Folate Receptors, GPI-Anchored; Folic Acid; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Nanomedicine; Nanotechnology; Paclitaxel; Receptors, Cell Surface; Young Adult | 2009 |
[Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Radiotherapy; Young Adult | 2008 |
Complete response of recurrent squamous cell carcinoma of the lung: dose the dose matter?
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel; Tomography, X-Ray Computed | 2009 |
Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aurora Kinase A; Aurora Kinases; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Flow Cytometry; G1 Phase; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Immunohistochemistry; Paclitaxel; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Transfection; Tumor Cells, Cultured | 2009 |
Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Fibrosis; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiotherapy Dosage; Skin; Survival Rate; Treatment Outcome | 2009 |
Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line; Cisplatin; Drug Resistance, Neoplasm; Endothelium, Vascular; Enzyme Inhibitors; Female; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Middle Aged; Nitric Oxide Donors; Nitric Oxide Synthase Type II; Nitrites; Nitroprusside; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; S-Nitroso-N-Acetylpenicillamine; Survivin; Umbilical Veins | 2009 |
Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelium, Vascular; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; Head and Neck Neoplasms; Humans; Paclitaxel; Poly(ADP-ribose) Polymerases | 2009 |
High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Iridium Radioisotopes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Radiotherapy; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Regression Analysis; Retrospective Studies; Survival Rate; Taxoids | 2009 |
The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Salvage Therapy; Uterine Cervical Neoplasms | 2009 |
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Ifosfamide; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Management of squamous cell carcinoma of the base of tongue with chemoradiation and brachytherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Retrospective Studies; Tongue Neoplasms; Treatment Outcome | 2009 |
A retrospective study of patients with locally advanced cancer of the cervix treated with neoadjuvant chemotherapy followed by radical surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Ifosfamide; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: a retrospective single-institution analysis.
Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Female; Humans; Laryngeal Neoplasms; Male; Middle Aged; Oropharyngeal Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Doxorubicin; Drug Resistance, Neoplasm; Esophageal Neoplasms; Etoposide; Fluorouracil; Humans; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured; X-Rays | 2009 |
Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms | 2009 |
Supraclavicular lymph node metastases of unknown origin: HPV-typing identifies the primary tumour.
Topics: Antineoplastic Agents, Phytogenic; Biopsy; Carcinoma, Squamous Cell; DNA, Viral; Female; Human papillomavirus 16; Humans; Incidental Findings; Lymphatic Metastasis; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Positron-Emission Tomography; Uterine Cervical Neoplasms | 2009 |
Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Survival Rate; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.
Topics: Acetylation; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Clinical Trials, Phase I as Topic; DNA Damage; DNA, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Protein Processing, Post-Translational; Tubulin; Tumor Stem Cell Assay; Vorinostat | 2010 |
Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Taxoids; Tumor Burden | 2010 |
Chemotherapy followed by surgery in patients with carcinoma of the distal esophagus and celiac lymph node involvement.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Squamous Cell; Celiac Plexus; Cisplatin; Databases, Factual; Esophageal Neoplasms; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Laparoscopy; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Retrospective Studies | 2009 |
Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cheek; Cranial Nerve Neoplasms; Facial Neoplasms; Humans; Magnetic Resonance Imaging; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Trigeminal Nerve Diseases | 2009 |
Folate-mediated targeting of albumin conjugates of paclitaxel obtained through a heterogeneous phase system.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Carrier Proteins; Cell Proliferation; Cell Survival; Chemistry, Pharmaceutical; Chromatography, Gel; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Folate Receptors, GPI-Anchored; Folic Acid; HT29 Cells; Humans; Inhibitory Concentration 50; KB Cells; Nasopharyngeal Neoplasms; Paclitaxel; Polyethylene Glycols; Receptors, Cell Surface; Serum Albumin; Solubility; Technology, Pharmaceutical; Triazines | 2009 |
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control Studies; Clinical Trials, Phase II as Topic; Cohort Studies; Cyclooxygenase 2; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hyperplasia; Ifosfamide; Immunoenzyme Techniques; Male; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Precancerous Conditions; Prognosis; Survival Rate | 2009 |
Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Radiotherapy Dosage; Young Adult | 2010 |
Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; SEER Program; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
[A case of aggressive primary squamous cell carcinoma of the breast refractory to preoperative neoadjuvant chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Epirubicin; Fatal Outcome; Female; Fluorouracil; Humans; Lung Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Vinblastine; Vinorelbine | 2009 |
Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Flow Cytometry; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Taxoids; Vincristine; Xenograft Model Antitumor Assays | 2009 |
[Advanced lung cancer with mediastinal lymph node metastasis and recurrence of brain metastasis completely responsive to combination chemotherapy and gamma knife radiosurgery--a case report].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinum; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiosurgery | 2009 |
Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Promoter Regions, Genetic; Telomerase; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Male; Middle Aged; Neck Dissection; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Recombinant Proteins; Tongue Neoplasms | 2010 |
Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Lapatinib; Mice; Paclitaxel; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2010 |
Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carbocyanines; Carcinoma, Squamous Cell; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Humans; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Paclitaxel | 2010 |
Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Drug Administration Schedule; Fatal Outcome; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Paclitaxel; Scalp; Sweat Gland Neoplasms; Young Adult | 2010 |
[Paclitaxel + carboplatin (TC)-resistant stage Ic squamous cell carcinomas arising in mature cystic teratomas of the ovary].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Radiography | 2010 |
Neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical surgery in early cervical cancer during pregnancy: three case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cesarean Section; Female; Humans; Hysterectomy; Magnetic Resonance Imaging; Neoadjuvant Therapy; Paclitaxel; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Cervical Neoplasms | 2010 |
Sporotrichoid metastases to the skin from cutaneous squamous cell carcinoma in an immunocompetent patient.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arm; Carcinoma, Squamous Cell; Cisplatin; Fatal Outcome; Fluorouracil; Hand; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Paclitaxel; Radiotherapy; Skin Neoplasms | 2010 |
Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Humans; MAP Kinase Signaling System; Mesoderm; Paclitaxel; Phenotype; Phosphatidylinositol 3-Kinases | 2010 |
Chemoradiation for esophageal cancer: institutional experience with three different regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Silencing; Head and Neck Neoplasms; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; RNA, Messenger; RNA, Small Interfering; Survivin | 2010 |
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Disease Models, Animal; ErbB Receptors; Flow Cytometry; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Random Allocation; Sensitivity and Specificity; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Combined therapy for thyroid squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Induction Chemotherapy; Middle Aged; Paclitaxel; Thyroid Neoplasms | 2012 |
Neoadjuvant weekly carboplatin and paclitaxel followed by radical hysterectomy for locally advanced cervical cancer: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
Sarcoidosis development during induction chemotherapy for lung cancer mimicked progressive disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease Progression; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoidosis, Pulmonary; Tomography, X-Ray Computed | 2010 |
Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytostatic Agents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Head and Neck Neoplasms; Humans; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2011 |
[Pulmonary non-tuberculous mycobacteriosis (Mycobacterium intracellulare) with cavities developing in a non-small cell lung cancer patient during chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Male; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Paclitaxel | 2010 |
[Digital necrosis related to gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Fingers; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Necrosis; Paclitaxel; Palliative Care | 2010 |
In vitro chemosensitivity of head and neck cancer cell lines.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Methotrexate; Paclitaxel | 2010 |
BMSC enhance the survival of paclitaxel treated squamous cell carcinoma cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow Cells; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coculture Techniques; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Mesenchymal Stem Cells; Paclitaxel | 2011 |
Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early r
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Kaplan-Meier Estimate; Laryngeal Neoplasms; Leukopenia; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Opportunistic Infections; Paclitaxel; Positron-Emission Tomography; Radiodermatitis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Salvage Therapy; Taxoids; Thrombocytopenia; Tomography, X-Ray Computed; Tongue Neoplasms; Treatment Outcome | 2011 |
Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure; Tumor Cells, Cultured | 2011 |
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Introns; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Survival Rate | 2011 |
Primary squamous cell carcinoma associated with ovarian endometriosis: a case report and literature review.
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Endometriosis; Female; Humans; Laparotomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms | 2011 |
The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Time Factors; Uterine Cervical Neoplasms; Vinblastine; Young Adult | 2011 |
Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell lines.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Mouth Neoplasms; Neoplastic Stem Cells; Paclitaxel; Wnt Proteins | 2011 |
Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
Topics: Adenoviridae Infections; Adenovirus E1A Proteins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bacterial Proteins; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, myc; Head and Neck Neoplasms; Humans; Neoplasms, Squamous Cell; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Receptors, Virus; RNA, Messenger; S Phase; Squamous Cell Carcinoma of Head and Neck; Streptolysins; Telomerase | 2011 |
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Boron Compounds; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; KB Cells; Methotrexate; Mitoxantrone; Models, Molecular; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Piperazines; Prazosin; Purines; Sildenafil Citrate; Sulfones | 2011 |
Effect of CD147 monoclonal antibody on paclitaxel resistance in HCE1 multicellular spheroids.
Topics: Antibodies, Monoclonal; Basigin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Spheroids, Cellular; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2011 |
Ovarian squamous cell carcinoma which metastasized 8 years after cervical conization for early microinvasive cervical cancer: a case report.
Topics: Adult; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Conization; Cyclin-Dependent Kinase Inhibitor p16; DNA, Viral; Female; Humans; Immunohistochemistry; Neoplasm Invasiveness; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Palliative Care; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Neoplastic; Radiotherapy, Adjuvant; Reoperation; Time Factors; Uterine Cervical Neoplasms; Watchful Waiting | 2011 |
Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Hysterectomy; Ifosfamide; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2011 |
Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Gamma Rays; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Preservation; Paclitaxel; Remission Induction; Survival Rate; Treatment Outcome | 2011 |
Second-line chemotherapy in patients with primary unknown cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2011 |
[Histological evaluation of cervical carcinomas in FIGO stage Ib2/IIa after neoadjuvant chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Preoperative Period; Prognosis; Retrospective Studies; Uterine Cervical Neoplasms; Vincristine; Young Adult | 2011 |
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2011 |
Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymphatic Irradiation; Male; Middle Aged; Paclitaxel; Preoperative Care; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Failure | 2011 |
Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Basigin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2012 |
FaDu cell characteristics induced by multidrug resistance.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Multiple; Female; Humans; Hypopharyngeal Neoplasms; Male; Neoplasm Proteins; Paclitaxel; Tumor Cells, Cultured | 2011 |
The effect of indomethacin on paclitaxel sensitivity and apoptosis in oral squamous carcinoma cells: the role of nuclear factor-κB inhibition.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Head and Neck Neoplasms; Humans; I-kappa B Proteins; Indomethacin; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Transfection | 2011 |
Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease Models, Animal; Humans; Hyaluronan Receptors; Hyaluronic Acid; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Paclitaxel; Tongue Neoplasms; Transplantation, Heterologous; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Adjuvant combined paclitaxel and carboplatin chemotherapy for glassy cell carcinoma of the uterine cervix: report of three cases with clinicopathological analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cervix Uteri; Disease-Free Survival; Female; Humans; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2011 |
Identification of cervical cancer proteins associated with treatment with paclitaxel and cisplatin in patients.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Neoplasm Proteins; Paclitaxel; Proteomics; Uterine Cervical Neoplasms | 2011 |
Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Intestinal Obstruction; Lymph Node Excision; Lymphedema; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Complications; Radiotherapy, Adjuvant; Retrospective Studies; Uterine Cervical Neoplasms | 2012 |
Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retreatment; Retrospective Studies; Thrombocytopenia | 2012 |
Chios mastic gum extracts as a potent antitumor agent that inhibits growth and induces apoptosis of oral cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; DNA; Drug Screening Assays, Antitumor; Humans; Mastic Resin; Mouth Neoplasms; Paclitaxel; Pistacia; Plant Extracts; Resins, Plant | 2011 |
Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Drug Synergism; Humans; Mice; Microscopy, Fluorescence; Microvessels; Paclitaxel; Radioimmunotherapy; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2012 |
Poly I:C inhibits cell proliferation and enhances the growth inhibitory effect of paclitaxel in oral sqaumous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Humans; Mouth Neoplasms; Paclitaxel; Poly I-C; Toll-Like Receptor 3 | 2012 |
Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Multimodal Imaging; Paclitaxel; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Effect of maintenance chemotherapy with gemcitabine and paclitaxel on recurrent squamous cell carcinoma of the bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Japan; Male; Methotrexate; Middle Aged; Paclitaxel; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy.
Topics: Adult; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Female; Fluorouracil; Humans; Male; Microtubules; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2011 |
[A case of lung resection after chemotherapy due to lung metastases derived from esophageal cancer resection].
Topics: Antineoplastic Agents, Phytogenic; Biopsy; Carcinoma, Squamous Cell; Esophageal Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Tomography, X-Ray Computed | 2011 |
Comparison of limited-volume perioperative high-dose-rate brachytherapy and wide-field external irradiation in resected head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy Dosage | 2012 |
Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Humans; Male; Middle Aged; Oropharyngeal Neoplasms; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation Tolerance; Radiography; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Spinal Cord | 2012 |
Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carbon; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Drug Carriers; Head and Neck Neoplasms; Humans; Male; Mice; Nanostructures; Paclitaxel; Polyethylene Glycols; Tumor Burden | 2012 |
[Neoadjuvant chemotherapy with paclitaxel and cisplantin or carboplatin for patients with locally advanced uterine cervical cancer].
Topics: Adenocarcinoma; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Hysterectomy; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Remission Induction; Serpins; Uterine Cervical Neoplasms | 2011 |
Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2012 |
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Genes, p53; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-mdm2; Treatment Outcome; Young Adult | 2012 |
Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Risk; Salvage Therapy; Survival Rate; Treatment Failure; Uterine Cervical Neoplasms; Young Adult | 2012 |
Paclitaxel-loaded ethosomes®: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses.
Topics: Administration, Cutaneous; Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Delivery Systems; Humans; Keratosis, Actinic; Paclitaxel; Skin Absorption; Skin Neoplasms; Tissue Distribution | 2012 |
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oropharyngeal Neoplasms; Paclitaxel; Panitumumab; Papillomavirus Infections; Proportional Hazards Models; Radiation Tolerance; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids; Treatment Failure | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cross-Sectional Studies; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2012 |
Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Medical Records Systems, Computerized; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Retrospective Studies; Salpingectomy; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2012 |
Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2012 |
The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials.
Topics: Adenocarcinoma, Papillary; Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Phthalazines; Piperazines; Quinazolines; Uterine Cervical Neoplasms | 2012 |
Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Multivariate Analysis; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2012 |
Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Treatment Failure | 2012 |
Knockdown of RhoGDIα induces apoptosis and increases lung cancer cell chemosensitivity to paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Dissociation Inhibitors; Humans; I-kappa B Proteins; Immunoenzyme Techniques; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; NF-KappaB Inhibitor alpha; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; rho-Specific Guanine Nucleotide Dissociation Inhibitors; RNA, Messenger; RNA, Small Interfering; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2012 |
Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Carcinoma, Papillary; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Paclitaxel; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2012 |
Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cervix Uteri; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Female; Fertility Preservation; Follow-Up Studies; Humans; Ifosfamide; Laparoscopy; Lymph Node Excision; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvis; Prospective Studies; Uterine Cervical Neoplasms | 2012 |
Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2012 |
Antitumor activity of photo-stimulated zinc oxide nanoparticles combined with paclitaxel or cisplatin in HNSCC cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Catalysis; Cell Line, Tumor; Cisplatin; Drug Synergism; Humans; Metal Nanoparticles; Mouth Neoplasms; Necrosis; Paclitaxel; Ultraviolet Rays; Zinc Oxide | 2012 |
Platinum-based combination chemotherapy for the treatment of advanced-stage squamous cell carcinoma of the vulva.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; HIV; HIV Infections; Humans; Middle Aged; Paclitaxel; Remission Induction; Taxoids; Vulvar Neoplasms | 2012 |
The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Reference Values; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase Inhibitors; Topotecan; Ubiquitin-Conjugating Enzymes; Uterine Cervical Neoplasms | 2012 |
HOXC6 is deregulated in human head and neck squamous cell carcinoma and modulates Bcl-2 expression.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Homeodomain Proteins; Humans; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Response Elements; Sequence Deletion | 2012 |
Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
Neoadjuvant chemoradiotherapy followed by esophagectomy does not increase morbidity in patients over 70.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Female; Hematologic Diseases; Hospital Mortality; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Survival Rate | 2013 |
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread.
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Diagnosis, Differential; Drug Administration Schedule; Fatal Outcome; Fluorodeoxyglucose F18; Fluorouracil; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Immunohistochemistry; Laryngoscopy; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Papillomavirus Infections; Positron-Emission Tomography; Pulmonary Artery; Radiopharmaceuticals; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic; Thrombophilia; Tomography, X-Ray Computed; Vascular Neoplasms | 2012 |
Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Paclitaxel; Phenotype; Phosphoproteins; Protein Serine-Threonine Kinases; Ribonucleoproteins; RNA-Binding Proteins; Serine-Arginine Splicing Factors; Signal Transduction | 2012 |
Moderately hypofractionated conformal radiation treatment of thoracic esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiation Injuries; Radiotherapy, Conformal; Survival Rate; Thoracic Neoplasms | 2012 |
Isolation and genomic characterization of stem cells in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cell Separation; Cisplatin; Flow Cytometry; Gene Expression Regulation, Neoplastic; Genomics; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Neoplastic Stem Cells; Paclitaxel; Radiation Tolerance; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured | 2013 |
Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Cell Survival; Chromones; Cisplatin; Cyclin B1; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Knockdown Techniques; Humans; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; RNA, Small Interfering; Signal Transduction | 2013 |
Surgical outcomes of robotic radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer: comparison with early stage disease.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Epirubicin; Feasibility Studies; Female; Humans; Hysterectomy; Ifosfamide; Laparoscopy; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Robotics; Safety; Treatment Outcome; Uterine Cervical Neoplasms; Vagina | 2013 |
Abnormal expression of the mitotic checkpoint protein BubR1 contributes to the anti-microtubule drug resistance of esophageal squamous cell carcinoma cells.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagus; Female; Humans; Male; Middle Aged; Mitotic Index; Neoplasm Staging; Nocodazole; Paclitaxel; Prognosis; Protein Serine-Threonine Kinases; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tubulin Modulators; Tumor Cells, Cultured | 2013 |
Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt.
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Interactions; Enzyme Activation; Epithelial-Mesenchymal Transition; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; MicroRNAs; Mitogen-Activated Protein Kinase 7; Neoplastic Stem Cells; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrans; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck | 2012 |
Expression and phosphorylation of stathmin correlate with cell migration in esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Chi-Square Distribution; Esophageal Neoplasms; Female; Gene Knockdown Techniques; Humans; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Phosphorylation; RNA, Small Interfering; Stathmin; Tubulin Modulators; Wound Healing | 2013 |
Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Confidence Intervals; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Netherlands; Paclitaxel; Proportional Hazards Models; Radiotherapy Dosage; Survival Rate; Tumor Burden | 2013 |
Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mutation; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Is preoperative chemoradiation with paclitaxel and carboplatin a new standard of treatment for esophageal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Clinical Trials as Topic; Esophageal Neoplasms; Humans; Paclitaxel; Preoperative Care; Radiation Pneumonitis; Treatment Outcome | 2013 |
Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Collagen Type I; Drug Resistance, Neoplasm; Fibronectins; Head and Neck Neoplasms; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Signal Transduction | 2013 |
The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasms; Paclitaxel; Taxoids | 2002 |
Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Paclitaxel; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vulvar Neoplasms | 2002 |
Postoperative complications of lung resection after induction chemotherapy using Paclitaxel (and radiotherapy) for advanced non-small lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Intraoperative Care; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Complications; Vinblastine; Vinorelbine | 2002 |
[Therapeutic strategy for a patient suffering from a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Humans; Laser Therapy; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Pneumonectomy; Taxoids; Tracheal Neoplasms | 2002 |
[Cardiac tamponade as the first clinical manifestation of squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carboplatin; Carcinoma, Squamous Cell; Cardiac Tamponade; Diagnosis, Differential; Fatal Outcome; Heart Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Pericardium | 2002 |
Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Squamous Cell; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Potentiation of the effect of paclitaxel and carboplatin by antioxidant mixture on human lung cancer h520 cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Carboplatin; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Drug Synergism; Flow Cytometry; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2002 |
[A case of hypopharyngeal carcinoma in which a complete response to chemotherapy was achieved with docetaxel, cisplatin, 5-FU and levofolinate].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Leucovorin; Male; Paclitaxel; Remission Induction; Taxoids | 2002 |
The role of MAPK pathways in the action of chemotherapeutic drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Cycle; Ceramides; Enzyme Activation; Enzyme Inhibitors; Etoposide; Female; Flavonoids; HeLa Cells; Humans; Imidazoles; MAP Kinase Signaling System; Microtubules; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Paclitaxel; Pyridines; Skin Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Nucleus; Cell Survival; Humans; Hyperthermia, Induced; Lung Neoplasms; Microscopy, Confocal; Paclitaxel; Phosphorylation; Precipitin Tests; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2003 |
Skin relapse from cervical cancer.
Topics: Carcinoma, Squamous Cell; Female; Humans; Lymphangitis; Middle Aged; Paclitaxel; Skin Neoplasms; Uterine Cervical Neoplasms | 2002 |
Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot.
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; DNA Primers; Docetaxel; Endothelial Growth Factors; fas Receptor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Development of an in vitro chemo-radiation response assay for cervical carcinoma.
Topics: Antineoplastic Agents; Buthionine Sulfoximine; Carcinoma, Squamous Cell; Carmustine; Cell Division; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Female; Humans; Paclitaxel; Pilot Projects; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Therapy, Combination; Humans; In Vitro Techniques; Injections, Intravenous; Lung Neoplasms; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Paclitaxel; Phenyl Ethers; Survival Rate; Taxoids | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Dose Fractionation, Radiation; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Lymph Nodes; Male; Middle Aged; Paclitaxel; Quality of Life; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2003 |
[Two patients with distant metastases from head and neck squamous cell carcinomas successfully treated with docetaxel and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Paclitaxel; Remission Induction; Taxoids | 2003 |
[Study on the effects of taxol on Hep-2 cell lines in larynx carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Dose-Response Relationship, Drug; Humans; Laryngeal Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1999 |
Aggressive multimodality treatment of invasive thymic carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Postoperative Care; Radiotherapy, Adjuvant; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed | 2003 |
Re: Folliculitis associated with weekly paclitaxel treatment.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug Administration Schedule; ErbB Receptors; Esophageal Neoplasms; Folliculitis; Humans; Male; Middle Aged; Paclitaxel | 2003 |
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Endpoint Determination; Head and Neck Neoplasms; Humans; Ifosfamide; Mesna; Neutropenia; Paclitaxel; Reproducibility of Results; Survival; Taxoids | 2003 |
Metastatic cutaneous squamous cell carcinoma arising from a previous area of chronic hypertrophic lichen planus.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chronic Disease; Cisplatin; Groin; Humans; Leg; Lichen Planus; Lymphatic Metastasis; Male; Paclitaxel; Skin Neoplasms | 2003 |
Clear cell adenocarcinoma in a female urethral diverticulum.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Pelvic Exenteration; Radiography; Radiotherapy, Adjuvant; Urethral Neoplasms | 2003 |
Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA, Neoplasm; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; HeLa Cells; Humans; In Vitro Techniques; Mice; Mice, Nude; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nucleosomes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Prognosis; Rats; Rats, Wistar; Tumor Virus Infections; Uterine Cervical Neoplasms | 2003 |
[Chemosensitivity testing of oral and maxillofacial cancer with biopsy specimens].
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Squamous Cell; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Maxilla; Maxillary Neoplasms; Mouth; Mouth Neoplasms; Paclitaxel; Teniposide; Tumor Cells, Cultured; Vindesine | 2002 |
Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids | 2003 |
Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bromodeoxyuridine; Carcinoma, Squamous Cell; Cell Hypoxia; Cisplatin; Combined Modality Therapy; DNA Damage; Gamma Rays; Genes, p53; Head and Neck Neoplasms; Humans; Hyperthermia, Induced; Mice; Mice, Inbred BALB C; Mice, Nude; Micronucleus Tests; Neoplasm Proteins; Paclitaxel; Radiation-Sensitizing Agents; Tirapazamine; Triazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2003 |
Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Caspase 3; Caspases; Cell Cycle; Cisplatin; DNA Fragmentation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2003 |
Additive effects of radiation and docetaxel on murine SCCVII tumors in vivo: special reference to changes in the cell cycle.
Topics: Animals; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Ki-67 Antigen; Male; Mice; Mice, Inbred C3H; Mitosis; Paclitaxel; Taxoids | 2003 |
Squamous cell carcinoma arising in a dermoid cyst of the ovary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dermoid Cyst; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2003 |
A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug Delivery Systems; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Paclitaxel; Particle Size; Serum Albumin; Tongue Neoplasms | 2003 |
Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Division; Cell Line, Transformed; Cyclin-Dependent Kinases; Cyclins; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Head and Neck Neoplasms; Humans; Interleukin-2 Receptor alpha Subunit; Janus Kinase 3; Multienzyme Complexes; Paclitaxel; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Receptors, Interleukin; Tumor Cells, Cultured; Ubiquitin | 2003 |
Voice and swallowing in patients enrolled in a larynx preservation trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Deglutition; Female; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Voice; Voice Disorders | 2003 |
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Dacryocystorhinostomy; Docetaxel; Drainage; Esophageal Neoplasms; Female; Humans; Intubation; Lacrimal Duct Obstruction; Lung Neoplasms; Male; Middle Aged; Nasolacrimal Duct; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Taxoids; Texas | 2003 |
Weekly paclitaxel for advanced non-small cell lung cancer patients not suitable for platinum-based therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate; Time Factors | 2003 |
[A case of posterior wall cancer of the hypopharynx treated with docetaxel followed by radiation].
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Hypopharyngeal Neoplasms; Paclitaxel; Taxoids | 2003 |
Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Biological Transport; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Radiopharmaceuticals; Retrospective Studies; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 2003 |
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ifosfamide; Neurologic Examination; Paclitaxel; Peripheral Nervous System Diseases; Severity of Illness Index; Taxoids; Uterine Cervical Neoplasms | 2003 |
[Non-platinum induction chemotherapy for stage III non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Low-dose irradiation and short-exposure suboptimal-dose paclitaxel adversely modulate metastatic potential of squamous carcinoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Line, Tumor; Colony-Forming Units Assay; Cytoskeleton; Data Interpretation, Statistical; Disease Models, Animal; Humans; Immunohistochemistry; Interphase; Liver Neoplasms; Mice; Mice, SCID; Microscopy, Confocal; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2003 |
Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Fibroblast Growth Factor 2; Humans; Interleukin-8; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Models, Biological; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A | 2003 |
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Paclitaxel; Quality of Life; Radiotherapy Dosage; Remission Induction; Survival Rate | 2003 |
Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Prognosis; Vault Ribonucleoprotein Particles | 2003 |
Trafficking of beta2-adrenergic receptors: insulin and beta-agonists regulate internalization by distinct cytoskeletal pathways.
Topics: Adrenergic beta-Agonists; Animals; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; CHO Cells; Cricetinae; Cytoskeleton; Green Fluorescent Proteins; Humans; Insulin; Isoproterenol; Luminescent Proteins; Microscopy, Confocal; Paclitaxel; Phosphorylation; Protein Transport; Receptors, Adrenergic, beta-2; Signal Transduction | 2004 |
Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.
Topics: Aged; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Cyclin E; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Primers; Estrogen Receptor alpha; Fluorouracil; G1 Phase; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Suppressor Protein p53; Vincristine | 2004 |
Severe dermatologic reactions at multiple sites after paclitaxel administration.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Humans; Male; Middle Aged; Paclitaxel; Skin Ulcer; Tongue Neoplasms | 2004 |
Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Penile Neoplasms; Penis; Remission Induction; Survival Analysis; Tomography, Emission-Computed | 2004 |
Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Spectrophotometry, Atomic; Thrombopoietin | 2004 |
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Remission Induction; Survival Rate | 2004 |
Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brachytherapy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Glossectomy; Humans; Intraoperative Care; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Radiotherapy Dosage; Radiotherapy, Adjuvant; Recovery of Function; Tongue Neoplasms; Treatment Outcome | 2004 |
[A case of recurrent pulmonary lymphoepithelioma-like carcinoma responding to treatment with CBDCA/paclitaxel combined chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymph Node Excision; Middle Aged; Paclitaxel; Pneumonectomy | 2004 |
Biweekly paclitaxel, cisplatin, tegafur, and leucovorin as neoadjuvant chemotherapy for unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2004 |
[Clinical observation of TP regiment for treating refractory and terminal squamous cancer of the esophagus].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Fluorouracil; Humans; Inhibitory Concentration 50; Mouth Neoplasms; Paclitaxel; Predictive Value of Tests | 2004 |
Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Evaluation; Female; Follow-Up Studies; Humans; Life Tables; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
[Experimental study of taxol combining accelerated radiation on laryngeal carcinoma cells].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Humans; Laryngeal Neoplasms; Paclitaxel; Particle Accelerators; Radiation-Sensitizing Agents | 2002 |
Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Nude; Mouth Neoplasms; Paclitaxel; Purines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2004 |
Auditory effects after organ preservation protocol for laryngeal/hypopharyngeal carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Audiometry, Pure-Tone; Auditory Threshold; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Hearing Loss, Sensorineural; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy; Radiotherapy Dosage | 2004 |
2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents, Phytogenic; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Squamous Cell; Carrier Proteins; Caspase 3; Caspase 7; Caspases; Cell Division; Cell Hypoxia; Drug Therapy, Combination; Enzyme Activation; Estradiol; Female; G2 Phase; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred BALB C; Mice, SCID; Microcirculation; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Transcription Factors; Vascular Endothelial Growth Factor A | 2004 |
Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carboplatin; Carcinoma, Squamous Cell; Cell Proliferation; Enkephalin, Methionine; Head and Neck Neoplasms; Humans; Male; Paclitaxel; Tumor Cells, Cultured | 2005 |
A case of pure-type ovarian squamous cell carcinoma for which combination chemotherapy consisting of paclitaxel and carboplatin was not effective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Failure | 2005 |
Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Carcinoma, Squamous Cell; Cell Proliferation; Disease Progression; Enkephalin, Methionine; Head and Neck Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Survival Analysis | 2005 |
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids | 2005 |
[A case of recurrent esophageal cancer successfully treated with weekly paclitaxel in combination with radiotherapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Radiotherapy Dosage; Remission Induction | 2005 |
Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Fragmentation; Dose-Response Relationship, Drug; Esophageal Neoplasms; Flow Cytometry; G2 Phase; Humans; Paclitaxel; Time Factors; Tubulin Modulators | 2006 |
Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Laryngoscopy; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Palliative Care; Radiation Dosage; Radiation Injuries; Remission Induction; Retrospective Studies; Salvage Therapy; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Osteoradionecrosis; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2005 |
Neoadjuvant chemotherapy for squamous cell carcinoma of the oral tongue in young adults: a case series.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Glossectomy; Humans; Male; Neck Dissection; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Tongue Neoplasms | 2005 |
Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Multivariate Analysis; Necrosis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Prospective Studies; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
Induction redux: once more with taxanes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Remission Induction; Treatment Outcome | 2005 |
[Preoperative radiochemotherapy of advanced resectable cancer of the oral cavity with cisplatin vs paclitaxel/carboplatin. Analysis of two multimodality treatment concepts].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mouth Neoplasms; Multicenter Studies as Topic; Neoadjuvant Therapy; Oropharyngeal Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
Differential gene expression in a paclitaxel-resistant clone of a head and neck cancer cell line.
Topics: Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, MDR; Head and Neck Neoplasms; Humans; Interferon-Stimulated Gene Factor 3, gamma Subunit; Paclitaxel; RNA, Neoplasm; Tubulin; Tubulin Modulators | 2006 |
Antitumor effects of IDN5109 on head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Neovascularization, Pathologic; Paclitaxel; Taxoids | 2006 |
Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Fusaric Acid; Growth Inhibitors; Head and Neck Neoplasms; Humans; Male; Mouth Neoplasms; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Time Factors; Tumor Cells, Cultured | 2006 |
Ultrasonographic guidance for spinal extracranial radiosurgery: technique and application for metastatic spinal lesions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phantoms, Imaging; Radiosurgery; Spinal Neoplasms; Taxoids; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2001 |
p16 gene alterations in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; Female; Gene Expression Regulation, Neoplastic; Genes, p16; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2006 |
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents, Phytogenic; Aspartic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Glutamic Acid; Humans; Mice; Mice, Nude; Microtubules; Paclitaxel; Point Mutation; Protein Conformation; Taxoids; Tubulin; Verapamil | 2006 |
Induction of apoptosis by paclitaxel in human oral carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Mouth Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2 | 2006 |
[Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous | 2006 |
[Improvement of postoperative radiotherapy in the complex treatment of stage II-III cervical cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2006 |
Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies | 2006 |
Clusterin confers paclitaxel resistance in cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Case-Control Studies; Cell Line, Tumor; Clusterin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Inhibitory Concentration 50; Middle Aged; Paclitaxel; Polymerase Chain Reaction; RNA, Small Interfering; Uterine Cervical Neoplasms | 2006 |
HIV-associated anal squamous cell cancer: an otherwise preventable disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Colostomy; Fatal Outcome; Fluorouracil; HIV Infections; Homosexuality, Male; Humans; Laparotomy; Male; Middle Aged; Mitomycin; Paclitaxel; Palliative Care; Radiotherapy, Adjuvant | 2006 |
Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2007 |
[A case of squamous cell carcinoma of unknown primary site with involvement of cervico-mediastinal lymph nodes successfully treated by chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Routes; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Neck; Neoplasms, Unknown Primary; Paclitaxel | 2006 |
[Chemotherapy guidance of the drug sensitivity test in vitro in human laryngeal squamous cell carcinoma].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Laryngeal Neoplasms; Paclitaxel | 2006 |
Comparison of paclitaxel penetration in normal and cancerous cervical model monolayer membranes.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Membrane; Cholesterol; Female; Humans; Lipid Bilayers; Paclitaxel; Sphingomyelins; Uterine Cervical Neoplasms; Uterus | 2006 |
Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Thymoma; Thymus Neoplasms; Treatment Outcome | 2006 |
Ambivalency at the bedside: intraperitoneal chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Ovarian Neoplasms; Paclitaxel; Physician-Patient Relations; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic | 2007 |
[A case of squamous cell carcinoma of the lung with a high titer of proteinase 3 antineutrophil cytoplasmic antibody].
Topics: Antibodies, Antineutrophil Cytoplasmic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Administration Schedule; Granulomatosis with Polyangiitis; Humans; Lung Neoplasms; Male; Middle Aged; Myeloblastin; Paclitaxel | 2006 |
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms | 2007 |
Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Capillaries; Carcinoma, Squamous Cell; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Carriers; Drug Compounding; Fibroblast Growth Factor 2; Immunohistochemistry; Lactic Acid; Laryngeal Neoplasms; Mice; Microspheres; Neoplasm Transplantation; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2007 |
Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Uterine Cervical Neoplasms | 2007 |
Bevacizumab for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiovascular Diseases; Humans; Lung Neoplasms; Paclitaxel | 2007 |
Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Basal Metabolism; Body Composition; Body Mass Index; C-Reactive Protein; Carboplatin; Carcinoma, Squamous Cell; Cytokines; Female; Head and Neck Neoplasms; Humans; Inflammation; Male; Middle Aged; Motor Activity; Paclitaxel; Radiotherapy, Adjuvant | 2007 |
[Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Topics: Adult; Antineoplastic Agents; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Cell Survival; Cells, Cultured; Cisplatin; Cyclophosphamide; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms | 2007 |
[A successful case of lower gingival cancer with pulmonary metastases by adjuvant chemotherapy including paclitaxel, cisplatin and 5-fluorouracil following a surgical procedure].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Gingival Neoplasms; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Pneumonectomy; Remission Induction; Thoracic Surgery, Video-Assisted | 2007 |
Enrichment of a squamous carcinoma vaccine.
Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Fibroblasts; Immunotherapy, Adoptive; Lung Neoplasms; Mice; Paclitaxel; Time Factors; Transfection; Tumor Burden; Vaccination; Vaccines, DNA | 2007 |
[Relationship between the expression of P-glycoprotein, glutathione S-transferase-pi and thymidylate synthase proteins and adenosine triphosphate tumor chemosensitivity assay in cervical cancer].
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Screening Assays, Antitumor; Feasibility Studies; Female; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; Thymidylate Synthase; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2007 |
Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Carcinoma, Squamous Cell; Cell Proliferation; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Paclitaxel; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Inositol hexaphosphate and paclitaxel: symbiotic treatment of oral cavity squamous cell carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Drug Synergism; Genes, Reporter; Humans; Mouth Neoplasms; NF-kappa B; Paclitaxel; Phytic Acid | 2007 |
Concurrent platinum-based chemotherapy and simultaneous modulated accelerated radiation therapy for locally advanced squamous cell carcinoma of the tongue base.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Follow-Up Studies; Gastrostomy; Humans; Male; Middle Aged; Neck Dissection; Paclitaxel; Radiotherapy Dosage; Tongue Neoplasms | 2008 |
Effect of fluidizing agents on paclitaxel penetration in cervical cancerous monolayer membranes.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Membrane Permeability; Drug Combinations; Fatty Alcohols; Female; Fluoresceins; Fluorescent Dyes; Humans; In Vitro Techniques; Liposomes; Membrane Fluidity; Membranes, Artificial; Models, Biological; Paclitaxel; Phospholipids; Phosphorylcholine; Polyethylene Glycols; Surface-Active Agents; Uterine Cervical Neoplasms | 2007 |
Neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer during pregnancy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Birth Weight; Carcinoma, Squamous Cell; Cesarean Section; Cisplatin; Female; Humans; Hysterectomy; Infant, Newborn; Neoadjuvant Therapy; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Cervical Neoplasms | 2007 |
Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Frozen Sections; Humans; Ifosfamide; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Preoperative Care; Reproducibility of Results; Uterine Cervical Neoplasms | 2008 |
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2007 |
[Radiosensitization of paclitaxel combined with radiation on nasopharygneal carcinoma cells (CNE-I) in vitro].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Nasopharyngeal Neoplasms; Paclitaxel; Particle Accelerators; Radiation Tolerance; Radiation-Sensitizing Agents | 2007 |
[Synergistic interactions of TRAIL and paclitaxel on the laryngeal squamous carcinoma cell line in vitro].
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; Humans; Laryngeal Neoplasms; Paclitaxel; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Activity of paclitaxel in metastatic squamous anal carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Anus Neoplasms; Carcinoma, Squamous Cell; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2008 |
Luteolin induces apoptosis in oral squamous cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinases; Cyclins; Humans; Luteolin; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Poly(ADP-ribose) Polymerases; Tongue Neoplasms; Transplantation, Heterologous | 2008 |
Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2008 |
[Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Female; Follow-Up Studies; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Particle Accelerators; Radiotherapy Dosage; Radiotherapy, High-Energy; Remission Induction; Survival Rate; Thrombocytopenia | 2007 |
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Hydroxyurea; Immunohistochemistry; Kaplan-Meier Estimate; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Organ Preservation; Paclitaxel; Probability; Quality of Life; Radiotherapy Dosage; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Papillomaviridae; Patient Selection; Proportional Hazards Models; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2008 |
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Squamous Cell; Cell Survival; Cetuximab; Cisplatin; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Myeloid Cell Leukemia Sequence 1 Protein; Oligonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2008 |
Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel; Proteomics; Reactive Oxygen Species; Taxoids | 2008 |
Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel.
Topics: Carcinoma, Squamous Cell; Cell Division; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Paclitaxel; Radiation Dosage; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1995 |
Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer.
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cells, Cultured; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Flow Cytometry; Growth Inhibitors; Humans; In Vitro Techniques; Laryngeal Neoplasms; Larynx; Male; Paclitaxel | 1995 |
[Effectiveness of taxol in head-neck tumors].
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Paclitaxel; Survival Rate | 1993 |
The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids | 1994 |
Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; DNA Damage; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Paclitaxel; Tumor Cells, Cultured; Video Recording | 1996 |
Pharmacodynamics of taxol in human head and neck tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1996 |
Paclitaxel is only a weak radiosensitizer of human cervical carcinoma cell lines.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Dose-Response Relationship, Radiation; Female; G2 Phase; Humans; Paclitaxel; Radiation Dosage; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1996 |
In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Humans; Linear Models; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vulvar Neoplasms | 1996 |
Typhlitis associated with docetaxel treatment.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cecal Diseases; Docetaxel; Enterocolitis, Pseudomembranous; Fatal Outcome; Humans; Ileal Diseases; Lung Neoplasms; Male; Middle Aged; Necrosis; Paclitaxel; Taxoids | 1996 |
Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Lymphoma; Male; Mice; Mice, Inbred C3H; Mitosis; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Sarcoma, Experimental | 1996 |
Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Survival; Combined Modality Therapy; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured | 1996 |
In vitro evaluation of Taxol combined with radiations in human squamous cell carcinoma spheroids.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Dose-Response Relationship, Radiation; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Spheroids, Cellular; Tumor Cells, Cultured | 1996 |
Evaluation of Taxol in head and neck squamous carcinoma multicellular tumor spheroids.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Division; Cell Line; Head and Neck Neoplasms; Humans; Paclitaxel; Spheroids, Cellular; Tumor Stem Cell Assay | 1997 |
Subadditive interaction of radiation and Taxol in vitro.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Survival; Drug Administration Schedule; Drug Screening Assays, Antitumor; G2 Phase; Humans; Laryngeal Neoplasms; Paclitaxel; Radiation Tolerance; Radiotherapy Dosage; Tumor Cells, Cultured | 1997 |
Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Up-Regulation | 1997 |
Enhanced radioresponse of paclitaxel-sensitive and -resistant tumours in vivo.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mitosis; Neoplasm Transplantation; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Skin | 1997 |
[Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Immunohistochemistry; Middle Aged; Mutation; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Tumor Suppressor Protein p53 | 1997 |
Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome | 1997 |
Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; CDC28 Protein Kinase, S cerevisiae; Cyclin B; Cyclin B1; Enzyme Inhibitors; Humans; Mitosis; Paclitaxel; Phosphorylation; Protein Synthesis Inhibitors; Tumor Cells, Cultured; Zinc | 1998 |
[Neutropenic enterocolitis].
Topics: Antineoplastic Agents, Phytogenic; Biopsy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Enterocolitis, Pseudomembranous; Female; Humans; Intestinal Mucosa; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Palliative Care; Radiation Injuries; Sigmoidoscopy | 1998 |
Remarkable response of primary squamous cell carcinoma of the ovary to paclitaxel and cisplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Ovarian Neoplasms; Paclitaxel; Tomography, X-Ray Computed | 1998 |
Ocular toxicity secondary to paclitaxel in two lung cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Vision Disorders | 1998 |
Cytotoxic and genotoxic effects of paclitaxel (Taxol) and radiation in a squamous cell carcinoma cell line of the larynx.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Cycle; Flow Cytometry; Humans; Laryngeal Neoplasms; Paclitaxel; Radiation Dosage; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1998 |
Regulation of parathyroid hormone-related protein expression in a canine squamous carcinoma cell line by colchicine.
Topics: Animals; Blotting, Northern; Carcinoma, Squamous Cell; Colchicine; Dogs; Epidermal Growth Factor; Gene Expression Regulation; Luciferases; Lumicolchicines; Neoplasm Proteins; Nocodazole; Paclitaxel; Parathyroid Hormone-Related Protein; Proteins; Radioimmunoassay; RNA, Messenger; Transcription, Genetic; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured; Vinblastine | 1998 |
[Recurrent squamous-cell lung cancer treated with bronchial-arterial infusion of docetaxel--case report].
Topics: Aged; Antineoplastic Agents, Phytogenic; Bronchial Arteries; Carcinoma, Squamous Cell; Docetaxel; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Paclitaxel; Taxoids; Tracheal Neoplasms | 1998 |
Effects of paclitaxel in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7).
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1999 |
Evaluation of In-111 DTPA-paclitaxel scintigraphy to predict response on murine tumors to paclitaxel.
Topics: Animals; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Fibrosarcoma; Liver; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Ovarian Neoplasms; Paclitaxel; Pentetic Acid; Radionuclide Imaging; Rats | 1999 |
Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Survival; Glycerol; Humans; Paclitaxel; Pharmaceutical Vehicles; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
[Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capillaries; Carcinoma, Squamous Cell; Docetaxel; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Taxoids; Tumor Cells, Cultured | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
[Experimental chemotherapy of xenotransplanted oral squamous epithelial carcinoma: effectiveness of docetaxel (taxotere) in the nude mouse model].
Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Docetaxel; Humans; Male; Mice; Mice, Nude; Mouth Mucosa; Mouth Neoplasms; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Colitis; Cytomegalovirus Infections; Docetaxel; Fatal Outcome; Fluorouracil; Ganciclovir; Humans; Hypopharyngeal Neoplasms; Immune Tolerance; Male; Middle Aged; Paclitaxel; Taxoids | 1999 |
Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Growth Inhibitors; Intestinal Mucosa; Jejunum; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 1999 |
[A case of synchronous bilateral double primary lung cancer successfully treated by Nd-YAG laser therapy and chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Laser Therapy; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Taxoids | 1999 |
[A case of squamous cell lung cancer in a nonsmoking female, successfully treated with docetaxel and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Smoking; Taxoids | 2000 |
The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 2000 |
Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2000 |
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Docetaxel; Enterocolitis; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Taxoids; Tomography, X-Ray Computed | 2000 |
Phantom limb pain as a manifestation of paclitaxel neurotoxicity.
Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Female; Hand; Humans; Leg; Lung Neoplasms; Male; Neurotoxins; Paclitaxel; Phantom Limb; Tendon Transfer; Ulnar Nerve | 2000 |
[Preoperative bronchial arterial infusion of docetaxel for squamous cell carcinoma of the lung--clinical evaluation and correlation between anti-tumor effect and apoptosis].
Topics: Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Bronchial Arteries; Carcinoma, Squamous Cell; Docetaxel; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Paclitaxel; Taxoids | 2000 |
Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Topics: Adenosine Triphosphatases; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Calcium Channel Blockers; Carcinoma, Squamous Cell; Colchicine; Cyclosporine; Cyclosporins; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Paclitaxel; Point Mutation; Structure-Activity Relationship; Transfection; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate | 2000 |
Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line.
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Ceramides; Drug Synergism; G1 Phase; G2 Phase; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Mitosis; Paclitaxel; Resting Phase, Cell Cycle; Tumor Cells, Cultured | 2000 |
Malignant craniopharyngioma.
Topics: Adult; Carboplatin; Carcinoma, Squamous Cell; Craniopharyngioma; Female; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Paclitaxel; Pituitary Neoplasms; Radiotherapy; Tumor Suppressor Protein p53 | 2000 |
A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2000 |
[Effect of paclitaxel on cisplatin resistant head and neck squamous multicellular tumor spheroids].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Death; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Paclitaxel; Tumor Cells, Cultured | 2000 |
Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Luminescent Measurements; Paclitaxel; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vulvar Neoplasms | 2000 |
Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; bcl-2-Associated X Protein; Blotting, Western; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; ErbB Receptors; Genes, p53; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitosis; Multidrug Resistance-Associated Proteins; Mutation; Neoplasm Transplantation; Paclitaxel; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Time Factors; Tumor Cells, Cultured | 2000 |
In regard to Suntharalingam et al. IJROBP 2000;47(1):49-56.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Paclitaxel; Survival Analysis | 2001 |
Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Endothelial Growth Factors; Female; Humans; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; RNA, Messenger; Thalidomide; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
[Refractory non-small-cell lung cancer responding to combination chemotherapy with docetaxel, gemcitabine and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Combined effect of docetaxel and cisplatin for non-small cell lung cancer cell lines in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cisplatin; Docetaxel; Drug Interactions; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2000 |
Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki ).
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy; Taxoids; Time Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2001 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Disease Models, Animal; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Ifosfamide; Methotrexate; Mice; Mice, Nude; Paclitaxel; Survival Rate; Taxoids | 2001 |
Radiosensitization effect by combination with paclitaxel in vivo, including the effect on intratumor quiescent cells.
Topics: Animals; Apoptosis; Bromodeoxyuridine; Carcinoma, Squamous Cell; Cell Survival; Humans; Mice; Mice, Inbred C3H; Micronucleus Tests; Neoplasms; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Radiobiology; Radiotherapy Dosage; Time Factors; Tirapazamine; Triazines | 2001 |
A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoembryonic Antigen; Carcinoma, Squamous Cell; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2001 |
Glassy cell carcinoma of the uterine cervix: combination chemotherapy with paclitaxel and carboplatin in recurrent tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cell Nucleolus; Cell Nucleus; Combined Modality Therapy; Cytoplasm; Fallopian Tubes; Female; Humans; Hysterectomy; Lymph Node Excision; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Ovariectomy; Paclitaxel; Radiotherapy; Tomography, X-Ray Computed; Uterine Cervical Neoplasms | 2001 |
Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Sternum; Taxoids | 2001 |
A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Combined Modality Therapy; Docetaxel; Half-Life; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Paclitaxel; Taxoids | 2001 |
[Outpatient chemotherapy for advanced lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies.
Topics: Antineoplastic Agents; Blotting, Western; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Flow Cytometry; Head and Neck Neoplasms; Humans; In Vitro Techniques; Paclitaxel; Signal Transduction; Tumor Cells, Cultured | 2002 |
Paclitaxel combined with fractionated radiation in vitro: a study with vulvar squamous cell carcinoma cell lines.
Topics: Carcinoma, Squamous Cell; Cell Survival; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; In Vitro Techniques; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vulvar Neoplasms | 2002 |
[A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Infusions, Intra-Arterial; Male; Paclitaxel; Taxoids | 2002 |
Neoadjuvant treatment with docetaxel and the effects of irradiation for human ovarian adenocarcinoma and cervical squamous cell carcinoma in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; DNA, Single-Stranded; Docetaxel; Female; Humans; In Vitro Techniques; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Failure | 2002 |
Squamous syringometaplasia associated with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Male; Metaplasia; Middle Aged; Necrosis; Paclitaxel; Sweat Gland Neoplasms; Sweat Glands; Taxoids | 2002 |
Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Practice Guidelines as Topic; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine; World Health Organization | 2002 |
Dynamic behavior of the transferrin receptor followed in living epidermoid carcinoma (A431) cells with nanovid microscopy.
Topics: Alkaloids; Azides; Benzimidazoles; Carcinoma, Squamous Cell; Cell Line; Cell Membrane; Humans; Microscopy, Electron; Microscopy, Phase-Contrast; Microtubules; Nocodazole; Organoids; Paclitaxel; Receptors, Transferrin; Sodium Azide | 1988 |